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      E            I                   L 
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          K            P               S 
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1. Current situation of antimicrobial resistance  
 
Nowadays, we are facing a very important problem, the rapid and steady increase of 
resistance of most of the bacteria against the antibiotics available to treat the infections. 
In the last report of the WHO (World Health Organization) (1), they alert about this 
dramatic situation. The number of antibiotics approved by the FDA (Food and drug 
administration) has been decreasing since 20 or 30 years ago, with a very few effective 
antibiotics in the past years. If we take a look into the data published by the WHO in 
2011, we have to be aware how big is the problem of the antimicrobial resistance, 
causing 3.2 millions of deaths per year just being lead by ischaemic heart disease and 
stroke with 7 and 6.2 millions respectively, and with higher numbers compared to AIDS 
or diabetes mellitus (Figure 1). In the EU the number of infections caused by multi-drug 
resistant (MDR) are approximately 400.000 per year, and of this number 25.000 per 
year are attribuible deaths, a part from the high number of people that acquire 
infections, there is an important burden which is the economical, these infections cost 
one billions per year in extra in-hospital days, and the losses of productivity are 600 
millions per year. Taking into account the scenario of the present situation, they called 
ESKAPE (Enterococcus faecium, Staphylococcus. aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa, Entereobacter species) to the 
most resistance bacteria.  
 
 
Figure 1: The 10 leading causes of death in the world in 2011. (WHO) 
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We can observe that ESKAPE group is composed by both Gram-positive and Gram-
negative bacteria. ESKAPE bacteria are really attractive bacterial targets due to its high 
resistance profile of the components. 
 
Another important issue is how to name the scale of resistance of the bacteria, because 
since a few years there was a lot of controversy about this topic, therefore it is very 
important to have the concepts of resistance very clear. We can define MDR when non-
susceptible to ≥ 1 agent in ≥ 3 antimicrobial categories, the next resistance grade is 
extensive drug-resistance (XDR) being non-susceptible to ≥ 1 agent in all but ≤ 2 
categories, and pandrug-resistance (PDR) is defined when the bacteria is resistance to 
all the antibiotics in all the antimicrobial categories. (2)  
 
Since a few years ago there was no controversy about the definition of these concepts 
because no pandrug-resistance were isolated, but in the last 10 years the number of 
pandrug-resistance strains isolated have been increasing rapidly, specially in the case of 
A. baumannii (3).  
In the resistance profile of this specie it is possible to observe the evolution by 
comparing studies performed at different years, the percentage of resistant of imipenem 
was 3% in 1993 and increase up to 70% in 2007, the same effect was observed with 
quinolones, with an increase from the 30 to 97% in the same period of time (4). The 
same evolution is observed in Spain focusing in carbapenems, in 2001 the percentage of 
resistant was around 45% and ten years later was more than 80% (5). Observing this 
data we can imagine a really dramatic future in the war against these bacteria. 
 
2. Current situation of antibiotics  
 
As commented previously, there is an urgent need of new antibiotics, as we can observe 
in the figure 2, the antibiotics approved by FDA during the last 20-30 years are unuseful 
in some situations. In the figure 2 it is possible to observe that the last antibiotics are 
linezolid and daptomycin, these compounds are only active against Gram-positive 
bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and 
vancomycin-resistant Enterococci (VRE). Indeed, even if they are the last antibiotics of 
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being released in the market some resistance to them have been reported, in the case of 
linezolid the most important mechanism of action are the alterations in the 23S rRNA 
target (6), and in the case of daptomycin is the modification of the lipids that composed 
the membrane of the Gram-positive bacteria, observed in Enterecocci (7), MRSA (8), 
and recently also some resistance to daptomycin in Streptococcus mitis, however the 
mechanism have not been elucidated yet (9). We want to highlight that the last 
antibiotics approved are only active against Gram-positive bacteria, so that means that 
the necessity of compounds active against gram-negative is more imperious. 
 
 
Figure 2: Timeline of development of new antibiotics. (Wright GD. The antibiotic resistome: the nexus 
of chemical and genetic diversity. Nat Rev Microbiol. 2007. 5;175-86.) 
 
3. Acinetobacter baumannii: The Archetype of resistance 
 
The Acinetobacter species are mainly nosocomial opportunistic pathogens, that means 
that normally affects people with a low immune system admitted in the hospital. 
Between 2 and 10% of the gram-negative infections in the ICU (Intensive care unit) are 
caused by Acinetobacter species (10). They are normally one of the most frequent 
causative agents in nosocomial pneumonia but they are also implicated in bacteremia, 
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UTI (Urinary track infections) and meningitis. Another important feature of this specie 
is the ability to colonize any type of surface (11). 
 
3.1. Characteristics and taxonomy 
 
The Acinetobacter genus is formed by several species, they are Gram-negative, 
cocobacillus, nonfermenting, unable to reduce nitrates, catalase positive, oxidase 
negative (12) and without mobility, that is were the name Acinetobacter is derived, in 
Greek the term (a-kineto) means a lack of motility, so its name means that this bacteria 
does not have motility on surfaces (13). 
 
In 1911 it was isolated the first Acinetobacter strain, it was from the soil and at that time 
it was named Micrococcus calcoaceticus, after 43 years, in 1954 Brisou and Prévot 
created the genus Acinetobacter, (14). In 1986 Bouvet and Grimont performed a really 
exhaustive taxonomic classification of this genus with 12 different species (15). 
Nowadays and due to the new techniques used for bacterial taxonomy new species are 
proposed, and now in 2014, 34 different species have been defined (16). 
 
3.2. Morphological and phenotypical aspects. 
 
Acinetobacter species (Figure 3) form smooth colonies in solid media, their colour can 
go from yellow to white-grey and from 1 to 2 mm of diameter (11,17). The oxidase test 
is the one used to differenciate the Acinetobacter genus from other related none 
fermentative Gram-negative bacteria (17). The ability to use different carbon sources in 
their metabolism give them an intrinsic resistance to the enviroment (18). 
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Figure 3. Acinetobacter baumannii morphology grouped. (Wikipedia Acinetobacter baumannii) 
 
For the direct isolation of clinical strains, selective solid media, such as MacConkey can 
be used, but is preferable to use other solid media that do not allow the growth of other 
microorganisms (11, 17). This type of selective media that suppresses the growth of 
other bacteria are Herellea agar and Leeds Acinetobacter media, both of them are 
selective media and they are uselfull for most of the genospecies of Acinetobacter, both 
clinical and environmental (19). 
 
3.3. Natural and clinical reservoirs 
 
The two main features that make Acinetobacter such a difficult bacteria to fight against, 
are the ability to develop multiresistant patterns and the ability to survive in different 
conditions.  
 
Acinetobacter species can be found in soil, water, animals and humans, growing 
normally in all the samples collected from soil or water (20). The places where or in 
which these bacteria have been isolated can go from fresh water ecosystems (21), to air 
samples from hospitals (22) or in kindergarden or high schools (23). This high 
resistance to environmental conditions comes from the ability to use different carbon 
sources, as previously commented. It has been observed that the ability of survival in 
different surfaces is different if we compare clinical isolates and standard strains from 
ATCC collection (24-28). 
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If we compare all the species of Acinetobacter, A. baumannii is the one which present a 
higher ability to survive to desecation, therefore with this information and also knowing 
that A. baumannii is the specie that presents more resistant profile patterns, we have the 
answer of why is A. baumannii the most common specie that cause nosocomial 
outbreak in hospitals (26, 27, 29). If we compare the ability to survive in dry surfaces 
we can observe that A. baumannii can live during more than 25 days, while A. lwofii can 
only survive during 7 (25). 
If we compare their survival with other bacteria the difference is even higher, P. 
aeruginosa can survive less than 24 hours and Escherichia coli at around 24 hours (30). 
 
3.4. Pathogenesis and virulence factors of Acinetobacter baumannii 
 
This part of the introduction is a summary of the review. (Part 3.4) 
Roca I, Espinal P, Vila-Farrés X, Vila J. The Acinetobacter baumannii Oxymoron: 
Commensal Hospital Dweller Turned Pan-Drug-Resistant Menace. Front Microbiol. 
2012. 3;148 
 
Virulence factors are required for the pathogenesis of infections caused by A. 
baumannii, these virulence factors allow the bacteria to colonize and infect the patient. 
There are not many studies about the pathogenicity of this microorganism (31). These 
are the most important virulence factors in Acinetobacter. 
 
3.4.1. Biofilm 
 
The first step in bacterial colonization is the adherence to the cell host. Once the first 
bacteria is adhered to the cell host a biofilm is build. Biofilm can be defined as a group 
of bacteria stacked to each other with a polymeric matrix, this matrix do not allow the 
antibiotic to be efficient against bacteria and also help the bacteria to survive. This 
polymeric matrix can be formed by carbohydrates, nucleic acids, proteins and other 
macromolecules (32). The ability of a strain to create biofilm can be one of the factors 
that can influence in its virulence. (33-35). The ability of each strain to perform biofilm 
can be influenced by different factors such as quorum sensing, bacterial surface 
components, amount of nutrients, macromolecular secretions (36-37). The two-
component regulatory systems and transcriptional regulators which have relation with 
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the genes associated with biofilm are also very important (38). The most important gene 
is CsuE, which is a component of the CsuA/BABCDE chaperone-usher complex, this 
gene is involved in the production of the pili, and when the inactivation of the gene is 
produced no biofilm formation is observed (39).  
A. baumannii can form biofilm also in the environmental surfaces not only in human 
cells, even in dry surfaces and with low amount of nutrients (40). 
 
3.4.2. Motility and adherence 
 
As previously commented the name Acinetobacter comes from the non-motility, this 
fact is due to the lack of flagella (41). This absence of flagella means that this bacteria 
does not move using swarming (42), however A. baumannii spreads really fast over 
surfaces, this fact may be as the twitching already described in A. calcoaceticus (43). 
There are large number of genes involved in everything related to the type IV pili, 
which is the one associated with twitching motility (44). It has been observed that pilT 
gene it is also involved in the twitching (42). Twitching motility is also controlled by 
two component sensor-regulators and complex chemosensory system (45). 
 
3.4.3. Surface polysaccharides 
 
LPS (lipopolysaccharide) plays an important role in the virulence of A. baumannii, this 
fact it is showed in the study performed by García et al. were they claimed that LPS and 
lipid A showed lethal toxicity in mice, pyrogenicity in rabbits and complement 
inactivation in vivo (46). The same results are obtained confirming the important role of 
the LPS in terms of virulence (47). Another study that confirms the importance of LPS 
in the virulence of A. baumannii was based on the study of a colistin-resistant strain. All 
mechanisms of resistance to colistin are related to LPS, modification by mutations in 
the gene pmrAB or lpxACD and this fact also make the strain less virulent (48) 
 
3.4.4. Outer membrane proteins 
 
When we talk about outer membrane proteins (OMPs) in terms of virulence and 
pathogenesis we have to highlight OmpA. OmpA is the most abundant protein in the 
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bacterial surface, it plays a major role in the adherence and invasion of epithelial cells 
and induce apoptosis (37).  
One of the mechanisms of A. baumannii is to induce cell death (HEp-2 cells) by cell 
surface death receptors and mitochondrial disintegration. It has been observed OmpA in 
the mitochondria, where it generates a release of pro-apoptotic molecules such as 
cytochrome c, and apoptosis-inducing factor (AIF), these apoptosis of the cells make 
the bacteria able to internalize trough the disrupted mucosal lining (49). 
Regarding the different outer membrane proteins found in A. baumannii, Smani et al., 
discovered that Omp33, a protein involved in carbapenem resistance, was also involved 
in the virulence and fitness of this microorganism (50). 
 
3.4.5. Outer membrane vesicles 
 
Another virulence mechanism which is also common to all Gram-negative bacteria are 
the outer membrane vesicles (OMVs). OMVs are spherical nanovesicles with a diameter 
between 20 and 200 nm, and are composed by DNA, RNA, lipids, lipopolysaccharides 
and even OMPs (51, 52). The role of these OMVs is different, they can transport 
virulence factors, they can participate in biofilm formation, and they can also be 
involved in quorum sensing and gene transfer (53,54). OmpA is the most abundant 
protein of the OMVs, these allow OmpA to adhere to the host cells (55). OMVs have 
also the ability to carry genetic material, like the blaOXA-24 gene which encodes a 
oxacillinase which produce resistance to carbapenems (54). With this information it is 
shown the importance of the OMVs, not because they are important in the interaction 
host-pathogen, but also because they are also able to spread resistant genes. 
 
3.4.6. Siderophores 
 
Siderophores are compounds that have the ability to chelate iron, as it is known, iron is 
essential for the growth of bacteria, therefore bacteria secrete these compounds in order 
to obtain iron from outside the bacteria. Just two different siderophores have been 
identified in Acinetobacter species, which are Acinetobactin (56) and Fimsbactin A-F 
(57). An A. baumannii isolate during an outbreak was deeply analyzed due to its high-
affinity iron-uptake, it was demonstrated that the genes dhb were the ones involved in 
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iron-uptake. It was also detected some proteins highly-related to iron transport like 
OM73, P45 and P114 (58).  
 
3.4.7. Quorum sensing 
 
Bacteria excreted chemicals compounds in order to perform communications with the 
other bacteria and environmental adaptation, this ability is called quorum sensing (QS). 
(59) These compounds secreted by the bacteria are normally acyl-homoserine lactone 
(AHL)-like signal molecules produced by the LuxI family of AHL synthases. The 
production and secretion of these compounds is controlled by the cell depending on the 
cell density and the growth phase, and it has been linked with the production of certain 
virulence factors such as motility or biofilm (59,60). All these processes mediated by 
AHL system in Gram-negative bacteria involve two important family proteins, LuxI 
which interact with LuxR. This complex binds to a specific promoter sequence known 
as lux-box, which regulates the expression of QS target genes. Among the LuxI 
proteins, AbaI protein, found in A. baumannii, is the one involved in the production of 
N-(3-hydroxydodecanoyl)-L-HSL and (3-hydroxy-C(12)-HSL) (61), It is also important 
to point out the high promiscuity if these receptors, as it is observed the similar effect 
when the same compound (R) and (S)-stereoisomer is tested (62). 
It was also observed that to isogenic strains with mutations in the abaI gene led to a 
reduction of biofilm production (36,62). 
 
3.5. Antimicrobial resistance of Acinetobacter baumannii 
 
This part of the introduction is a summary of the review. (Part 3.5) 
Roca I, Espinal P, Vila-Farrés X, Vila J. Front Microbiol. 2012. 3;148 
 
Acinetobacter have innate ability to survive in difficult conditions and in difficult 
places, but another important feature that makes Acinetobacter such a successful 
pathogen is the ability to acquire and keep different mechanisms of resistant that makes 
it able to survive against all the antibiotics used to treat the infections caused by this 
pathogen.  
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Acinetobacter has become resistant to all the antibiotics used to treat infections, here we 
report the mechanisms of resistance used by this pathogen to survive to the action of the 
antibiotics. 
 
3.5.1. β-lactams  
 
The mechanisms of resistance against this group of antibiotics can be divided into two 
main groups:  
i) Enzymatic mechanism (β-lactamases)  
ii) Non enzymatic mechanism. 
 
i) Enzymatic mechanisms. 
β-lactamases are enzymes produced by some bacteria that provide resistance to β-
lactams. These antibiotics family all have a common element in their molecular 
structure which is four atom ring with an amide group, known as β-lactam. The effect of 
the enzyme is opening this β-lactam ring by hydrolysis, deactivating the molecule 
antibacterial activity. 
 
Chromosomal cephalosporines (AmpC /ADC) 
 
AmpC enzymes belong to class C β-lactamases, and they are responsible of the 
resistance to penicillins and extended-spectrum cephalosporins, except cefepime, as 
well as to β-lactam-β-lactamase inhibitor combinations (63). The basal level of 
expression of these enzymes in Acinetobacter do not affects the susceptibility to the 
most of β-lactams, however the presence of an insertion sequence (ISAbaI) upstream of 
the blaADC gene promotes the increase of its expression and increase the minimal 
inhibitory concentration to expanded-spectrum cephalosporins (64). This is due to the 
fact that the IS element carries a promoter that can be used for the RNA polymerase to 
express the blaADC gene. 
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Oxacillinases 
 
Oxacillinases, also called Ambler Class D enzymes, as their name shows are able to 
hydrolyzed oxacillin and cloxacillin, apart from some oxyimino-β lactams, but they are 
weakly inhibited by clavulanic acid, however there is a subgroup called carbapenem-
hydrolyzing class D-β lactamases (CHDL) which are able to inhibit the action of 
imipenem and meropenem but not the action of extended-spectrum cephalosporins and 
aztreonam (65). 
We can divide the OXA found in A. baumannii into five groups: i) OXA-51/49 which is 
the only one naturally occurring, found in the chromosome of all strains of A: 
baumannii. ii) The other four groups are acquired CHDLs (OXA-23, OXA-24/40, OXA 
58, and OXA-143). 
 
Metallo-β lactamases 
 
Nowadays carbapenems are the most used antibiotics to treat infectious caused by 
Acinetobacter species, however during the last decades resistance to carbapenems is 
increasing worldwide (66,67), there is also a big problem when dealing with 
carbapenem-resistance Acinetobacter, most of the strains are resistant to almost all the 
antibiotics classes, except intermediade resistance to rifampicin and being susceptible to 
tigecycline and colistin.  
 The main feature of class B-metallo-β-lactamases or MBLs is their broad spectrum, 
they are able to hydrolyze all the β-lactams except aztreonam (68). There are several 
MBLs described such as IMP metallo- β-lactamases (69), VIM enzyme (70), SIM-1 
(71) or the most recent one which is NDM (72), This MBL enzyme has the ability to 
spread really fast (73). 
 
 
ii) Non enzymatic mechanism. 
When we talk about non enzymatic mechanism of resistance to β-lactams we refer to 
membrane alterations, normally by alterations in OMP or overexpression of efflux 
pumps. In addition modifications in the penicillin binding proteins (PBPs) have also 
been shown as a potential mechanism of resistance. An example is the protein CarO that 
it was associated to carbapenem resistance, with out the presence of any known 
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carbapenemases (74), the same effect was observed in 33- to 36- kDa OMP in a A. 
baumannii strain isolated in Spain (75). Other proteins like the heat-modifiable HMP-
AB is also involved in resistant to carbapenemases in A. baumannii, and it is very 
similar to OmpA from Enterobacteriacae. (76) Another mechanism of action that could 
be also compatible with the production of β-lactamases, is the change of affinity or 
expression of the PBPs (77).  
 
3.5.2. Aminoglycosides 
 
There are two different ways to achieve resistance to aminoglycosides, the first way is 
by the expression of aminoglycoside-modifying enzymes (AMEs), the most common 
are, acetyltransferases, nucleotidyltransferases, and phosphotransferases (78), the 
acivity of this AMEs result in the modification of the amino or hydroxyl group present 
in the aminoglycosides which make them to decrease their affinity for the target site 
(79). The second way is by efflux proteins, these efflux pumps, and specially RND 
family plays an important role in MDR (80). We want to focus in the AdeABC which 
confers resistance to aminoglycosides apart from other antibiotics families (81). There is 
a third mechanism which has not been reported in A. baumannii which is the 
modification of some ribosomal proteins. 
 
3.5.3. Quinolones 
 
The most important mechanism of resistance is, as in all the species, the mutations in 
the quinolone-resistance determining region (QRDR) in the A subunit of the DNA 
gyrase and DNA topoisomerase IV. Both mutations in the gyrA (encoding the A subunit 
of the DNA gyrase) and parC (encoding the A subunit of topoisomerase IV) have been 
described. The substitution of Ser83 to Leu83 in GyrA and the substitution of Ser80 to 
Leu80 in ParC are the most frequently found (82). It is important to mention that 
mutations in the parC gene are always accompanied by mutations in the gyrA gene, that 
suggests that gyrA is the preferred target when compares to parC (83). Efflux pumps are 
also important as an alternative mechanism of resistance to quinolones, being the most 
common these belonging to the RND family such as AdeIJK (84) and AdeFGH (85).  
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3.5.4. Polymyxins 
 
In spite of their toxicity, polymyxins are the last option in the treatment of infections 
caused by A. baumannii. Up today most of the strains of A. baumannii are still 
susceptible to colistin, however in the last years colistin-resistant A. baumannii clinical 
isolates have been reported (86). Regarding the mechanism of action of colistin not 
many things are known, but all the hypothesis indicates that it acts in the outer 
membrane, however recently some inhibition of the NADH-quinone oxidoreductase 
have been descrived as a secondary mechanism of action (87). Two different 
mechanisms of resistance to colistin have been elucidated, they are related to each other 
because somehow they have some relation with membrane components. Adams et al. 
observed mutations in pmrABC, pmrAB is a two component regulatory system that 
regulates the expression of pmrC which encodes a phosphoethanolamine transferase 
enzyme involved in lipid A modification (88-90). 
The second mechanism of resistance is the complete loss of the lipopolysaccharide by 
mutations in lpxACD genes, which are involved in the lipid A biosynthesis (91).  
 
4. Colistin and daptomycin 
 
Currently, two peptidic antibiotics are widely used, colistin and daptomycin. The first is 
an old antibiotic that was not used for a long time since it showed an important toxicity 
and other antibiotics were available, however it is now used as a last resort to treat 
infections caused by multidrug resistant bacteria such as A. baumannii, P. aeruginosa or 
K. pneumoniae. The second one, is together with linezolid the two antibiotics launched 
during the last 30 years, both having activity only against Gram-positive bacteria. Both 
compounds have a similar structure being both lipopeptides, with a cyclic peptidic part 
and a fatty acyl tail. 
 
4.1. Colistin 
 
Colistin, also called polymyxin E, is a lipopeptide isolated from Bacillus polymyxa. It 
has a very narrow spectrum of activity, only being active against some Gram-negative 
bacteria, so it is used as “salvage” to treat multidrug-resistant infections. It was used 
before the 1970s but then was replaced by aminoglycosides due to its nephrotoxicity 
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and neurotoxicity (92, 93). In 1959 it was the beginning of its use in the clinical setting 
The procedures carried out by the Food and Drugs Administration (FDA) at that time 
were not so strong as today, and colistin became an antibiotic easily (94). During the 
last decades we have witnessed a dramatic increase both in the proportion and absolute 
number of pathogens such a A. baumannii presenting extensive-drug-resistance to 
antibacterial agents, being susceptible only to tigecycline and colistin. Therefore, 
colistin is used widely and hence the emergence of colistin-resistant A. baumannii has 
been observed. Two aspects are important to be studied, both are related to each other, 
these aspects are potential nephrotoxicity and neurotoxicity and optimizing dose 
(PK/PD). In terms of nephrotoxicity and neurotoxicity, we want to highlight that 
neurotoxicity is not as common as nephrotoxicity. It has been proved that colistin has 
the same nephrotoxicity levels as tobramycin, an aminoglycoside (95, 96). In another 
more extensive study, the results were that patients who received colistin more than 14 
days had a 3.7 fold increased risk of nephrotoxicity, thereby what is important is the 
accumulative dose more than the daily dose, in this sense it is important to monitor the 
kidney function in long term treatments (97). It is now accepted that renal injury caused 
by colistin is not as strong as it was though in the beginning and is also totally reversible 
over weeks to months after ceasing therapy (97). The other important aspect is the 
adjustment of the dose treatment. In the last decade, the pharmacokinetic and 
pharmacodynamic (PK/PD) has been examined in different ways like mouse model or 
just in vitro, these ways try to find out the right dose that should be given (98-101). It 
should be noted that colistin is administered as a prodrug colistin methane sulfonate 
(CMS), and the conversion to the active specie, colistin, is really slow, therefore during 
the first dose, the concentration of colistin is below the break point (2 mg/L) for that 
reason monodose therapy is not useful to treat A.baumannii (102). The dosage of 
intravenous CMS recommended by the manufacturers in the USA is 2.5–5 mg/kg 
(31,250–62,500 IU/kg) per day, divided into two to four equal doses, however the dose 
in the UK is 4–6 mg/kg (50,000–75,000 IU/kg). CMS is normally administered during 
10-14 day, however it can change depending on the renal function of the patient 
 
The chemical structure of the colistin, and all the polymyxins, is formed by a cyclic 
peptide and a fatty acyl group, as commented previously. It is a decapeptide and the 
loop is produced between the side chain of the diaminobutyric acid (Dab) at position 4 
and the carboxyl group of the C-terminal threonine residue at position 10. Some 
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different polymyxins have been isolated, the 3 differences are, positions 6 and 7, and the 
different fatty acyl group present in the N-terminal of the peptide, all of them are 
showed in Table 1. 
 
 
 
Table 1. Different structure of all the polymyxins.  
 
Velkov T, Roberts KD, Nation RL, Thompson PE, Li J. Pharmacology of polymyxins: new insights 
into an ‘old’ class of antibiotics. Future Microbiol. 2013. 8;711-24.  
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We want to focus only in polymyxin E. It has a D-Leu in the position 6, being the only 
D-amino acid in all the peptide, and Leu also in the position 7. We have to take into 
account that polymyxin E, contain several species, but the majority (more than the 80%) 
belongs to a mixture of polymyxin E1 and polymyxin E2, they just differ in the fatty acyl 
group, having (S)-6-methyloctanoyl for polymyxin E1 and 6-methylheptanoyl for 
polymyxin E2. 
The mechanism of action of colistin seems to be in the outer membrane, due to its big 
size, probably unable to penetrate inside the bacteria, however some authors have 
suggested that it can accumulate inside the bacteria and interact with a intracellular 
target, as commented previously. First of all we need to have very clear which are the 
components of the Gram-negative bacteria, and why its not effective against Gram-
positive. The main difference between the cell wall of Gram-negative and Gram-
positive bacteria is that Gram-positive bacteria is composed by a lipid bilayer, and 
protected by a thick peptidoglycan layer, while the Gram-negative bacteria have a more 
complex arquitecture having inner and outer membrane separated by periplasmic space. 
In the outer membrane layer is where lipopolysaccharides are located, and especially 
lipid A which is one of the components. The structure of lipopolysaccharides is divided 
in three parts: the variable O-antigen chain (repited saccharide units), a core 
oligosaccharide domain and the lipid A, Figure 5 (103). 
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Figure 5. A) Interaction between polymyxin and lipid A. B) Components of the Lipopolysaccharide 
(LPS).  
 
Velkov T, Roberts KD, Nation RL, Thompson PE, Li J. Pharmacology of polymyxins: new insights 
into an ‘old’ class of antibiotics. Future Microbiol. 2013. 8;711-24.  
 
 
Lipid A is formed by a β-1´-6-linked D-glucosamine disaccharide which is 
phosphorylated at positions 1´and 4´ (104). It is important to mention the function of the 
cations  Mg2+ and Ca2+, which are able to link adjacent LPS moieties (105), however as 
it has been commented previously there is a suspicion that it could also have an 
intracellular target (87). 
If we take a look into the peptidic structure of polymyxin B and colistin, just two 
residues are different, due to its different activity, that means that these variable residues 
are important in the mechanism of action, also the amphipathicity of the molecule has a 
crucial role. Several theories of the mechanism of action have been proposed, but 
nowadays the accepted model is the one called ‘self-promoted uptake’ (Figure 5), the 
action of the amines of the Dab residue interact electrostatically with the anionic lipid A 
phosphates, this interaction leads to the displacement of the cations commented 
previously, that allows the two key residues (amino acids 6 and 7) and the fatty acid 
acyl tail to internalize into the outer membrane, this is the part where most the articles 
published about this topic agrees, the rest of the mechanism remain unclear. (106). 
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4.2. Daptomycin. 
 
Daptomycin is one of the lastest antibiotics released in the market, it was discovered by 
Lilly in the late 80s from Streptomyces roseosporus a saprotroph isolated in soil. Lilly 
researchers observed a really good “in vitro” activity against Gram-positive bacteria but 
they gave up the development of the antibiotic due to the fact that surfactants found in 
the lung inhibit the effect of this antibiotic, therefore can not be used to treat respiratory 
tract infections such as pneumoniae. Later on the rights were sold to Cubist 
Pharmaceuticals. In 2003 this antibiotic was approved by the FDA (107). Daptomycin 
has a similar structure as polymyxins, a cyclic peptide with a fatty acyl chain, 
daptomycin has 13 residues, 10 of them are forming the cycle and the rest are forming 
the lipophilic tail. From the 13 amino acid residues, five of them are nonproteinogenic, 
such as L-ornithine (L-Orn), L-threo- 3-methylglutamic acid, L- Kyrunenine (L-Kyn) 
and two D-amino acids. In the begining one of the D-residues was assignated as L-, but 
recently they corrected into D-configuration (108). The cyclization is produced between 
the carboxyl group of the L-Kyn (residue 13) and the hydroxyl group of the Thr (residue 
4), and the fatty acid is formed by a decanoyl. Figure 6 
 
 
Figure 6. Chemical structure of daptomycin.  
 
Bionda N, Pitteloud JP, Cudic P. Cyclic lipodepsipeptides: a new class of antibacterial agents in the 
battle against resistant bacteria. Future Med Chem. 2013. 5;1311-30.  
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Table 2. Chemical structure of daptomycin and analogs, and MIC against S. aureus.  
 
Bionda N, Pitteloud JP, Cudic P. Cyclic lipodepsipeptides: a new class of antibacterial agents in the 
battle against resistant bacteria. Future Med Chem. 2013. 5;1311-30.  
 
Several compounds were found when they discover daptomycin (109), all of them had 
the same scaffold just changing the fatty acid side chain, in table 2, the activity of the 
other daptomycin analogues can be observed (108). When comparing all the analogues 
and daptomycin they observed that the penetration into the lipid bilayer was inversely 
proportional to the length of the fatty acid chain, however the length of the fatty acid 
chain was also really important in the toxicity of the compounds, longer side chain fatty 
acid exhibited higher toxicity (110) 
 
The mechanism of action of daptomycin is in the same stage as polymyxins, it is known 
that the mechanism of action is very similar, first of all it was demonstrated that the 
activity of daptomycin and their analogues are intrinsically related to the amount of 
Ca2+, present in the serum, no activity is present when divalent cations such as Mg2+, 
Zn2+ or Ba2+ are present in the medium (111), this calcium may induce conformational 
changes into daptomycin (112,113), or neutralize the repulsion between the daptomycin 
(anionic) and anionic phospholipid heads of the membrane (114). The initial step is the 
interaction of the polar head groups of the phospholipid and the fatty acid chain of the 
lipopeptide, and after the accumulation of the compound, oligomers can be formed, 
these oligomers are the responsible of the depolarization of the membrane, but there is 
not a clear evidence of this hypothesis.  
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In terms of pharmacokinetics, daptomycin is a bactericidal antibiotic with a really long 
half-life (8h), and showed a postantibiotic effect of up to 6.8 hours (115). The fact that it 
has this high values may be due to its high affinity with the serum proteins (90%) (116). 
Doses approved by the FDA are 4 mg/Kg for soft tissue infections and 6 mg/Kg for S. 
aureus bacteremia, however the data obtained in animal model and in vitro suggest that 
the doses could be higher, and that will reduce the development of resistance and will 
increase the activity (117). 
As we have commented previously the spectrum of activity of daptomycin is in front 
Gram-positive bacteria, before being approved by the FDA, it was tested in over 70 
medical centers located in Europe and America, and the results were that 99.4% of the 
isolates were inhibited by ≤2 mg/L daptomycin (118). The spectra of activity of 
daptomycin include both methicillin-susceptible and –resistant S. aureus, vancomycin –
susceptible and –resistant Enterococcus, coagulase-negative Staphylococcus, and 
streptococci.  
Although daptomycin is a really new antibiotic, some resistance have already been 
reported in the Gram-positive bacteria against which daptomycin is more commonly 
used, such as S. aureus, Enterococcus and Streptococcus. Since the mechanism of 
action of daptomycin is associated with the depolarization of the cell membrane and the 
cell wall, the mechanisms of resistance of the bacteria commented below are related to 
modifications of the cell wall and cell membrane. 
In S. aureus, the first gene identified when a daptomycin resistant strain was isolated 
was the mprF gene with some single nucleotide polymorphisms (SNPs) observed, 
(119,120). When the MIC of daptomycin start to increase the amount of SNPs in 
different genes are increasing, these genes are the yycFG gene, were the yyc operon is 
involved in the generalized response to stressors such as antimicrobials, and 
consequently the rpoB or rpoC genes, beta and beta’ subunits of RNA polymerase. The 
SNPs observed in these genes, specially in the mprF gene, lead to an increase of the 
relative positive surface charge. The mprF gene encodes a protein which has a double 
function being the responsible for the lysinylation of the lysylphosphotidylglycerol (L-
PG) to generate the positively charged cell membrane phospholipid, L-PG, and the 
second function which is involved in the inner-to-outer cell membrane translocation of 
L-PG (121), apart from the SNPs in the mprF gene, the same genes lead to a change of 
the rigidity/fluidity of the cell membrane, that do not allow the interaction of 
daptomycin with the bacteria (119), this rigidity can be associated to the overproduction 
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of staphyloxantin as well (122). It has been observed that the thickness of the cell wall 
is also an important fact of the daptomycin -resistant, the increase of the thickness may 
act as physical barrier in the interaction of daptomycin. (123) 
Resistance in Enterococcus have also been observed , the group of Arias CA et al. (7) 
isolate a strain of E. faecalis after the therapy with daptomycin, they observed by 
comparing genomically both daptomycin-susceptible and daptomycin-resistant the 
mutations in three genes that were the ones involed in this resistance. The genes 
associated with daptomycin resistance in E. faecalis were the LiaF gene, this gene 
belongs to a three component regulatory system (LiaFSR) which is involved in the cell 
envelope stress-sensing response to antibiotics. The second and third gene (GdpD and 
Cls) encodes proteins involved in the metabolism of membrane phospholipids (7). The 
mechanism of resistance to daptomycin in both S. aureus and E. faecalis involves 
components of the membrane such as lipids or proteins. 
The Dr. Miro’s group from Hospital Clinic of Barcelona (9), observed also resistance to 
daptomycin in S. mitis when it was exposed to daptomycin in an animal model. To 
elucidate the mechanism of resistance of S .mitis to daptomycin is a chapter of the 
thesis. 
 
5. New antibacterial drugs. 
 
The discovery of new antibacterial agents is one of the strategies to be used to control 
the emergence and spread of multi-drug resistant bacteria. Here we describe different 
options in order to search new antimicrobials. 
5.1. Antimicrobial peptides (AMPs) 
 
This part of the introduction is a summary of the review. (Part 5.1.1 and 5.1.2) 
Vila-Farrés X, Giralt E, Vila J. Update of peptides with antibacterial activity. Curr 
Med Chem. 2012;19;6188-98 
 
Hundreds of peptides have been tested in order to know if they have the ability of being 
able to beat bacteria. It would be really difficult to explain all the peptides active against 
all types of bacteria, therefore we are going to focus only in the peptides tested against 
A. baumannii, which is the main bacteria of this thesis.  
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There are different ways to obtain an active peptide, some of them use natural extracts 
and perform a high troughput screening against the desired bacterial species, some 
others have just a peptide or a few peptides, totally synthetics, and try to find out their 
activity. The use of peptides as antimicrobial agents has several advantages such as the 
broad spectrum activity (active against even virus and fungi) compared to normal 
antibiotics, or the less specific target, that reduce the ability of the bacteria to acquire 
resistant to the peptide. Apart from the advantages, it has also some drawbacks like poor 
stability in human serum, due to the activity of proteases and peptidases and the rapid 
clearance. This fact could also been solved by using D-amino acids (124), by the 
methylation of some amino acids (125), by the cyclization of the peptide (126), by the 
introduction of some fluorinated residues, (127) or by introducing a PEG chain in order 
to protect the peptide (128). Another disadvantage is the most expensive production of 
the antimicrobial peptides compared to normal antibiotics (129). 
 
When trying to find out an active peptide against a certain bacteria, the strategy adopted 
could be different, trying to find a natural peptide, and afterwards try to optimize the 
important features that generates the activity of the peptide against bacteria. The other 
strategy is to synthesize a de novo peptide, with a new sequence that somehow could be 
active against bacteria, therefore we are going to divide the antimicrobial peptides 
active against A. baumannii into two different groups, the natural and the synthetics. 
  
5.1.1. Natural and optimized antimicrobial peptides 
 
First of all we will start highlighting some of the typical antimicrobial peptides, which 
most of them are commercially available, such as indolicidin, buforin II, cecropin P1, 
magainin II, ranalexin, cecropin A and melittin. We have to point out the importance of 
the kind of strain used to test the peptide. It has not the same importance to test a 
peptide against an ATCC strain or against a pandrug-resistant strain. All these peptides 
commented previously were tested against multidrug-resistant A. baumannii strains, the 
best results were for buforin II and magainin II with a MIC50 and MIC90 of 2 and 16 
mg/L respectively, the same MIC90 was observed in the case of melittin and cecropin 
P1, but the MIC50 is one dilution higher (4 mg/L). The other three peptides, indolicidin, 
ranalexin and cecropin A have slightly higher values for MIC50 with 8 mg/L, and the 
MIC90 is 32 mg/L for cecropin A and ranalexin and 64 mg/L for indolicidin (130,131).  
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Two of the peptides commented previously, cecropin A and melittin, were mixed in 
order to achieve higher activity against colistin-resistant A. baumannii strains. First of 
all mention that the same peptide cecropin A(1-7)melittin (2-9) (CA(1-7)M(2-9)) was 
tested in two different studies against multidrug-resistance A. baumannii and colistin-
resistance A. baumannii, and is curious that the best results were obtained (MIC50 2 
mg/L, MIC90 4 mg/L)(130) when tested against colistin-resistant bacteria, compared to 
the multidrug-resistant strains (MIC50  4 mg/L, MIC90 12 mg/L) (131). Several versions 
of this hybrid peptide were tested against colistin-resistant A. baumannii strains, the 
results were indentical for all the analogs (MIC50 4 mg/L, MIC90 8 mg/L), the analogues 
were CA(1-8)M(1-18), CA(1-7)M(5-9) and Oct-CA(1-7)M(2-9) (132). 
The original hybrid CA(1-7)M(2-9) was also improved in terms of selectivity and 
stability by methylating the lysines present in the peptide, however the in vitro activity 
decreased (125). The method of mixing two or more chimeric parts of natural 
antimicrobial peptides is done also in the article published by Gopal et al. (133), they 
synthesize hybrid peptides mixing cecropin A (CA) and melittin (ME), as the same 
strategy as commented previously but adding also the N-terminal region of the 
Helicobacter pylori ribosomal protein L1 (HP) (134), and magainin II (MA). The four 
hybrid peptides HP(2-9)-ME(1-12), HP(2-9)-MA(1-12), CA(1-8)-ME(1-12) and CA(1-
8)-MA(1-12), have a MIC slightly higher compared to polymyxin but better than some 
antibiotics, which the strains tested are resistant to (133). The source where 
antimicrobial peptides can be found is very diverse, they can be isolated from frog skin 
secretions. A peptide obtained from there with moderate activity against A. baumannii 
has been found. They tried to improve it by changing some residues but they did not 
success, just similar values but with less hemolytic activity (135). Other antimicrobial 
peptides such as hymenochirin-1B can be found in frog skin secretions as well. It has a 
good activity against multidrug-resistant A. baumannii (136). Frog skin seems to be 
really good source for the isolation of active peptides against A. baumannii, as well as 
other peptides which have not been tested against this microorganism (137,138). 
Another natural source of antimicrobial peptides is the venom of the Australian 
scorpion in which several antimicrobial peptides with an interesting activity against A. 
baumannii has been found (139). 
There are other natural sources which could lead to an interesting hit when a good 
optimization is done, for instance, apidaecin, a peptide isolated from honeybee. The 
activity of the original compound was optimized and it led to an antimicrobial peptide 
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apidaecin 88 (Api88) with good activity in vitro against several multidrug-resistant 
bacteria. It was also tested in vivo against E. coli, observing good activity when dealing 
with systemic infections (140). Even though if it was active in vivo, the half-life time 
was really low, therefore the sequence of Api88 was optimized in order to obtain a more 
stable peptide, leading to apidaecin 137 (Api137), which should a better compound in 
vivo compared to Api88 (141).  
 
5.1.2. Synthetic Antimicrobial peptides 
 
Some other peptides active against A. baumannii did not have any relationship with 
natural sources, they are fully synthetic, this is the case of the two peptides which only 
contains leucines and lysines (LKLLKKLLKKLLKLL), one with all L-amino acids and 
the other one with 33% of D- amino acids (3Lys, 7Lys, 8Leu, 10Lys, 13Leu). The peptide 
containing D-residues has a better activity (5.6 mg/L) compared to the peptide with just 
L-amino acids (11.2 mg/L), it was also more stable to hemolysis, at 180 mg/L goes 
from 0 to 100% (142). In the work performed by Huang Y et al. (143) also two peptides 
with Leucines and Lysines were synthesized, but in this case they also have one or two 
cystein that are funcionalized. C(LLKK)2C had a MIC50 and MIC90 of 50 and 75 mg/L 
respectively, meanwhile for the other peptide, (LLKK)2C, the values were MIC50 30 
mg/L and MIC90 40 mg/L. If the values of these peptides are compared with the other 
values commented previously it is possible to observe that this values are significantly 
higher, however they have a really low toxicity in vivo with a lethal dose of 173 and 
192.4 mg/Kg for C(LLKK)2C and (LLKK)2C, respectively. This low toxicity allows to 
obtain the ED50, which the effective dose that keep alive the 50% of the mice, this ED50 
is 5,05 and 6,75 for C(LLKK)2C and (LLKK)2C, respectively, which is not so common 
when working with AMPs (143). 
Another peptide which was a synthetic hybrid was the one synthesized by the group of 
Pini (144), their idea was to use dendrimers, in this case tetrabranched with a lysine 
core, and in each branch to have the active peptide which was the KKIRVRLSA, both 
L- and D- amino acids were synthesized but D-version was more active and more 
stable. The MIC of M33 (D-amino acids) for A. baumannii was 1.5-3 µM, more or less 
at the same level as polymyxin B. The mechanism of action of this dendrimer was to 
neutralize the LPS, that as has previously been commented is one of the virulence 
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factors of A. baumannii. It had a good activity in vivo against E. coli  and P. aeruginosa 
(144). 
 
5.2. New polymyxins. 
 
As we have commented previously, polymyxins are the last option in the treatment of 
carbapanem-resistance A. baumannii infections. Another method to find out new 
antibiotics is by modifying the original polymyxin. Several groups have been working 
in the development of new polymyxins. The strategy followed to synthesize these new 
polymyxins could be different, due to the uncomplete understanding of the mechanism 
of action. The group from the Monash University (Australia) suggested that the problem 
of resistance to polymyxins could be overcome by introducing new hydrophobic groups 
in the positions 6 and 7, and in the fatty acyl tail. The groups introduced were 
octylglycine, bipheylalanine, O-Benzyltyrosine, S-Benzylcysteine, S-Hexylcysteine. It 
is important to mention that they kept the same stereochemistry of the original 
compound, which is D-amino acid for the residue in the position 6 and L- amino acid 
for the position 7, L-Ala and L-Phe were also introduced. If the results with polymyxin 
B and colistin are compared, it is possible to observe the same behaviours when the 
strain has lower (0.5-1 mg/L) and higher MICs (16 and 128 mg/L) of polymyxins, the 
MICs of the analogues were between 1 and 32 mg/L for both type of strains (145). The 
pharmaceutical company Pfizer developed also new polymyxin analogues trying to 
improve the potency against A. baumannii, as well as reduce its toxicity, these 
analogues were obtained by changing in all of them the Dab in position 3 for a Dap 
(2,3-diaminopropionic acid), this was the scaffold they use in order to test different 
motifs in the position of the fatty acyl tail, most of them containing two aromatic rings, 
the most active compound was the one with a relatively polar 6-oxo-1-phenyl-1,6-
dsihydropyridine-3-carbonyl, this compound showed the same results as polymyxin B 
in polymyxin-susceptible strains, and better results in polymyxin-resistant A. baumannii 
strains, it showed also less renal cytotoxicity, however the efficacy of this new 
compound compared to polymyxin B in a murine neutropenic tight model of P. 
aeruginosa was worst (146). 
Another strategy, but in this case with worse results is the one followed by Vaara et al. 
(147), their analogs have just three positive charges only compared with the five that 
original polymyxins and the other analogs have, they remove the Dab next to the fatty 
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acyl chain, and they substitute the other Dab of the side chain by a D-serine, the fatty 
acyl chain remains as octanoyl. These changes removed all the positive charges in the 
side chain, however the results were not so promising, for polymyxin-susceptible 
strains, the MIC50 and MIC90 were 4 and 8 mg/L, respectively. These results were not so 
bad if they would have the same for the polymyxin-resistance, but this was not the case, 
the results for polymyxin-resistance were >64 mg/L for both MIC50 and MIC90 
compared to 32 and 64 mg/L, respectively for polymyxin B with the same strains (147). 
 
5.3. Novel therapies against A. baumannii 
 
There also are emerging therapies to treat infections caused by A. baumannii, that take 
another point of view completely different from normal antibiotics.  
 
-  Iron quelation. 
The siderophores are really important compounds for the survival of bacteria, therefore 
to inhibit their activity is an alternative of antibiotics or can even be a complement for 
the treatment with antibiotics. Several compounds such as deferoxamine, deferiprone, 
VK28, Ap6619 and 2,2 dipyridyl have been tested as iron quelators in order to inhibit A. 
baumannii growth (148,149). All of them present moderate values, observing some 
inhibition but not achieving the level of most of the compounds commented below. 
Another method used is to change the cation Ga3+ for the Fe3+ that bacteria need to 
survive, Ga3+ have the same valence, and similar atomic radius as Fe3+, this fact allows 
Ga3+ to compete against Fe2+, with the advantatge that it can not do the same processes 
as Fe3+. It is administered as the salt gallium nitrate, and it was has a good activity in 
vivo (galleria mellonela infection model) against multidrug-resistant A. baumannii 
(150). In the article published by Wencewicz and Miller (151), they found another 
application for the siderophores, they use it as drug a “Trojan horse”, in the way to use 
biscatecholate−monohydroxamate mixed ligand sideromycins as a drug delivery that 
allow the compound to cross all the biological barriers and go inside the bacteria. They 
use biscatecholate−monohydroxamate mixed ligand sideromycins plass a succinyl 
linker and different antibiotics already known, in this case they use quinolones and β-
lactams, the MICs using quinolones are very high, however when β-lactams are 
attached to this “Trojan horse” the results obtained against A.baumannii were extremely 
good with a MIC of 0.0078 µM (151). 
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-  Biofilm 
Another virulence factor is biofilm, therefore it is also a interesting target to beat A. 
baumannii. Some oroidin analogs, natural marine compound, have been synthesized, 
they have the common feature of having a 2-aminoimidazole ring, but this motif remain 
untouchable, just changing a substituent in the N-pyrrole group. The best compound of 
all the analogs is the one with 3-bromophenyl as N-substituent in N-pyrrole (152), the 
same group optimized the biofilm inhibitor activity of the original compounds, in this 
case the 2-aminoimidazole ring was disubstituied in position 4 and 5, they keep the 
same moiety in position 5 as found in the article published in 2008 (153) named (2-AIT) 
2-aminoimidazole–triazole conjugate. In all the analogs synthesized the most active 
were the ones that had a 3-propylphenyl, 3-flurorphenyl and a biphenyl group, obtaining 
IC50 values of 1.42, 1.39 and 1.43 µM, respectively (154).  
 
-  Phage therapy 
It is known that phages are virus able to infect and sometimes lysate the bacterial cells. 
The utility of phages as antimicrobial agents was known a long time ago, however due 
to the effectivity of the actual antibiotics no further development was done. Since a few 
years ago phages active against A. baumannii started to appear but they had a big 
problem which was the ability to infect, at the beginning the effectiveness of these 
phages, was really low less than 30% in multidrug-resistant strains (155,156), however 
the improvements on this field make achieve a 90% of effectiveness of the strains tested 
(157). Moreover some in vivo studies have been performed achieving good results 
(158). 
 
- Vaccines 
Nowadays, vaccines are a really hot topic and the study of them is increasing a lot. The 
creation of vaccines to deal with A. baumannii infections has an interesting point which 
is the nosocomial aspect of A. baumannii. Most of the vaccines currently in the market 
are devoted to microorganisms causing community-acquired infections, therefore it will 
be another approach of the vaccine development. Multidrug, extended-drug and pan-
drug-resistant A. baumannii cause mainly infections in immunocompromised patients in 
ICU, therefore its really interesting idea to perform a prophylactic vaccine against 
Acinetobacter. The first idea is to choose a highly conserved molecule in Acinetobacter 
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species in order to have a broader spectrum of action. The first prophylactic vaccine was 
targeting multiple antigens, and it had a good activity by proctecting mice to develop 
infections by pandrug-resistant strains (159). Other vaccines were done using outer 
membrane veiscles as antigens (160, 161). There is one may drawback of these vaccines 
and is the fact that most of them carry a high amount of LPS which is not good for 
humans. The vaccine created using the virulence factor ompA as the antigen was also 
active, protecting mice from disseminated sepsis (162). 
 
-  Photodynamic therapy 
Photodynamic therapy was developed long time ago, but it was used for other purposes 
like cancer or ophthalmology, however, due to the lack of antimicrobial agents, the 
research using these therapies has currently increased. The concept of this therapy is to 
generate a reactive oxygen, this oxygen will interact with some components of the 
bacteria such as DNA or membrane proteins that will lead to bacterial death. In order to 
generate this reactive oxygen, it is necessary to have, oxygen, light (visible or near 
infrared light) and a photosensitizer. The photosensitizer could be porphyrins, chlorins, 
pthalocyanines, xanthenes or phenotiazines, these compounds are commonly used due 
to its high singlet oxygen quantum yields. Some of these photosensitizers such as 
tetrapyrroles, deuteroporphyrin, Cd-texaphyrin, tetramethylpyridyl porphine, and propyl 
gallate are active against multidrug-resistant bacteria (163,164). Another option is to 
link a compound active against bacteria such as AMPs to the photosensitizer in order to 
help the oxygen, one example of this option is to attach the AMP (KLAKLAK)2 to the 
photosensitizer Eosin Y, it is demonstrated that they have a really good activity against 
both Gram-positive and Gram-negative bacteria and with low activity against human 
cells (165). 
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The general aim of this thesis is to contribute to the development and evaluation of the 
antibacterial activity of peptides and peptidomimetics against MDR-bacteria aswell as 
to the knowledge of the molecular bases of the resistance to colistinin A. nosocomialis 
and resistance to daptomycin in S .mitis. 
 
One strategy to design new antibacterial agents is based on the mechanism of resistance 
in order to develop derivatives of the known antibacterial agents which circunvents 
these resistant mechanism. We have mainly focused on A .baumannii since multi-, 
extended- and pan-drug resistant strains have been descrived, therefore there is a need 
of new therapeutic alternatives  
 
Specific objectives: 
1. Elucidation of the mechanism of resistance of S. mitis to daptomycin using a 
proteomic approach. 
 
2. Generation of A. nosocomialis colistin-resistant strains, and complete analysis of 
these mutants using genomic and proteomic approaches. 
 
3. Screening of lineal peptides against colistin-susceptible and colistin-resistance A. 
baumannii strains, and optimization of the best candidates. 
 
4. In vivo studies of the best candidates against pandrug-resistance A. baumannii strains. 
 
5. Test several frog skin secretion peptides against colistin-susceptible and colistin-
resistance Acinetobacter species. 
 
6. Investigate the activity of several peptidomimetics (ceragenins) against colistin-
susceptible and colistin-resistance A. baumannii, K. pneumoniae and P. aeruginosa. 
 
7. In silico design and synthesis of a library of cyclic hexapeptides able to bind ompA. 
 
8. In vitro and in vivo (mice) studies of the antivirulence activity of the above cyclic 
hexapeptides. 
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Context. 
 
Daptomycin is one of the last antibiotics released, and it is used to treat several 
infections such as those caused by both methicillin-susceptible and -resistant S. aureus, 
vancomycin-susceptible and -resistant Enterococcus, coagulase-negative 
Staphylococcus, and streptococci. Up to today only resistance to S. aureus and 
Enterococcus have been reported. As it is known daptomycin’s target is the cell 
membrane or cell wall, therefore the main mechanisms of resistance to daptomycin are 
associated with that. In previous studies performed by the group of Dr. Miró, it was 
found that when comparing the efficacy of vancomycin (30 mg/Kg in two doses) and 
daptomycin (6 mg/Kg in one dose) for endocarditis caused by S. mitis, the strains 
recovered from the vegetations after 2 days of treatment had a high-level of daptomycin 
resistance (MIC>256 mg/L). Taking into account these results, the main idea was to 
know if that tendency of acquiring resistance was the same for all the viridans 
streptococci group. All the strains from the viridans groups were incubated with 0.5 and 
1 mg/L of daptomycin, and after 48h the strains were subcultured on blood agar and the 
MIC experiments were performed in order to observe the new MIC, the results are 
showed in the table 1.1 
 
 
 
 
Table 1.1. Rates of selection of resistance and high-level resistance after exposure to daptomycin. (9) 
 
Daptomycin non-susceptibility strains were indentified from mitis group in 61 cases 
(66%) and 5 (50%) from the anginosus group, the global amount of daptomycin non-
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susceptible isolates were 39% (66/168). The highest rates of resistance were observed in 
mitis group: 74/92 (80%) were resistant, 61/74 (82%) were daptomycin non susceptible, 
and 25/61 (41%) developed high level of daptomycin resistant. 
Some in vivo studies with rabbits were also performed. Rabbits were infected with S. 
mitis, causing endocarditis. Two types of dosing were used recommended dose (RD, 
6mg/kg iv once daily) and high dose (HD, 10 mg/kg iv once daily) for daptomycin and 
the previous dose commented for vancomycin. The results are showed in table 1.2 
 
 
 
Table 1.2. Treatment of experimental endocarditis caused by S. mitis 351 strain. (9) 
 
Results obtained using both types of dosing were the same. When daptomycin and 
vancomycin were compared, the effectiveness of the last one is higher, observing 3.4 
log CFU/g vegetation, whereas for daptomycin was between 6 and 7 log CFU/g. 
Moreover, between 60 and 70 % of the vegetations recovered presented high level of 
daptomycin resistant. 
With the scenario commented previously and with the idea that it was the first time that 
daptomycin resistant against S. mitis was reported, we though it would a good idea to 
study the mechanism of resistance. 
 
1.1. Cell wall thickness in daptomycin resistant S. mitis. 
 
The mechanisms of resistance to daptomycin might be associated with the cell wall or 
the cell membrane, in fact previous mechanisms of resistance to daptomycin reported in 
S. aureus and Enterococcus faecium reinforce this hypothesis, therefore the first thing 
was to find out if there was an increase of the thickness of the cell wall that did not 
allow daptomycin to disrupt or to permeabilize the membrane of this Gram-positive 
bacteria.  
The technique used to calculate the cell wall thickness was transmission electron 
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microscopy (TEM). Figure 1.1. Following the procedures developed in the manuscript 
published by Yang et al. (166), 100 cell wall thickness measurements were taken from a 
minimum of 50 cells at X190,000 magnification. The results obtained of these 
measurements are showed in Table 1.3 and the images of the cells in Figure 1.1 
 
a) D6-7     b) D6-14 
            
c) 351     d) D6-2 
            
Figure 1.1. TEM images of S. mitis. a), b) and d) are daptomycin-resistant S. mitis; c) is a daptomycin-
susceptible S. mitis strain.. 
 
Strains 
Membrane thickness 
(nm) 
MIC to daptomycin 
(mg/L) 
351 20.03±1.47 0.38 
D6-2 25.21±2.05 >256 
D6-7 22.35±2.84 >256 
D6-14 24.44±2.56 >256 
 
Table 1.3. Membrane thickness and MIC to daptomycin to different S. mitis strains. 
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The differences in the thickness of the cell wall in all the strains measured (1 
daptomycin-susceptible and 3 daptomycin-resistant) were not statistically significant 
using ANOVA and Dunnet tests. The cell wall thickness of the daptomycin-susceptible 
strain was 20.03±1.47 nm, and the rest of strains, daptomycin-resistant, were 
22.35±2.84 nm, 24.44±2.56 nm and 25.21±2.05 nm (Table 1.3). 
1.2. Comparative proteomics of daptomycin-susceptible and 
daptomycin-resistant S. mitis strains. 
 
Two different approaches can be used in order to have an initial idea about which are 
the proteins or the genes involved in a mechanism of action, these two approaches are 
proteomics and genomics. Both approaches could be complementary but we decided to 
start by using the proteomic approach.  
Whole-cell proteins of daptomycin-susceptible (strain 351), and daptomycin-resistant 
(strain D6-14) S. mitis strains were extracted following the procedure described in the 
materials and methods Section. Three different experiments with the abovementioned 
extracts were carried out. Isobaric tag for relative and absolute quantitation (iTRAQ) 
was performed, thus we had methodological triplicates. The iTRAQ experiment is based 
on the covalent labeling of the N-terminus and side chain amines of peptides from 
protein digestions with tags of varying mass. There are currently two reagents mainly 
used: 4-plex and 8-plex, which can be used to label all peptides from different 
samples/treatments. These samples are then pooled and usually fractionated by nano 
liquid chromatography and analyzed by tandem mass spectrometry (MS/MS). A 
database search is then performed using the fragmentation data to identify the labelled 
peptides and hence the corresponding proteins. The fragmentation of the attached tag 
generates a low molecular mass reporter ion that can be used to relatively quantify the 
peptides and the proteins from which they originated. 
The proteins which have a significantly difference of expression are showed in the table 
1.4 and table 1.5 
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NCBI GenInfo 
Identifier 
Replicates for 
quantitation 
Replicates % 
p<0.05 
Protein ratio (Fold change)  
Dapto R/Dapto S 
    
gi|77409507| 1 100,0 0,24 
gi|419780699| 3 33,3 0,30 
gi|15900151| 1 100,0 0,36 
gi|15900549| 1 100,0 0,55 
gi|293364197| 1 100,0 0,62 
gi|417793472| 1 100,0 0,64 
gi|306825386| 1 100,0 0,65 
gi|293365248| 1 100,0 0,65 
gi|315612275| 1 100,0 0,69 
gi|322376983| 2 100,0 0,72 
gi|293364663| 2 100,0 0,73 
gi|406576657| 1 100,0 0,74 
gi|293365311| 1 100,0 1,19 
gi|293364514| 3 33,3 1,22 
gi|289168021| 2 50,0 1,27 
gi|270292667| 1 100,0 1,29 
gi|293364272| 3 66,7 1,33 
gi|194396827| 2 50,0 1,36 
gi|315611998| 1 100,0 1,36 
gi|331266333| 1 100,0 1,48 
gi|419781125| 1 100,0 1,50 
gi|293365494| 3 66,7 1,59 
gi|306830250| 2 100,0 2,26 
 
Table 1.4. Proteins identified by iTRAQ which have different expression rate. 
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NCBI GenInfo 
Identifier 
Protein description 
     
gi|77409507| NADP-specific glutamate dehydrogenase [Streptococcus agalactiae COH1]  
gi|419780699| PF08006 family protein [Streptococcus oralis SK100]   
gi|15900151| 30S ribosomal protein S3 [Streptococcus pneumoniae TIGR4]  
gi|15900549| PTS system transporter subunit IIB [Streptococcus pneumoniae TIGR4]  
gi|293364197| glutamate--ammonia ligase [Streptococcus oralis ATCC 35037]  
gi|417793472| ABC transporter, ATP-binding protein, partial [Streptococcus oralis SK255]  
gi|306825386| peptidyl-prolyl cis-trans isomerase [Streptococcus sp. oral taxon 071 str. 73H25AP]  
gi|293365248| peptidyl-prolyl cis-trans isomerase [Streptococcus oralis ATCC 35037]  
gi|315612275| ABC superfamily ATP binding cassette transporter, binding protein [Streptococcus sanguinis ATCC 49296]  
gi|322376983| hypothetical protein HMPREF0851_00776 [Streptococcus sp. M334]  
gi|293364663| PTS family maltose and glucose porter, IIABC component [Streptococcus oralis ATCC 35037]  
gi|406576657| peptidyl-prolyl cis-trans isomerase [Streptococcus sp. GMD6S]  
gi|293365311| 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase [Streptococcus oralis ATCC 35037]  
gi|293364514| serine protease HtrA [Streptococcus oralis ATCC 35037]  
gi|289168021| phosphotransacetylase [Streptococcus mitis B6]   
gi|270292667| putative PTS system, IIC component [Streptococcus sp. M143]  
gi|293364272| conserved hypothetical protein [Streptococcus oralis ATCC 35037]  
gi|194396827| L-lactate oxidase [Streptococcus pneumoniae G54]   
gi|315611998| group B streptococcal surface immunogenic protein [Streptococcus sanguinis ATCC 49296]  
gi|331266333| glycogen biosynthesis protein,glucose-1-phosphate adenylyltransferase [Streptococcus oralis Uo5]  
gi|419781125| pyruvate oxidase [Streptococcus oralis SK100]   
gi|293365494| glucose-1-phosphate adenylyltransferase [Streptococcus oralis ATCC 35037]  
gi|306830250| group B streptococcal surface immunogenic protein [Streptococcus mitis ATCC 6249]  
 
Table 1.5. Proteins description of the proteins identified by iTRAQ which have different expression rate. 
 
Taking into account that the mechanism of action of daptomycin is associated with the 
membrane, the initial idea would be to search for proteins related to membrane 
compounds or metabolites involved in the membrane synthesis in the iTRAQ. 
 
Two proteins fulfill the requirements, both proteins were overexpressed in the 
daptomycin-resistant S. mitis strain. The protein group B streptococcal surface 
immunogenic protein, is overexpressed 2.26 fold. Moreover, this protein have also been 
found belonging to Streptococcus sanguinis. The protein group B streptococcal surface 
immunogenic protein was quantified twice from the three replicates, and all of the 
quantifications were significantly different. The second interesting protein was, 
conserved hypothetical protein found in Streptococcus oralis, this protein was found in 
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all the three replicates performed and in two of the three replicates was significantly 
different, and over expressed 1.33 fold.  
  
1.3. Development of mutants with a knockout in the interesting genes. 
 
The information acquired in the iTRAQ is interesting but other experiments need to be 
performed in order to check that these two proteins are really the ones involved in the 
daptomycin resistant. One of the options to prove that these proteins are important is to 
truncate their genes and check out that the MIC of daptomycin in the generated mutant 
is different.   
Two knockouts were tried, one with each gene mentioned above, the constructions of 
the plasmid with the truncated genes were built perfectly and it was confirmed by PCR, 
however the transformation of these plasmids into S. mitis did not worked. Further 
experiments to obtain a S. mitis transformant with the recombinant plasmid will be 
performed in the future. 
 
In summary, from the work in this chapter we can conclude that daptomycin resistance 
did not imply an increase in the thickness of the cell wall. Using proteomic techniques, 
several proteins with a different rate of expression, comparing daptomycin-resistant 
and daptomycin-susceptible S. mitis, have been identified. We have the hypothesis, 
based on the mechanism of daptomycin resistance reported in other microorganisms, 
that two of them are involved in daptomycin resistance. However until the knockout of 
the genes enconding these proteins will not be completed its role in the resistance 
remains a working hypothesis. 
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Context. 
 
As commented in the introduction, among the different species of the Acinetobacter 
genus, A. baumannii is the most frequently reported as a cause of nosocomial infections. 
However the number of non-baumannii isolates have been increasing during the last 
years (167), being A. nosocomialis (previously named Acinetobacter genospecies 13) 
and A. pittii (previously named Acinetobacter genospecies 3) the most important species 
apart from A. baumannii. It is not easy to differentiate phenotypically these three 
species which constitute the A. baumannii group (A. baumannii, A. nosocomialis and A. 
pittii), therefore and due to the increase of non-baumannii strains isolated, the 
techniques of identifying each species have been improved (168) and updated with new 
techniques such as MALDI-TOF (169). Indeed, the treatment used to fight against the 
new Acinetobacter species is controversial (170,171). 
Although A. nosocomialis is a relatively new specie some resistance to several 
antibiotics have been published such as the acquisition of the blaOXA-23 (172) and 
blaOXA-51 genes (173) which confer resistance to carbapenems, or the famous blaNDM 
gene, encoding a metallo-beta-lactamase, which makes the bacteria highly resistance to 
all β-lactam antibiotics but aztreonam (174). Most of the NDM-producing 
Acinetobacter sp. strains carried other mechanisms of resistance conferring XDR, thus 
being resistance to all antimicrobial agents except tigecycline and colistin (polymyxin). 
Until now, no colistin resistance has been reported for A. nosocomialis, therefore it will 
be interesting to know if the mechanisms of resistance of this bacteria are similar to A. 
baumannii reported.  
 
2.1. Selection of colistin-resistant A. nosocomialis mutants. 
 
No colistin-resistant A. nosocomialis strains have been isolated but, following the 
tendency of the past years seen in A. baumannii and taking into consideration the 
increased used of colistin to treat infections caused by MDR K. pneumoniae, P. 
aeruginosa and A.baumannii, some resistant strains will be isolated in the near future. 
As we did not have this colistin-resistant A. nosocomialis strains we decided to generate 
these mutants. The same procedure was done for ATCC 19606 A. baumannii, and 2 
clinical strains, one A. pittii and one A. nosocomialis, however we are just going to 
focus in A. nosocomialis.  
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The strains used were subjected to serial passages on plates with increasing 
concentrations of colistin. The selected A. nosocomialis wild-type strain had an initial 
MIC < 1 mg/L. During the mutant production, there was an inflection point (16 mg/L of 
colistin in the plate for selection) where the strain showed a drastic change in the MIC 
of colistin (from < 1mg/L to 128 mg/L). The strains isolated previous to this inflection 
point tolerate up to 8 mg/L of colistin. Other characteristics seen in this high colistin-
resistant mutant compared to the wild type strain were that the mutant had a change in 
colony morphology with tiny colonies observed and it did not grow on MacConkey 
agar. The strains, recovered after the initial passages on plates with colistin, were 
tolerant to this antibiotic (up to 8 mg/L of colistin) since they grew on increasing 
concentrations of this antibiotic but their initial MIC was not modified. At a given point, 
two different morphologies were observed which corresponded to a colistin-susceptible 
and a colistin-resistant strains (Fig 2.1). After this inflection point, the strains were not 
able to grow on selective MacConkey media and the MIC for the resistant strain went 
up to ≥ 128 mg/L (Table 2.1). To our knowledge, this is the first description of a 
colistin-resistant mutant with a decreased ability to grow on MacConkey selective 
medium.  
 
STRAINS COLISTIN IN MIC (mg/L) 
GROWTH   
ON 
  PLATE*(mg/L)   McConkey 
 0 ≤1 YES 
 0.25 ≤1 YES 
 0.5 ≤1 YES 
 1 ≤1 YES 
 2 ≤1 YES 
Acinetobacter 4 ≤1 YES 
nosocomialis 8 ≤1 YES 
 16 128 NO 
 32 128 NO 
 64 256 NO 
 128 512 NO 
  256 512 NO 
 
Table 2.1. MIC of colistin and growth on McConkey plates for the Acinetobacter nosocomialis. 
* Colistin in plate represents the colistin concentration used in the agar plate to select for colistin 
resistance. 
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Figure 2.1 Morphological changes observed when the Acinetobacter nosocomialis clinical isolate became 
resistant to colistin. Before becoming resistant to colistin the wild-type strain grew in all the plates. 
Afterwards, the resistant mutant did not grow on McConkey media.  
 
2.2. Antimicrobial resistance profiles of the generated mutants. 
 
The mutants generated were colistin-resistant but it is important to know if they also 
showed changes in the MIC of other types of antibiotics. In table 2.2, the MIC of 
different strains against different antimicrobial agents is showed. 
 
 
MIC (mg/L)      Antimicrobial  Agents           
COLISTIN IN FX VA AZ CI TM IP TZ ETP CO 
PLATE(mg/L)                 
0,125 24 64 0,38 0,125 0,38 0,5 2 3 ≤1 
2 24 64 0,38 0,125 0,38 0,5 2 3 ≤1 
8 24 64 0,38 0,125 0,38 0,5 2 3 ≤1 
16 1.5 0,75 0,047 0,064 0,19 0,064 0,75 0,016 128 
32 1,5 0,75 0,047 0,064 0,19 0,064 0,75 0,016 128 
512 1,5 0,75 0,047 0,064 0,19 0,064 0,75 0,016 512 
FX (cefoxitime) VA (vancomycin) AZ (azitromicin) CI (ciprofloxacin) TM (tobramycin) IP (imipenem) 
TZ (ceftazidime) ETP (ertapenem) CO (colistin) 
 
Table 2.2. MIC of differensts strains generated against several antibiotics. 
 
 
In the table 2.2 is it possible to observe that the mutants generated with resistance to 
colistin had lower MICs for most of the antibiomicrobial agents tested. For 
ciprofloxacin and tobramycin the MIC just decreased one dilution and for ceftazidime 
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slightly more, however for the rest of the antibitoics the number of dilutions that the 
MIC decreases is higher, like the case of cefoxitime and vancomycin, that the MIC went 
from 24 mg/L to 1.5 mg/L and from 64 mg/L to 0.75 mg/L, respectively. For the 
carbapenems, imipenem and ertapenem, the decreases were from 0.5 mg/L to 0.064 
mg/L and 3 mg/L to 0.016 mg/L, respectively. The MIC of azitromycin for the colistin-
resistant mutants decreased four dilutions respect to the initial strain. 
 
2.3. In vivo virulence using the C. elegans model. 
 
It was demonstrated that the new strains generated are highly resistant to colistin, 
however their ability to be resistant to the other antibiotic families decreases 
dramatically. One important factor apart from the resistance profile of the new strains is 
their ability to cause virulence, this ability sometimes is even more important than the 
resistant profile, therefore some experiments to test the virulence of the new strains 
were performed. 
In collaboration with Dr. Paula Espinal some experiments using Caenorhabditis elegans 
were performed. These experiments allow us to investigate the virulence of the strains 
selected. The results are showed in Figure 2. 2. 
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A. nosocomialis 0.125 vs A. nosocomialis 512: p<0.0001 
E. coli vs A. nosocomialis 0.125: p<0.0001 
E. coli vs A. nosocomialis 512: p=0.1647 
 
Figure 2.2. Percentatge of survival after the infection in three different strains. (red E. coli as a control) 
(Blue A. nosocomialis colistin-susceptible) (Orange A. nosocomialis colistin-resistant) 
 
 
The figure 2.2 showed a significantly different virulence of both strains being more 
virulent the initial strain colistin-susceptible compared to the colistin-resistant. The LT50 
for the colistin-susceptible (blue line) is 7 days compared to the 9 days for the colistin-
resistant (orange line). For the control strain of E. coli the LT50 is 11 days which is 
showed in the green line. 
 
2.4. Sequence of the genome of the colistin-susceptible and colistin-
resistant A. nosocomialis strains. 
 
This part was done in collaboration with the Prof. Marc Rolain (University of Marseille, 
Marseille, France). The genomes of these two strains were sequenced and analyzed 
following the methodology described in the Material and Methods Section. The initial 
strain colistin-susceptible and the colistin-resistant mutant (512) A. nosocomialis were 
sequenced. On comparing the two sequences of the genomes of both strains several 
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differences were observed in those genes potentially related to colistin resistance and 
which have been previously reported in A. baumannii. 
 
- The pmrABC operon. 
The pmrABC operon encodes two component regulatory system (genes pmrA and 
pmrB) that regulates the expression of the pmrC gene which encodes a 
phosphoethanolamine transferase enzyme involved in lipid A modification. 
 
 
 
Figure 2.3. Comparative analysis of pmrA protein in colistin-resistant and colistin-susceptible A. 
nosocomialis and A. baumannii. 
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Figure 2.4. Comparative analysis of pmrB protein in colistin-resistant and colistin-susceptible A. 
nosocomialis and A. baumannii. 
 
No mutations were found in any of the three genes that conformed pmrAB, however 
several mutations and deletions are observed when comparing with A. nosocomialis and 
A. baumannii. 
 
- The lpxACD operon. 
 
The LpxACD operon is constituted by genes involved in the synthesis of lipid A, which 
is one of the parts of the LPS, which its modification is involved in the resistance to 
colistin. The biosynthetic pathway of the synthesis of lipid A, in which the proteins 
lpxACD are involved, is observed in the Figure 2.5. 
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Figure 2.5. Biosynthetic pathway of the synthesis of lipid A. 
 
Several mutations, deletions or insertions have been reported for A. baumannii .The 
three genes were analyzed in both strains sequenced and the results are showed in  
figure 2.6 for lpxA, figure 2.7 for lpxC and figure 2.8 for lpxD. 
 
Figure 2.6. Comparative lpxA protein from colistin-susceptible and colistin-resistant A. nosocomialis. Col 
S (Colsitin susceptible). ColR (Colistin resistant) 
 
 
Figure 2.7. Comparative lpxC protein from colistin-susceptible and colistin-resistant A. nosocomialis. Col 
S (Colsitin susceptible). ColR (Colistin resistant) 
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Figure 2.8. Comparative lpxD protein from colistin-susceptible and colistin-resistant A. nosocomialis. Col 
S (Colsitin susceptible). ColR (Colistin resistant) 
 
Figures 2.6, 2.7 and 2.8 show the amino acid sequences of the lpxA, lpxC and lpxD 
proteins of the wild-type and the colistin-resistant A. nosocomialis mutant, and several 
mutations have been observed in all the three genes, but it is important to highlight the 
stop codon present in lpxD. 
Next step was to know if the mutations and the stop codon were associated with colistin 
resistance, therefore PCRs to amplify the all the lpxACD genes of the different colistin-
tolerant and resistant A. nosocomialis mutants were performed, these mutants covered 
before and after the inflection point.  
 
The PCR products confirmed that all the wild-type strains (0.125/2/8) showed the same 
sequence, and the same sequence was also observed in all the colistin-tolerant strains 
(16/32/512).  
 
2.5. LPS production of the wild-type and mutants A. nosocomialis 
strains. 
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In previous assays it was observed the stop codon present in the lpxD gene, the 
hypothesis is that this stop codon together with other mutations in the lpxAC genes, did 
not allow the bacteria to form the LPS and the strain did not have LPS in their 
membrane, therefore, the amount of LPS present in two colistin-susceptible A. 
nosocomialis and two colistin-resistant A. nosocomialis strains was calculated. The 
method used is a commercial kit that allow us to calculate the amount of LPS or 
endotoxin present in the bacteria. The results are showed in table Z.6 
 
 
A. nosocomialis strains LPS (EU/mL) 
0.125 1.74 x 105 
2 6.24 x 104 
16 59.9 
512 143 
 
Table. 2.3. Concentration of LPS in four different strains of A. nosocomialis. 
 
 
 
2.6. Proteomic approach of the different strains generated. 
 
This work was done in collaboration with Dr. Mario Ferrer-Navarro. 
After the genomic approach, proteomic studies were performed in order to know if there 
were potential proteins involved in the mechanism of resistance of colistin to A. 
nosocomialis. 
 
Comparative studies of the most susceptible and resistant strain of A. nosocomialis, 
were performed using DIGE experiments with the OMPs of the two strains. Prior to 
perform the DIGE experiments, one-dimensional SDS-PAGE experiments as an initial 
approach were performed in order to have an initial idea about the expression of the 
proteins. The results of the SDS-PAGE are showed in the Figure 2.9. 
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Figure 2.9. SDS-PAGE of six of the generated mutants. Each column is named by the amount of colistin 
used when the mutants were generated. 
 
In the Figure 2.9 the OMP profiles of the colistin-susceptible strains (0.125/2/8) and the 
colistin-resistant strains (16/32/512) are presented. Due to the high amount of proteins 
present in the one-dimensional SDS-PAGE it was difficult to affirm which proteins 
were overexpressed or repressed, therefore 2D electrophoresis were carried out in order 
to observe better differences between the proteins expressed in the different strains. 
Next step was to use the 2D electrophoresis technique for the same strains used for the 
one-dimensional SDS-PAGE. Figure 2.10. 
 
 
0,125    2        8       16     32     512 
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Figure 2.10. 2D electrophoresis gel of six Acinetobacter nosocomialis strains. Three colistin-susceptible 
(0.125/2/8) and three colistin-resistant (16/32/512). 
 
 
     0,125                      2 
         8                     16 
         32                    512 
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Some differences between the outer-membrane protein expression in colistin- 
susceptible and colistin-resistant strains were observed. However with 2D 
electrophoresis is not possible to have a real quantification of the expression of the 
proteins, therefore DIGE experiments taking the initial strain (0.125) and the most 
resistant (512) were performed. The results are showed in Figure 2.11, and the proteins 
identified in the table 2.4. 
 
Figure 2.11. 2D electrophoresis resultant from the DIGE gel. The numbers show the proteins that have a 
different expression between 0.125 and 512 strains. 
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*Positive values indicate an increased presence in the resistant strain. Negative values indicate a 
decreased presence in the resistant strain. 
 
Table. 2.4. Proteins identified by DIGE with a significative expression level.  
. 
Eleven different proteins were identified with different expression rates, just two 
proteins were down-regulated in the resistant strains, these two proteins were OprB with 
-1.9 fold, and a signal peptide protein with -1.2 fold protein, the rest of the proteins 
found were overexpressed in the colistin-resistant A. nosocomialis strain. The role of 
ompA has been commented previously, and the resistant strain has 2 fold the protein 
overexpressed compared with the wild-type. Another outer membrane protein, OmpW, 
it is up-regulated 1.4 fold. Several efflux systems together with some unknown proteins 
are overexpressed in the resistant strain. 
 
 
 
 
 
 
 
 
Spot 
number Protein id Protein 
Fold 
change* 
Anova 
P-value 
1 gi|407441282 OmpA_C-like 1.3 0.0239 
2 gi|490848590 hypothetical protein F984_02367 (NodT family 
RND efflux system) 
2.1 0.00911 
3 gi|497190250 hypothetical protein (tetratricopeptide repeat 
family protein) 
1.5 0.0167 
4 gi|593656836 
 
putative carbapenem-associated resistance protein  
(CarO) 
1.7 0.00914 
5 gi|446899273 OmpW-like protein 1.4 0.0274 
6 gi|354459714 OmpA (Isoform) 2 0.0233 
7 gi|487978330 succinate dehydrogenase flavoprotein subunit 1.7 0.000768 
8 gi|487978520 Porin (OprB) Carbohydrate-selective porin -1.9 0.00533 
9 gi|493628869 membrane protein (outer membrane beta-barrel 
domain protein) 
1.4 0.0774 
10 gi|487981035 signal peptide protein -1.2 0.0237 
11 gi|587819016 putative porin 1.1 0.0613 
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In summary we can conclude that the colistin-resistant A. nosocomialis mutants 
generated by step-wise method had a certain rate of colistin-tolerance during the first 
steps, and an inflection point was observed, becoming highly resistant. The A. 
nosocomialis with high level of colistin resistance lost the virulence and showed an 
increase susceptibility top other antimicrobial agents. The resistance to colistin is 
mainly due to mutations and a stop codon in lpxD, that lead to a complete loss of the 
LPS. The down and up-regulation of outer membrane proteins could be related to both 
colistin-resistant or the decrease in the MIC of several antibiotics as previously 
commented. 
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Context. 
 
There is an urgent need of new antibiotics, especially against the ESKAPE group of 
bacteria. In particular we are going to focus mainly in Acinetobacter species, that 
together with K. pneumoniae and P. aeruginosa are the only bacteria isolated from 
patients resistant to colistin, that as commented previously, is the last option to treat 
infections caused by strains with a high resistance profile. 
 
There are not many works published in the literature about active compounds against 
colistin-resistant strains. In fact, there is a real need of new active compounds that could 
substitute, or be used at the same time as colistin or polymyxin B. 
 
In this chapter of the thesis we have tackled the search of new antimicrobials by using 
compounds from different sources, some of them natural compounds, others optimized 
natural compounds and some others fully synthetic. 
 
3.1. Active peptides against colistin-resistant Acinetobacter species 
 
3.1.1. Screening of antimicrobial peptides against colistin-susceptible and colistin-
resistant A. baumannii strains 
 
Some years ago, and due to the difficulty to have access to Acinetobacter strains 
resistant to colistin, (there were just a few worldwide), some Acinetobacter colistin 
mutants were generated using a multi-step method in the laboratory of Prof. Vila. 
Mutants for Acinetobacter baumannii, Acinetobacter pitti and Acinetobacter 
nosocomialis were generated as explained before. (Chapter 2.1) 
The main purpose of this study was to perform an initial screening of peptides already 
known, but never tested before against colistin-resistant A. baumannii strains, in order 
to obtain a hit to be optimized. 
Some commercially available peptides (Table 3.1) were tested against both colistin-
resistant and colistin-susceptible A. baumannii strains, the results are shown in Table 
3.2.  
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Name Sequence  Source  Structure 
Mastoparan INLKALAALAKKIL Vespula lewisii Helix 
Indolicidin ILPWKWPWWPWRR Bovine neutrophils Extended 
Melittin GIGAVLKVLTTGLPALISWIKRK
RQQ 
Honeybee venom Helix 
Cecropin B KWKIFKKIEKVGRNIRNGIIKAGP
AVAVLGEAKAL 
Chinsese oak silk mouth Unknown 
Cecropin A KWKLFKKIEKVGQNIRDGIIKAG
PAVAVVGQATQIAK 
Hyalophora cecropia Helix 
Cecropin P1 SWLSKTAKKLENSAKKRISEGIAI
AIQGGPR 
Sus scrofa Helix 
Magainin II GIGKFLHSAKKFGKAFVGEIMNS Xenopus laevis Helix 
Magainin I GIGKFLHSAGKFGKAFVGEIMKS Xenopus laevis Helix 
β-Defensin DHYNCVSSGGQCLYSACPIFTKI
QGTCYRGKAKCCK 
Homo sapiens 3 (S-S) 
Buforin I AGRGKQGGKVRAKAKTRSSRAG
LQFPVGRVHRLLRKGNY 
Bufo bufo gargarizans Helix 
HNP-1 ACYCRIPACIAGERRYGTCIYQG
RLWAFCC 
Homo sapiens 3 (S-S) 
HNP-2 CYCRIPACIAGERRYGTCIYQGRL
WAFCC 
Homo sapiens 3 (S-S) 
Histatin 5 DSHAKRHHGYKRKFHEKHHSHR
GY 
Homo sapiens Helix 
Histatin 8 KFHEKHHSHRGY Homo sapiens Fragment 
of 
Histatin 5 
Bactenicin RLCRIVVIRVCR Bovine neutrophils Extended 
 
Table 3.1 Peptides used in the initial screening 
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Antimicrobial 
peptide  Colistin susceptible  Colistin resistant 
(mg/L) [µM]  A. baumannii ATCC 19606 
wt  
A. baumannii ATCC 19606 
mutant 
Histatin 5  >256 [>84.3 µM]  >256 [>84.3 µM] 
Buforin I  >256 [>60 µM]  >256 [>60 µM] 
Magainin II  256 [103.8 µM]  256 [103.8 µM] 
β-defensin  256 [65.2 µM]  256 [65.2 µM] 
Magainin I  64 [23.6 µM]  64 [23.6 µM] 
Histatin 8  32 [20.5 µM]  32 [20.5 µM] 
HNP-2  50 [14.8 µM]  50 [14.8 µM] 
Cecropin A  32 [>8 µM]  256 [63.9 µM] 
Cecropin B  32 [8.3 µM]  128 [33.4 µM] 
Bactenicin  64 [43.1 µM]  16 [10.8 µM] 
Cecropin P1  1,6 [0.48 µM]  >25 [> 7.5 µM] 
HNP-1  50 [14.5 µM]  3,25 [0.95 µM] 
Indolicidin  8 [4.2 µM]  16 [8.4 µM] 
Melittin  4 [1.4 µM]  2 [0.7 µM] 
Mastoparan  4 [2.7 µM]  1 [0.68 µM] 
Colistin   0,5 [0.43 µM]  256 [221.6 µM] 
 
Table 3.2 MICs of different peptides against colistin-susceptible and colistin-resistant A. baumannii 
strains. 
 
According to the results obtained, it was possible to classify the peptides into four 
different groups. In the first group all of the peptides were inactive against both colistin-
susceptible and colistin-resistant A. baumannii strains. Buforin and histatin 5 had a 
high MIC, with more than 256 mg/L against both strains, magainin II and β-defensin 
had also a high MIC with 256 mg/L for both strains. The results for magainin I were 
slightly better with a MIC of 64 mg/L for both strains, in addition histatin 8 and HNP-2 
had also the same MIC for both colistin-susceptible and colistin-resistant A. baumannii 
strains, with 32 and 50 mg/L respectively. The results for cecropin A and B were 
similar, with a MIC of 32 mg/L for colistin-susceptible, and higher MICs of 256 and 
128 mg/L for colistin-resistant respectively. The case of bactenicin was strange, 
obtaining a MIC (16 mg/L) lower for colistin-susceptible compared to 64 mg/L for 
colistin-resistant A. baumannii. 
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The only compound present in the second group was cecropin P1, it had the same 
behaviour as colistin, having a low MIC (1.6 mg/L) for colistin-susceptible compared 
with a higher MIC (>25 mg/L) when was tested against colistin-resistant A. baumannii.  
The opposite behaviour was observed in the third group with HNP-1, with a low MIC 
(3.25 mg/L) for colistin-resistant, compared to high MIC (50 mg/L) when was tested 
against colistin-susceptible.  
 
The last group was formed by three peptides, which showed good activity against both 
strains used. The less active peptide of this group was indolicidin, with a MIC of 8 and 
16 mg/L against colistin-susceptible and colistin-resistant strains respectively. Melittin 
had a MIC of 4 mg/L when tested against colistin-susceptible and 2 mg/L when tested 
against colistin-resistant, and mastoparan, had similar behaviour, having the same MIC 
as melittin (4 mg/L) for colistin-susceptible and a MIC (1 mg/L) for colistin-resistant.  
 
After analyzing the results, it was found that melittin was a really active peptide against 
both colistin-susceptible and colistin-resistant A. baumannii, however it had a high 
cytotoxicity whats makes it impossible to be used as a future antimicrobial (175). For 
indolicidin, a lot of optimizing studies have been performed (176), however the analogs 
synthesized were never tested against colistin-resistant A. baumannii. In order to 
confirm the results obtained in the first screening, mastoparan and indolicidin, (melittin 
was discarded due to its high lytic activity), were tested against more strains of both 
colistin-susceptible (14 strains) and colistin-resistant (13 strains) A. baumannii. The 
results are shown in the table 3.3. 
 
 
(mg/L) [µM] 
Antimicrobial    
Strains peptides MIC50 MIC90 Range 
Colistin-susceptible Mastoparan 4[2.7] 8[5.4] 1-16[0.68-10.8] 
A. baumannii (14) Indolicidin 16[8.4] 32[16.8] 4-32[4.2-16.8] 
 Colistin <0,5[<0.4] <0,5[<0.4] <0,5[<0.4] 
Colistin-resistant Mastoparan 8[5.4] 8[5.4] 2-8[1.4-5.4] 
A. baumannii (13) Indolicidin 16[8.4] 16[8.4] 16 [8.4] 
 Colistin >512[>443.3] >512[>443.3] 32->512[27.7->443.3] 
 
Table 3.3 MIC50 and MIC90 of different peptides for colistin-susceptible and colistin-resistant A. 
baumannii clinical isolates. 
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The results from table 3.3 shows that MICs of mastoparan and indolicidin slightly 
increase. In the case of mastoparan, they are below two digit numbers with a MIC50 and 
MIC90 of 4 and 8 mg/L respectively and a range of 1-16 mg/L in colistin-susceptible A. 
baumannii. For colistin-resistant, the results were similar, showing the same MIC50 and 
MIC90 (8 mg/L), and a range of 2-8 mg/L. The results for indolicidin for colistin-
susceptible MIC50 and MIC90 were 16 and 32 mg/L respectively, and a range between 4 
and 32 mg/L, and all the MICs for indolicidin when tested against colistin-resistant 
strains were 16 mg/L. If we compare these peptides in front of colistin, it is possible to 
observe that for the colistin-susceptible strains, the MIC of colistin was better than 
indolicidin and mastoparan, however colistin-resistant A. baumannii strains were tested, 
the values of MIC50 and MIC90 of colistin were >512 mg/L and a range between 32 and 
>512, so these results confirmed a good in vitro activity of mastoparan. Also confirmed 
our initial hypothesis that mastoparan was more active than indolicidin, therefore we 
will focus only in mastoparan. 
 
 
3.1.2. Killing curves of mastoparan against colistin-susceptible and colistin-
resistant A. baumannii strains. 
 
In order to have an idea of the behaviour of this peptide in front of both colistin-
susceptible and colistin-resistant A. baumannii strains, killing curve experiments were 
performed. The two strains of the initial screening were used for these experiments. The 
results are shown in the figure 3.1. 
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Figure 3.1 Results of time-killing experiments. a) colistin-resistant ATCC 19606 A. baumannii incubated 
with mastoparan (MIC 1mg/L). b) colistin-susceptible ATCC 19606 A. baumannii incubated with 
mastoparan (MIC 4mg/L). 
 
When comparing the values of mastoparan against the two strains, it was possible to 
observe a better activity against colistin-resistant A. baumannii, were the effect of both 
8xMIC and 4xMIC was bactericidal by decreasing from 6 log cfu/mL to 2 log cfu/mL 
aproximately in four hours. At the same concentrations against colistin-susceptible the 
same bactericidal effect was observed at 8xMIC, however no bactericidal behaviour was 
observed at concentration 4xMIC and a regrowth was observed after four hours. At the 
rest of the concentrations no bactericidal effect was observed neither in the colistin-
susceptible nor in the colistin-resistant, however it was important to point out the fact 
that at MIC concentration, in the colistin-resistant A. baumannii strain, a small decrease 
of the number of bacteria was observed, however in the colistin-susceptible the curve 
was almost similar to the control. 
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3.1.3. Stability assay and design of mastoparan analogs  
 
As commented previously, one of the most important drawbacks of the antimicrobial 
peptides is their poor in vivo stability. Most of them have a very short half-life, therefore 
stability is one of the most important properties that need to be improved when working 
with peptides. 
Stability assays incubating mastoparan with human serum were performed in order to 
check the stability of the peptide, and to found out the most susceptible positions of the 
peptide. 
A preliminary stability assay incubating mastoparan with human serum was performed 
in order to evaluate the stability of the peptide and, specially, to identify those peptide 
bonds more susceptible to hydrolytic cleavage. Samples of mastoparan were analyzed 
after different incubation times both by reverse-phase HPLC and MALDI-TOF. A 
precised determination of the half-life of mastoparan from this experiment was not 
possible due to the fact that mastoparan, in the analytical conditions used, co-eluted 
with one of the degradation products. 
After analyzing all the data obtained from mass-spectrometry, it was observed that the 
stability of mastoparan was surprisingly high for being a lineal peptide with L-amino 
acids (appearing the mass until 6 hours), and the only compound resulting from the 
action of the proteases was [2-14]-mastoparan, the product of hydrolysis of the Leu1-
Asn 2 peptide bond (figure 3.2 and 3.3).  
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Figure 3.2. MALDI-TOF spectra of mastoparan after incubation with human serum at 24 hours. The main 
compound is [2-14]-mastoparan. Molecular weight: 1366 Da (+H). Molecular weight (+Na): 1388. 
Molecular weight (+K): 1404 Da 
 
 
 
Figure 3.3. Chemical structure of mastoparan, showing the hydrolysis susceptible point. 
 
Taking into account the information obtained in the stability assay, a library of 
mastoparan analogs were designed and synthesized with the purpose of increasing the 
stability without losing activity. The analogs that were designed are shown in figure 3.4. 
Peptide 1 
   Gu-Ile-Asn-Leu-Lys-Ala-Lys-Ala-Ala-Lys-Ala-Lys-Lys-Ile-Leu-NH2 
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Peptide 2 
 
D-Ile-Asn-Leu-Lys-Ala-Lys-Ala-Ala-Lys-Ala-Lys-Lys-Ile-Leu-NH2
 
 
Peptide 3 
   Ile-D-Asn-Leu-Lys-Ala-Lys-Ala-Ala-Lys-Ala-Lys-Lys-Ile-Leu-NH2
 
 
Peptide 4 
 
Asn-Leu-Lys-Ala-Lys-Ala-Ala-Lys-Ala-Lys-Lys-Ile-Leu-NH2
 
 
 
 
Peptide 5 
 
Ac-Ile-Asn-Leu-Lys-Ala-Lys-Ala-Ala-Lys-Ala-Lys-Lys-Ile-Leu-NH2
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Peptide 6 (Mastoparan) 
 
Ile-Asn-Leu-Lys-Ala-Lys-Ala-Ala-Lys-Ala-Lys-Lys-Ile-Leu-NH2 
 
      Peptide 7 
 
D-Ile-D-Asn-Leu-Lys-Ala-Lys-Ala-Ala-Lys-Ala-Lys-Lys-Ile-Leu-NH2
 
Figure 3.4. Chemical structure of all the mastoparan analogs synthesized.  
 
Peptide 1 had only an extra guanidinium group in the N-terminal, this allow the last 
residue (isoleucine) to be more protected, due to its steric hindrance produced by this 
group, moreover it keeps the positive charge in the N-terminal. The last isoleucine from 
peptide 2 and asparagine from peptide 3 are D-amino acids. Peptide 4 is the species 
observed after the action of the enzymes present in the human serum,[2-14]-mastoparan 
. The design of Peptide 5 followed the same strategy as peptide 1. The N-terminal was 
protected with an acetyl group, this protection had also a steric hindrance, however the 
positive charged of the N-terminal was removed. Peptide 6 was the original mastoparan. 
Finally, peptide 7 had both D-isoleucine and D-asparagine at positions 1 and 2 
respectively.  
 
The synthesis of these peptides was carried out using a Fmoc/tBu solid phase peptide 
synthesis approach. As most of the peptides had common amino acids at the C-terminal, 
the strategy was to synthesize first the common part and then to split the resin in 
different batches to synthesize all the different analogs. figure 3.5 
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Figure 3.5. Scheme of the synthesis of mastoparan analogs 
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The peptides were synthesized and purified as explained in the materials and methods 
part. The HPLC and MALDI-TOF spectra are showed in the Figure 3.6  
 
Peptide 1 (Gu-INLKALAALAKKIL-NH2) 
       
 
Peptide 2 (iNLKALAALAKKIL-NH2) 
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Peptide 3 (InLKALAALAKKIL-NH2) 
          
 
 
 
 
Peptide 4 (NLKALAALAKKIL-NH2) 
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Peptide 5 (Ac-INLKALAALAKKIL-NH2) 
     
 
 
 
Mastoparan (INLKALAALAKKIL-NH2) 
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Peptide 7 (inLKALAALAKKIL-NH2) 
         
 
Figure 3.6. HPLC spectra and MALDI-TOF of the mastoparan analogs synthesized.  
 
3.1.4.  Evaluation of activity, stability and toxicity of the mastoparan analogs. 
 
All the peptides synthesized were tested against four different strains of A. baumannii. 
All of them were colistin-resistant clinical isolates with a high resistance profile. The 
cytotoxicity of mastoparan and all the analogs synthesized was also tested. The 
evaluation of stability of the new compounds in order to know if our aim, increase the 
stability, was achived was also performed. The results are showed in Table X.4 
 
   Minimal inhibitory concentration mg/L (µM)   
  Antimicrobial peptide CR17 CR86 Ab11 Ab113 
Stability in 
human 
serum 
Toxicity MTT 
IC50 (HeLa) 
1 Gu-INLKALAALAKKIL 4 (2,6) 4 (2,6) 4 (2,6) 4 (2,6) > 24h 13 µM 
2 iNLKALAALAKKIL 32 (21,6) 32 (21,6) 64 (43,3) 64 (43,3) > 24h 41 µM 
3 InLKALAALAKKIL 32 (21,6) 64 (43,3) 128 (86,5) 256 (173) > 24h 73 µM 
4 NLKALAALAKKIL 32 (19,2) 64 (38,4) 128 (76,8) 128 (76,8) > 24h 109 µM 
5 Ac-INLKALAALAKKIL 16 (10,5) 32 (21) 64 (42) 64 (42) > 24h 29 µM 
6 Mastoparan 4 (2,7) 4 (2,7) 4 (2,7) 4 (2,7) 6h 32 µM 
7 inLKALAALAKKIL 128 (86,5) 128 (86,5) 128 (86,5) 256 (173) > 24h 21 µM 
 
       
Table 3.4. MIC against colistin-resistant A. baumannii clinical isolates, stability in human serum and 
toxicity in HeLa cells of mastoparan analogs. D- amino acids are represented in lower case. 
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As it was possible to observe in the MIC results of the analogs, the only peptide that 
keeps the same level of activity was peptide 1, with the same values as the original 
mastoparan peptide (4 mg/L). The rest of the peptides had really high values compared 
with the two previous peptides commented. 
It was important to highlight that this high MICs obtained by most of the analogs, gave 
us also very useful information. When comparing the results obtained by peptide 5 and 
1 it was possible to observe how important was the positive charge present in the N-
terminal residue. It also gave us an idea of how important was to have all L-amino 
acids, and the importance of having a high life-time, because the resulting peptide after 
the incubation of human serum (peptide 4) does not have any activity, therefore it is 
important to have a high half-life time in order to have the active species more time 
present in blood. 
 
In terms of cytotoxicity, HeLa cells were selected in order to be tested against all the 
analogs synthesized. HeLa cells are cervical cancer isolated from a patient in 1951. The 
most important feature of this cell line is that cells are remarkably durable and prolific, 
therefore is one of the most common type of cells used when cytotoxicity want to be 
tested, in this case MTT was they assay used. The initial assay performed was to have 
an idea of how toxic was mastoparan, and the result obtained was an IC50 of 32 µM, this 
value is in the middle range of toxicity. Some of the compounds synthesized had 
approximately the same toxicity, like peptide 5 and 7 with an IC50 of 29 µM and 21 µM, 
respectively. Peptide 2 was slightly less toxic with IC50 of 41 µM. Peptide 3 and 4 were, 
significantly less toxic with IC50 of 73 µM and 109 µM. The only peptide that seems to 
be more toxic than mastoparan was the active peptide 1, with an IC50 of 13 µM. 
 
3.1.5. New mastoparan analogs: synthesis, activity, stability and toxicity. 
 
Before to start with the design of a second serie of mastoparan analogs a careful 
analysis of the literature was performed.  
Three peptides were synthesized following the article published by Jones and Howl, 
were they claimed that the enantiomeric version of mastoparan (peptide 10), together 
with the retro version (peptide 8) and the retroenantiomeric version (peptide 9) were 
less cytotoxic than mastoparan, therefore these three peptides were synthesize in order 
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to test their activity (177). Peptide 11 was synthesized for the same reason, in the article 
published by Lozano et al., demonstrate that just changing the leucine present in 
position 9, for a lysine, it decreases the cytotoxicity, and add a positive charge in the 
peptide (178). Peptide 12 was synthesized in order to observe the behaviour of a non-
natural amino acid (D-ornithine) in the peptide, together with an extra positive charge. 
The last two peptides were synthesized according to the information obtained during the 
synthesis of the first analogs. As it was important to keep the positive charge in the N-
terminal, and changing the sequence was dangerous, due to the fact that by changing 
one residue the activity could decrease a lot. The idea was to introduce another extra 
positive charge in the C-terminal. Peptide 13 and peptide 14 were the original 
mastoparan and retro sequence with a positive charge in the C-terminal.  
Putting together these precedents and our own previous results we undertook the 
synthesis of peptides 8-14 (figure 3.7) 
 
Peptide 8 
 
Leu-Ile-Lys-Lys-Ala-Leu-Ala-Ala-Leu-Ala-Lys-Leu-Asn-Ile-NH2 
 
            Peptide 9 
 
           D-Leu-D-Ile-D-Lys-D-Lys-D-Ala-D-Leu-D-Ala-D-Ala-D-Leu-D-Ala-D-Lys-D-Leu-D-Asn-D-Ile-NH2 
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Peptide 10 
 
                          D-Ile-D-Asn-D-Leu-D-Lys-D-Ala-D-Leu-D-Ala-D-Ala-D-Leu-D-Ala-D-Lys-D-Lys-D-Ile-D-Leu-NH2 
        
Peptide 11 
 
Ile-Asn-Leu-Lys-Ala-Lys-Ala-Ala-Leu-Ala-Lys-Lys-Ile-Leu-NH2 
 
 
Peptide 12 
 
                       D-Ile-D-Asn-D-Orn-D-Lys-D-Ala-D-Leu-D-Ala-D-Ala-D-Leu-D-Ala-D-Lys-D-Lys-D-Ile-D-Leu-NH2 
        
Peptide 13 
 
    Ile-Asn-Leu-Lys-Ala-Lys-Ala-Ala-Lys-Ala-Lys-Lys-Ile-Leu-CH2-CH2-NH2  
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Peptide 14 
 
     Leu-Ile-Lys-Lys-Ala-Leu-Ala-Ala-Leu-Ala-Lys-Leu-Asn-Ile-CH2-CH2-NH2 
 
Figure 3.7. Chemical structure of all the mastoparan analogs synthesized. 
 
The synthesis of the new analogs was carried out using the same procedure as has been 
commented previously, however the resin used for the peptides 13 and 14 was different 
due to the fact that they have a different C-terminal. The procedures used are explained 
in detail in the materials and methods part. The HPLC and MALDI-TOF spectra are 
showed in the (figure 3.8)  
Peptide 8 (LIKKALAALAKLNI-NH2) 
          
Peptide 9 (likkalaalaklni-NH2) 
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Peptide 10 (inlkalalakkil-NH2) 
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Peptide 11 (INLKAKAALAKKIL-NH2) 
                 
 
 
 
Peptide 12 (in(orn)kalaalakkil-NH2) 
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Peptide 13 (INLKALAALAKKIL-CH2-CH2-NH2) 
               
 
Peptide 14 (LIKKALAALAKLNI-CH2-CH2-NH2) 
               
 
Figure 3.8. HPLC spectra and MALDI-TOF of the mastoparan analogs synthesized. 
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All the peptides synthesized were tested against the same strains used to test the activity 
of the first mastoparan analogs. In the table 3.5 it is possible to observe the results, as 
well as the toxicity and the stability in human serum.  
 
 
      Minimal inhibitory concentration mg/L (µM)   
  Antimicrobial peptide CR17 CR86 Ab11 Ab113 
Stability 
in 
human 
serum 
Toxicity MTT 
IC50 (HeLa) 
8 LIKKALAALAKLNI 256 (173) 256 (173) 256 (173) 256 (173) 2h 192 µM 
9 likkalaalaklni 256 (173) 256 (173) 256 (173) 256 (173) > 24h 200 µM 
10 inlkalaalakkil 4 (2,7) 4 (2,7) 4 (2,7) 4 (2,7) > 24h 10 µM 
11 INLKAKAALAKKIL 256 (171,5) 256 (171,5) 256 (171,5) 256 (171,5) 6h 290 µM 
12 in(or)kalaalakkil 128 (86,5) 64 (43,2) 64 (43,2) 128 (86,5) >24h 200 µM 
13 
INLKALAALAKKIL-
CH2CH2NH2 4 (2,6) 4 (2,6) 2 (1,3) 4 (2,6) 6h 5 µM 
14 
LIKKALAALAKLNI-
CH2CH2NH2 64 (42) 128 (84,1) 128 (84,1) 64 (42) 2h 150 µM 
 
Table 3.5. MIC against colistin-resistant A. baumannii clinical isolates, stability in human serum and 
toxicity in HeLa cells of mastoparan analogs. D- amino acids are represented in lower case. 
 
In terms of activity just two peptides maintain the same activity as the best compounds 
from the previous series, these compounds were peptide 10, and peptide 13, with the 
same activity as peptide 1 and mastoparan, the rest of the peptides synthesized had 
really high MICs.  
About the cytotoxicity and stability in human serum, it was possible to observe, that the 
peptides that had D-amino acids in their sequence were highly stable compared to 
peptides with just L-amino acids. The first three peptides synthesized followed the same 
behaviour as commented previously, however peptide 8, had even lower stability than 
mastoparan. It was also important to mention that both retro versions of mastoparan 
(peptides 8 and 9) were less cytotoxic with IC50 of 192 and 200 µM respectively, 
compared to mastoparan (IC50 of 32 µM) and its enantiomer (peptide 10) with a IC50 of 
5 µM. The aim of synthesizing these peptides was due to the low cytoxicity observed in 
the manuscript published by Jones and Howl, however only peptides 8 and 9 showed 
less cytotoxicity.  
Peptide 11, as following the manuscript published by Lozano et al., had a really low 
cytotoxicity, although it has no activity and the same stability as mastoparan. 
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For peptide 12, it was important to mention that even though it has an extra positive 
charge it is less cytotoxic, this result break with the idea that positive charged residues 
introduce cytotoxicity in the peptide, however in some positions it probably make 
increase it. This cytotoxicity is not related to the global positive charge of the peptide, 
just associated with the positive charge in some key residues. 
The last two peptides synthesized, with the extra positive charge in the C-terminal, had 
a low half-life due to the L-amino acids that had in their sequence, noticing that they 
both had the same stability as their analogs without the positive charge in C-terminal. 
The activity of peptide 13 was the same as the active peptides, however was the most 
cytotoxic peptide with a IC50 of 5 µM. Peptide 14 was slightly more active than peptide 
8, however it was not enough for considering good activity, and was also more 
cytotoxic.   
 
3.2. In vivo studies of the best compounds. 
 
After analyzing all the data obtained from all the peptides synthesized we decided to 
move into the in vivo model, therefore we had to select which were the best candidates 
to be tested in vivo. Three peptides (peptides 1, 10 and 13) and mastoparan were active 
against colistin-resistant A. baumannii strains. Mastoparan was the first candidate 
selected because it was the less toxic compound, although it was also the less stable. 
When talking about the other three peptides, peptide 13 was the first discarded, due to 
its high toxicity and the most expensive and difficult in terms of large-scale. When 
comparing peptides 1 and 10 it was possible to observe that both had the same activity 
and stability, and similar cytotoxicity, however peptide 1 is made by L-amino acids and 
peptide 10 is made by D-amino acids. Even though they had the same stability in vitro 
we though peptide 10 would be more stable when administering it into mice. So we 
decided to study in vivo both peptide 10 and mastoparan.  
The in vivo studies were performed in a stage in the laboratory of Professor Jerónimo 
Pachón from the Hospital Virgen del Rocío. 
 
The first experiment that was performed was to calculate the hemolytic activity of these 
two peptides. figure 3.9 
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Figure 3.9. Percentatge of hemolysis of mastoparan and peptide 10 at different concentrations.  
 
The figure X.9 shows that before 100 mg/L of the peptide concentration almost no 
hemolysis was observed, however if the concentration increases some hemolysis was 
observed with 35% and 39% of hemolysis for mastoparan and peptide 10 respectively. 
These results were promising because the percentage of hemolysis at the active 
concentration of the peptides (4 mg/L) was almost negligible. 
 
Next step was to calculate the in vivo toxicity of the two peptides. 32 mg/kg was taken 
as the initial dose taking into account previous assays performed by Dr. Pachón group 
with antimicrobial peptides (179). 32 mg/kg of each peptide were injected into six mice 
respectively, after 24 hours the mice injected with mastoparan were alife, however the 
mice treated with peptide 10 were dead. Taking into account this information we 
increased the amount of peptide for mastoparan up to 64 mg/kg and decreased to 16 
mg/kg for peptide 10, after 24 hours the 12 treated mice were dead, with that data it was 
possible to knew the maximum dose for mastoparan which was 32 mg/kg. Next dose 
tested for peptide 10 was 8 mg/Kg, and after 24 hours all the treated mice were alife, so 
the maximum dose for peptide 10 was 8 mg/kg.  
The results obtained fitted really good with the in vitro data, The higher in vivo toxicity 
of peptide 10 correlates well with its higher cytotoxicity, compared with mastoparan, 
and its higher stability in human serum. This high stability in human serum allow the 
peptide to be more time inside of the mice causing also more damage. 
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After calculating the lethal dose of the peptides it was time to calculate the lethal dose 
of the strain that will be used in further experiments. The strain used was a pan-resistant 
strain. Three groups of four mice each were inoculated. The amount of bacteria injected 
per group was 105, 106 and 107 cfu/mL. From all the groups, the only survival mice 
were the ones inoculated with 105 cfu/mL, therefore the lethal dose of bacteria, and the 
concentration used for the experiments will be 106 cfu/mL. 
 
Once the toxicity of the peptides in mice and the lethal dose were calculated it was time 
for calculating the ED50, this parameter is the effective dose that keeps alife the 50% of 
the mice. table 3.6 
 
 
(4h) 
Administration 
Doses 
Peptide 10 
(10 mice) 
Mastoparan 
(10 mice) 
Control 
(3 mice) 
16 mg/Kg - 7 exitus 3 exitus 
8 mg/Kg 9 exitus 10 exitus - 
4 mg/Kg 9 exitus - - 
Table 3.6. ED50 of peptide 10 and mastoparan. 
 
Analyzing the data obtained in the first assay, no ED50 was obtained, none of the groups 
had 5 mice alife (50%). The closest dose to ED50 was 16 mg/kg in mastoparan with a 
30% of survival, the other dose of mastoparan, 16 mg/kg, had no survivals, and both 
doses for peptide 10, 8 and 4 mg/kg, had just a 10% of survival. 
 
Taking into account that we did not have any ED50 for any of the peptides, we took a 
look into the procedure of performing the ED50 assay. The mice were inoculated 
intraperitoneally with the lethal dose of bacteria, in this case 106 cfu/mL, and after 4 
hours the dose of peptide was administered intraperiteoneally. The time of 
administration of the peptide could be too long, therefore it was decided to monitor the 
infection after 1, 2, 3 and 4 hours.  
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3 mice per group were selected, each group belongs to a period of time. The 12 mice 
were inoculated with the lethal dose at the same time, and after each period of time, 3 of 
them were sacrificed using sodium thiopental. Lungs and spleen were extracted from 
each mice. Once all the spleens and lungs were isolated, each one was inserted into a 
sterile bag and 1 mL of LB media was added, all of it was homogenized and after 
several dilutions, the amount of bacteria in each organ was calculated, the results are 
showed in figure 3.10. 
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b) 
 
 
 
 
 
 
 
 
 
 
Figure 3.10. a) Number of bacteria in lungs at a different time points. b) Number of bacteria in spleen at a 
different time points.  
 
The Figure 3.10 shows the amount of bacteria in each organ at different periods of time. 
At 1 hour the amount of bacteria in lungs and spleen was similar with 105,5 cfu/mL, this 
information allows us to have an idea how fast does bacteria disperses. It would be 
normal to have 105,5 cfu/mL in the spleen due to the intraperitoneally injection. 
However the same amount of bacteria was observed in lungs were bacteria need to 
achieve the blood vessels in order to arrive into the lungs. 
In the second point time, 2 hours, the amount of bacteria continue increasing reaching 
more than 106 cfu/mL in the spleen and slightly less than 106 cfu/mL in lungs. The 
differences between both organs were not so high but at 3 and 4 hours time the 
differences reached were higher with at around 108 in the spleen for both times 
compared to the 106,7 and 107 cfu/mL in lungs for 3 and 4 hours respectively. 
Apart from the counting of bacteria in these organs, hemocultures were performed in 
each mice. Hemocultures consist in extracting blood from the heart while is pumping, 
this blood is spread into a blood agar plate in order know if there were bacteria in the 
blood torrent, all of the samples collected were positive. 
 
After analyzing the data obtained after monitorizing the infection process, the decision 
was to reduce the time of administration of the peptides to two hours, this should allow 
the peptide to be more effective.  
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The same procedure was performed, with the same doses only decreasing the time of 
administration of the peptide in 2 hours, the results are shown in table 3.7  
 
(2h) 
Administration 
Doses 
Peptide 10 
(10 mice) 
Mastoparan 
(10 mice) 
Control 
(3 mice) 
16 mg/Kg - 10 exitus 3 exitus 
8 mg/Kg 10 exitus 10 exitus - 
4 mg/Kg 10 exitus - - 
Table 3.7. ED50 of peptide 10 and mastoparan. 
  
The results obtained when reducing the time of administration of the peptide were 
surprising, instead of having best results, worst results were obtained with any survivals 
in any of the groups, that means that the mice that survive during the first experiment 
was due to an administration failure. 
 
In a third experiment a new set of doses of peptides was used 32, 4 and 2 mg/Kg for 
mastoparan; and 2 and 1 mg/Kg for peptide 10. Only three mice were used for this 
experiment with the idea to repeat with higher mice if two or three mice survived, 
however there was just one survival with 32 mg/kg for mastoparan. Table 3.8 
 
(2h) 
Administration 
Doses 
Mastoparan 
(3 mice) 
Peptide 10 
(3 mice) 
Control 
(3 mice) 
32 mg/Kg 2 exitus - 3 exitus 
4 mg/Kg 3 exitus - - 
2 mg/Kg 3 exitus 3 exitus - 
1 mg/Kg - 3 exitus - 
Table 3.8. ED50 of peptide 10 and mastoparan. 
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Eventhough we did not have any ED50, a pneumonia model was performed in order to 
know if there were some systemic activity with n=3 in each time point. Doses used were 
8 mg/kg for peptide 10 and 32 mg/kg for mastoparan. Peptides were administered after 
2 hours of infection. Time points were 2 hours and 24 hours. Table 3.9 
 
 
Log cfu/mL 0h 2h  
control 
       2h  
mastoparan 
      2h  
peptide 10 
   24h  
control 
       24h  
mastoparan 
   24h  
peptide 10 
Average 6.99 7.50 7.51 7.51 7.05 7.04 7.09 
SD 0.38 0.61 0.42 0.30 0.13 0.18 0.21 
 
Table 3.9. Number of bacteria in lungs at different times in the treatment with mastoparan and peptide 10. 
 
No systemic effect was observed at any time nor peptide. In order to find any activity in 
the peptides we decided to change the strain into a more susceptible strain and also 
reduce the administration of the peptide to 1 hour. The strain selected was the ATCC 
19606 mutant colistin-resistant, which was used for the screening of the first peptides. 
This strain is less virulent than the pan-resistant and does not have a high resistant 
profile against all the antibiotic families. The number of mice used in each group was 
three and the set doses used were 32 mg/kg for mastoparan and 8 mg/kg for peptide 10. 
None of the mice survived the infection. 
The same model of peritoneal sepsis was used to analyze and count the amount of 
bacteria in the peritoneal in order to observe a local effect of the peptide. In this case the 
doses used were 8 mg/kg for peptide 10 and 16 mg/kg for mastoparan. The procedure 
used was, infection followed by a treatment with peptide after 1 hour, and sacrifice them 
after 1h. 10 mice for each group were used. Results are showed in table 3.10 
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Log cfu/mL Control Mastoparan Peptide 10 
1 8.43 9.06 8.49 
2 8.32 7.70 8.58 
3 8.67 8.75 8.26 
4 8.20 8.99 8.20 
5 8.59 9.03 7.33 
6 8.15 8.83 8.61 
7 8.71 8.74 8.73 
8 8.75 8.67 8.59 
9 8.52 8.96 8.72 
10 8.61 8.95 8.77 
Average 8.50 8.77 8.43 
SD 0.21 0.40 0.43 
 
Table 3.10. Number of bacteria in the peritoneal after 2h of treatment with mastoparan and peptide 10. 
 
When comparing the average of log cfu/mL in all three groups no significance is found. 
After all the experiments performed have been proved to be unsuccessful, we started 
thinking about the reasons of the lack of in vivo antimicrobial activity and the first 
hypothesis was that a possible binding to any of the proteins or compounds present in 
the serum reducing the effective concentration of the peptide. Furthermore this could be 
the reason why a linear peptide with L-amino acids will have this high stability in 
human serum. 
Taking into account the first hypothesis a MIC assay in presence of serum was 
performed in order to see if the MICs were higher or at the same level. The results of 
the MIC values are showed in table 3.11. 
 
MIC mg /L(µM)   CR17     Ab14  
% of Serum 0% 25% 50% 75%  0% 25% 50% 75% 
          
Mastoparan 4(2.7) 16(10.8) 64(43.3) 128(86.5)  4(2.7) 32(21.6) 128(86.5) 128(86.5) 
Peptide 10 4(2.7) 16(10.8) 64(43.3) 128(86.5)  2(1.35) 32(21.6) 64(43.3) 128(86.5) 
 
Table 3.11. MICs of mastoparan and peptide 10 against colistin-resistant A. baumannii in the presence of 
different percentage of human serum. 
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The information obtained with this assay showed that the MIC of the two peptides 
increase progressively when more human serum is added. This fact support the 
hypothesis suggested previously. The amount of different proteins present in the serum 
is very high therefore it will be almost impossible to test all of them in order to know 
which is the one involved in the interaction with the peptide.  
We just tested albumin (human serum concentration is 40 g/L) because is the main 
protein present in the human serum, and the results obtained are showed in table 3.12 
 
 
MIC mg/L (µM) 
  CR17     Ab14  
% of albumin 0% 25% 50% 75%  0% 25% 50% 75% 
 
         
Mastoparan 4(2.7) 16(10.8) 32(21.6) 64(43.3)  4(2.7) 16(10.8) 32(21.6) 64(43.3) 
Peptide 10 4(2.7) 4(2.7) 4(2.7) 4(2.7)  4(2.7) 4(2.7) 4(2.7) 4(2.7) 
 
Table 3.12. MICs of mastoparan and peptide 10 against colistin-resistant A. baumannii in the presence of 
different percentage of albumin. 
 
The results represented in the table 3.12 showed that mastoparan had a high affinity for 
the albumin, having almost the same MIC values as when it is incubated with human 
serum, however the activity of peptide 10 remains the same, this information together 
with the one obtained when MICs are performed with human serum, suggest that it has 
a high affinity for a protein or compound present in the serum different than albumin. 
 
3.3. Mechanism of action of mastoparan and analogs 
 
Two different approaches were used in order to get insight in the mechanism of action 
of mastoparan and the analogs synthesized. The first approach was based on the use of a 
leakage assay, this experiment will allow us to have an idea of how lytic is the peptide 
tested quantifying the amount of carboxifluorescein released by each peptide 
synthesized, using different lipid compositions. The second approach was using 
transmission electron microscopy (TEM), to observe the effect of the peptides in the 
bacterial membrane. 
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3.3.1. Leakage 
 
Leakage assays were performed using two different membrane mimetics, a negatively 
charge membrane, mimicking bacterial membranes and a neutral membrane. Negatively 
charged membranes are composed by phosphatidylethanolamine (PE), cardiolipin (CL) 
and phosphatidylglycerol (PG) (63:14:23), this composition was from P. aeruginosa but 
due to its high similarity with A .baumannii it can be used as well (180). 0.1, 0.25, 0.5, 
1, 10 and 50 µM are the concentrations of peptides used to test the ability of them to 
release carboxyfluorescein from the liposome. (figure 3.11)  
 
 
Figure 3.11. Percentage of carboxyfluoriscein released of all the mastoparan analogs at different 
concentrations using negatively charged liposomes. 
 
The Figure 3.11 shows the percentage of release of each peptide at the concentrations 
commented below. No release is observed at concentrations below 1µM. At 10 µM it is 
possible to observe differences between all the peptides. Most of the active peptides 
against colistin-resistant strains of A. baumannii had a higher ability to release the 
fluorophore from the negative liposomes. Peptide 10 had a 87% of release followed by 
mastoparan and peptide 1 with 72 and 60 % respectively. The next peptide, the change 
of D-lysine for a D-ornithine (peptide 12), had a MIC of 43-86 µM and a percentage of 
release of 57%, however the following peptides, both with 53% of release have a lower 
MIC, the peptide 13 (2.7 µM) and 5 (MICs between 10.5 and 42 µM). The next three 
peptides, 2,3 and 4, had both high MICs and middle release values, with 33, 37 and 35% 
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respectively. All these peptides commented released all the carboxifluorescein present 
inside the liposome at 50 µM. The last four peptides were the less active in terms of 
both in vitro activity against A. baumannii and carboxyfluorescein release. For peptide 
8, the percentage of release at 10 µM was 14% and increased up to 51% at 50 µM, 
peptide 11 released 10% at 10µM and increased up to 38% when liposomes were 
incubated with 50µM of the peptide. The last three peptides, 7, 9 and 14, had high MICs 
and a very low release values at 10µM with 10%, at 50µM the only peptide in which it 
was possible to observe a slightly increase was in peptide 7 which increased up to 20%, 
the other two peptides maintain their values at around 10%. 
 
 
Figure 3.12. Percentatge of carboxyfluoriscein release of all the mastoparan analogs at different 
concentrations and using neutral liposomes. 
 
The values observed for the neutral liposomes (EPC/Cholesterol)(5:1) are showed in 
figure 3.12. According to the results obtained they can be divided into four groups, the 
best compound was peptide 10, with a 65% of carboxyfluorescein release at 50µM, the 
second group that was composed by peptides 13, 1, 5, 12, 3, 2, 6 and 5, the percentage 
of release of all these peptides went from 44% to 36% at 50µM. The peptide 11 and 
both retro peptides, 8 and 9 belonged to the third group, the percentage of release were 
20, 19 and 17% at 50µM respectively, and the last group with almost no activity 
observed neither at 10µM nor at 50µM with values less than 10%, these peptides were 
number 14 and 7.  
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3.3.2. Transmission electron microscopy.  
 
(Samples were prepared by Dr. Carmen López) 
The effects of mastoparan and peptide 10 on the cell morphology of colistin-resistant A. 
baumannii were also investigated by transmission electron microscopy. Untreated cells 
of A. baumannii in LB medium showed a normal morphology with an undamaged 
structure of any of the membranes (figure 3.13). After 1 hour of incubation with 
mastoparan and the peptide 10 version (at MIC for each peptide), it was possible to 
observe that bacteria had a considerable damage by observing some fractures in the 
membrane in both bacteria incubated with mastoparan (figure 3.14) or incubated with 
peptide 10 (figure 3.15). We can not claimed with the information obtained in the TEM 
studies that the mechanism of action of this peptides is due to a membrane disruption or 
permeabilization but with the data obtained with the leakage experiments and also with 
all the information known about the mechanism of action of all the mastoparan peptides 
family, it seems that this is the mechanism in which the peptides might kill bacteria.  
 
                                       
Figure 3.13. TEM of untreated colistin-resistant A. baumannii cells. 
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Figure 3.14. TEM of mastoparan incubated with colistin-resistant A. baumannii cells 
 
          
Figure 3.15. TEM of peptide 10 incubated with colistin-resistant A. baumannii cells 
 
3.4. Frog-skin peptides against colistin-resistant A. baumannii species. 
 
The approach used since now was to tested different commercial natural peptides, and 
the following optimization of the hit, however in this part of the chapter we are going to 
use a new approach by using a completely new peptides. In this case we tested six 
peptides isolated from frog-skin secretions, this work was done in collaboration with 
Prof. Conlon from United Arab Emirates University. The group of Prof. Conlon bought 
the crude secretions, and isolated the peptides by purifying it. The peptides isolated are 
showed in table 3.13.  
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Peptide Primary structure LC50 (µg/mL) 
[G4K]XT-7 GLLKPLLKIAAKVGSNLL-NH2 >1000 
[E4K]alyteserin-1c GLKEIFKAGLGSLVKGIAAHVAS-NH2 >1000 
PGLa-AM1 GMASKAGSVLGKVAKVALKAAL-NH2 >1000 
B2RP-Era GVIKSVLKGVAKTVALGML-NH2 560 
CPF-AM1 GLGSVLGKALKIGANNLL-NH2 300 
[D4K]B2RP GIWKTIKSMGKVFAGKILQNL-NH2 250 
LC50. Mean concentration of peptide producing 50% haemolysis in three independent experiments. 
 
Table.3.13. Primary structures and haemolytic activities (LC50) against human red blood cells of the frog 
skin-derived antimicrobial peptides used in this study. 
 
Six peptides were isolated from different sources, CPF-AM1 and PGLa-AM1 are from 
Xenopus amieti (181), B2RP-ERa is from Hylarana erythraea (182), [E4K]alyteserin-
1c is from Alytes obstetricans (183), [D4K]B2RP is from Lithobates septentrionalis 
(184) and [G4K]XT-7 is from Silurana tropicalis (185).  
The first assays performed prior to be tested its antimicrobial activity was the hemolytic 
assay. In this assay it was possible to observe that three of the peptides had a low 
hemolytic activity, with a LC50 of more than 1000 µg/mL, the other three peptides, 
B2RP-ERa, CPF-AM1 and [D4K]B2RP had LC50 values of 560, 300 and 250 µg/mL 
respectively.  
All six peptides were tested against both colistin-resistant and colistin-susceptible 
Acinetobacter species strains. The colistin-susceptible Acinetobacter strains used were 
the ATCC 19606, one strain of Acinetobacter nosocomialis and six strains of A. 
baumannii clinical isolates each one with different features. For colistin-resistant 
strains, three lab generated mutants (two A. baumannii and one A. nosocomialis), the 
other three strains used colistin-resistant were A. baumannii clinical isolates. The results 
of the MIC assays are showed in table 3.14 and table 3.15. 
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Peptide Acinetobacter sp.Strains           
mg/L (µM)  19606 77778 G13 NM8 NM35 NM75 NM109 NM124 
[G4K]XT-7 32(17.3) 32(17.3) 4(2.2) 32(17.3) 32(17.3) 32(17.3) 16(8.7) 16(8.7) 
[E4K]alyteserin-1c 8(3.5) 8(3.5) 8(3.5) 8(3.5) 16(7) 8(3.5) 4(1.8) 4(1.8) 
PGLa-AM1 64(30.9) 64(30.9) 128(61.9) 16(7.7) 16(7.7) 16(7.7) 16(7.7) 16(7.7) 
B2RP-Era 32(17) 32(17) 8(4.2) 32(17) 32(17) 16(8.5) 32(17) 32(17) 
CPF-AM1 64(39.5) 64(39.5) 128(78.9) 16(9.9) 16(9.9) 16(9.9) 16(9.9) 16(9.9) 
[D4K]B2RP 16(6.9) 8(3.4) 8(3.4) 8(3.4) 8(3.4) 8(3.4) 4(1.7) 4(1.7) 
Colistin 0.5(0.43) 2(1.7) <0.5(<0.43) 1(0.86) 1(0.86) 1(0.86) <0.5(<0.43) <0.5(<0.43) 
 
Table 3.14. Minimum inhibitory concentrations (mg/L) of the frog skin-derived antimicrobial peptides 
against colistin-susceptible strains of Acinetobacter baumannii and Acinetobacter nosocomialis 
 
 
Peptide Acinetobacter sp.Strain         
(mg/L) (µM) 19606 mutant 77778 mutant G13 mutant Ab22P Ab1 Ab113 
[G4K]XT-7 4(2.2.) 32(17.3) 4(2.2) 8(4.3) 32(17.3) 64(34.7) 
[E4K]alyteserin-1c 4(1.8) 8(3.5) 8(3.5) 4(1.8) 8(3.5) 16(7) 
PGLa-AM1 16(7.7) 64(30.9) 16(7.7) 16(7.7) 64(30.9) 128(61.9) 
B2RP-ERa 8(4.2) 64(34) 8(4.2) 8(4.2) 32(17) 64(34) 
CPF-AM1 4(2.5) 64(39.5) 8(4.9) 8(4.9) 64(39.5) 128(78.9) 
[D4K]B2RP 4(1.7) 16(6.9) 16(6.9) 8(3.4) 16(6.9) 16(6.9) 
Colistin 256 (221.6) >256 (>221.6) >256 (>221.6) 64(55.4) >512 (>443.3) 256 (221.6) 
 
Table 3.15. Minimum inhibitory concentrations (mg/L) of the frog skin-derived antimicrobial peptides 
against colistin-resistant strains of Acinetobacter baumannii and Acinetobacter nosocomialis. 
 
 
Peptides [E4K]alyteserin-1c and [D4K]B2RP, were tested against multi-drug resistant 
A. baumannii previously (183, 184), and with these MIC assays performed confirmed 
that are the best two peptides with MICs between 4 and 16 mg/L, the rest of the 
peptides tested had higher MICs with doble digit values. 
For colistin-resitant Acinetobacter strains, the values are similar or slightly better, some 
of the peptides that had high MICs for colistin-susceptible strains had good MIC values 
in colistin-resistant strains, however the best peptides were still the same, 
[E4K]alyteserin-1c and [D4K]B2RP, and the MIC values for both were also between 4 
and 16 mg/L.  
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3.5. Active peptidomimetics against colistin-resistant Acinetobacter 
baumanii 
 
This work have been done in collaboration with professor Paul Savage from (Brigham 
Young University). 
3.5.1. Ceragenines used in the experiments 
 
Ceragenines or also called CSA (Cationic steroid antibiotics), are antimicrobial 
compounds derived from the original structure of cholic acid. As shown in the figure 
3.16, cholic acid has a large planar structure with a highly hydrophobic face (upper face 
in the figure); a more hydrophilic face (lower face in the figure) containing three polar 
hydroxyl groups; and a highly polar charged tail (a negatively charged carboxylate ion 
at physiological pH). The anphipaticity of the cholic acid molecule is even increased in 
the structure of ceragenins (figure 3.17), that keep the hydrophobic face of cholic acid 
and contain several cationic groups (at physiological pH) in the hydrophilic face. 
Ceragenins have no peptide bonds but due to this amphipathic structure, similar to that 
of several antimicrobial peptides, are classed as peptidomimetics.  
 
 
a)                                                       b) 
  
 
Figure 3.16. a) planar representation of cholic acid. b) chair representation of cholic acid 
 
Ceragenins are promising compounds that could supersede antimicrobial peptides in 
terms of metabolic stability or toxicity. In our case, the peptidomimetics used for the 
experiments were supplied by Professor Paul Savage, and the structures of these 
compounds are showed in figure 3.17 
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CSA-138 
 
 
CSA-13 
 
 
CSA-131 
 
 
CSA-44 
 
Figure 3.17. Chemical structure of ceragenins used. 
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The modification of the cholic acid for CSA-13, CSA-131 and CSA-138 in the 
hydrophilic face was by converting the three hydroxyl groups into three aminopropyl 
ethers (positively charged at physiological pH). For CSA-44 the modification 
introduced to cholic acid is an aminopropyl esther. The highly polar charged tail 
containing a carboxylate, was modified to obtain a secondary amine that was substituted 
by octyl, dodecyl and tridecyl in CSA-13, CSA-131 and CSA-138, respectively. The 
modification of the carboxylate group of the CSA-44 was performed introducing an 
octyl esther. 
 
3.5.2.  In vitro activity of Ceragenins against colistin-resistant and colistin-
susceptible A. baumannii, K. pneumoniae and P. aeruginosa. 
 
The initial aim was to test these ceragenins against colistin-resistant A. baumannii, 
however in order to know if these compounds were able to be active against several 
colistin-resistant bacteria, were also tested against both colistin-resistant K. pneumoniae 
and P. aeruginosa strains. Results are showed in table 3.16 
 
MIC 
(mg/L)  A. baumannii  K. pneumoniae  P .aeruginosa 
[µM]          
ceragenins  Col-S col-R  col-S col-R  col-S col-R 
138  2 [2.7] 4[5.4]  16[21.4] 16[21.4]  1[1.3] 1[1.3] 
13  4[5.9] 4[5.9]  8[11.8] 16[23.6]  <0,5[<0.7] <0,5[<0.7] 
131  2[2.7] 2[2.7]  8[10.9] 8[10.9]  <0,5[<0.7] <0,5[<0.7] 
44  8[10.9] 4[5.4]  4[5.4] 16[21.8]  1[1.4] 1[1.4] 
 
TableX.16. MIC of the ceragenins against colistin-susceptible and colistn-resistant A. baumannii, K. 
pneumonia and P. aeruginosa clinical isolates. 
 
Four diferent ceragenins were tested against both colistin susceptible and resistant 
strains of A. baumannii, K. pneumoniae and P. aeruginosa. In A. baumannii, CSA-131 
showed the best results with a MIC of 2 mg/L for both strains. For CSA-138 the MIC of 
colistin-susceptible was also 2 mg/L and 4 mg/L for the colistin-resistant strain, which 
was the same value for CSA-13 in both strains. CSA-44 had a MIC of 4 mg/L for the 
colistin-resistant strain and 8 mg/L for the colistin-susceptible. 
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For K.pneumoniae the best results correspond to CSA-131 with a MIC of 8 mg/L 
against both colistin-susceptible and colistin-resistant K. pneumoniae strains, CSA-13 
and CSA-44 had the same values, with 8 mg/L and 16 mg/L for colistin-susceptible and 
colistin-resistant respectively. CSA-138 showed 16 mg/L for both strains. 
CSA-131 and CSA-13 showed the best results for P. aeruginosa showing a MIC less 
than 0.5 mg/L for both colistin-susceptible and resistant. The MIC of CSA-138 and 
CSA-44 was slightly higher being 1 mg/L. 
 
All the ceragenines had a good activity against all the strains, specially interesting was 
the activity against P. aeruginosa. It was also important to point out that ceragenins had 
a good activity independently of the grade of resistance to colistin of the strain, having 
approximately the same MIC in both strains, specially in A. baumannii and P. 
aeruginosa.  
 
3.5.3.  In vitro activity of ceragenins against a collection of A. baumannii and P. 
aeruginosa. 
 
The best results were obtained when working with A. baumannii and P. aeruginosa, 
although the results against K. pneumoniae were relatively good, we discarted it due to 
its doble digit values in some MICs. 
As it was done in the initial screening of the antimicrobial peptides, MIC assays were 
performed using more strains, all of them were colistin-susceptible, however the results 
of both colistin-resistant and colistin-susceptible are similar. The reuslts are showed in 
Table 3.17 
 
 
MIC (mg/L)  A. baumannii (15)  P. aeruginosa (15) 
[µM]       
ceragenins  MIC50 MIC90  MIC50 MIC90 
138  2[2.7] 4[5.4]  2[2.7] 4[5.4] 
13  2[2.9] 8[11.8]  4[5.9] 4[5.9] 
131  2[2.7] 2[2.7]  1[1.4] 2[2.7] 
44  4[5.4] 8[10.9]  4[5.4] 8[10.9] 
 
Table 3.17. MIC50 and MIC90 of the ceragenins against colistin-susceptible and colistin-resistant A. 
baumannii, and P. aeruginosa clinical isolates 
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A collection of 15 diferents clinical isolates were tested against CSA-131, CSA-13, 
CSA-44 and CSA-138. In A. baumannii, CSA-13, CSA-131 and CSA-138 showed a 
MIC50 of 2 mg/L, and one dilution higher for CSA-44 with 4 mg/L. The MIC90 of CSA-
131 and CSA-138 maintain the same value, 2 mg/L but for CSA-13 and CSA-138 
increased up to 8 mg/L. 
In the case of P. aeruginosa, the best results belonged to CSA-131 showing 1 mg/L and 
2 mg/L for MIC50 and MIC90 respectively. The results for CSA-138 were 2 mg/L as 
MIC50 and 4 mg/L as MIC90. Both CSA-13 and CSA-44 showed the same MIC50 of 4 
mg/L, however in the MIC90 CSA-44 increased up to 8 mg/L while CSA-13 stayed with 
the same value.  
The results obtained reaffirm the good activity of these compounds against A. 
baumannii and P. aeruginosa, highlighting CSA-131 as the best compound with lower 
MICs against all the strains. 
 
3.5.4. Time-killing curves experiments. 
 
Time-killing curves were performed for CSA-131 in order to observe the behaviour of 
this ceragenin against A. baumannii and P. aeruginosa. The results are showed in 
Figure 3.18. 
a) 
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b) 
 
 
Figure 3.18. Results of time-killing experiments. a) colistin-resistant A. baumannii incubated with CSA-
131. b) colistin-resistant P. aeruginosa incubated with CSA-131. 
 
For P. aeruginosa both 4xMIC and 8xMIC were bactericidal throughout the curve, 
however MIC and 2xMIC were bactericidal only at 4 and 8h and observing a regrowth 
at 24h.  
In the case of A. baumannii, only 8xMIC was bactericidal along the curve, both 2xMIC 
and 4xMIC were bactericidal at 1, 4 and 8h and a regrowth was observed at 24h, for the 
MIC only bactericidal activity was observed at 4h. 
 
During these chapter, three different approaches have been presented. In the first 
approach, focused on mastoparan and analogs, the results obtained were not 
satisfactory, although alternatives are suggested in order to achieve better in vivo 
activities. Natural peptides tested from frog-skin secretions have shown good 
antimicrobial activity, however due to its sequence it might be a very susceptible 
peptide for the action of proteases and peptidases, so further optimization should be 
performed prior to in vivo studies. Finally, the ceragenins, due to its structure, should 
avoid all the problems commented for the frog-skin secretions peptides, and should be 
good candidates to be active in vivo.  
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Context 
 
OmpA is an important virulence factor, and is one of the most abundant proteins in the 
cell wall. OmpA is the most important protein involved in the adherence to eukaryotic 
cells. Together with the group of Dr. Jeromino Pachón we set up a project in which the 
approach was different from the typical antimicrobial agent discovery. In this case the 
idea was to find out a compound able to inhibit the adherence between ompA and the 
epithelial cells. Therefore, we design a cyclic peptide able to block the activity of the 
OmpA. 
 
 
4.1. Protein homology, and virtual screening of EXORIS library 
 
The initial hypothesis was to synthesize compounds able to block the adherence effect 
of ompA to the epithelial cells. OmpA is a highly conserved protein in most of the 
Gram-negative bacteria. This 325-residue protein was thought to contain two domains. 
The classic N-terminal domain, consisting of 171 amino acid residues, was shown to 
cross the membrane eight times in antiparallel β-strands with four relatively large and 
hydrophilic surface-exposed loops and short periplasmic turns. The C-terminal domain 
is located in the periplasm, and binds to the peptidoglycan thus connecting it to the 
outer membrane In the PDB (Protein Data Bank), some of the structures are reported, 
two from X-ray and other two from NMR, but all of them belong to E. coli. figure 4.1 
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Figure 4.1. Chemical structure of OmpA. 
 
The size of the pore of the trasmembrane protein is between 13 to 16 Å, this size fits 
quite good with the hexacyclic peptide library present in our lab called EXORIS. 
EXORIS library is a hexacyclic simetric peptide library containing all types of amino 
acids, but always with two prolines in it. EXORIS library cover all types of properties, 
polar, none polar, positively and negatively charged, aromatic. 
 
After analyzing all the data from the PDB related to ompA, no structure of A. 
baumannii was found, however, and taking into account the high homology of ompA in 
all the Gram-negative bacteria, an homology model taking E. coli structure as a 
template was performed using I-TASSER program. Once the protein was obtained 
virtual screening of the EXORIS against the new ompA protein was launched. The 
results obtained are showed in the table. 4.1, and in the figure 4.2 to 4.8. 
 
 
 
 
13-16 Å 
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Cyclic peptide Docking score 
&Arg-D-Pro-Trp-Arg-D-Pro-Trp& -10.8 
&D-Trp-Pro-Arg-D-Trp-Pro-Arg& -10.6 
&Arg-Pro-Trp-Arg-Pro-Trp& -10.3 
&Trp-Pro-Arg-Trp-Pro-Arg& -10.0 
&Trp-Pro-D-Arg-Trp-Pro-D-Arg& -9.2 
&Arg-Pro-D-Trp-Arg-Pro-D-Trp& -8.9 
&Arg-D-Pro-D-Ile-Arg-D-Pro-Ile& -8.5 
&Trp-D-Pro-Arg-Trp-D-Pro-Arg& -8.5 
&Arg-D-Pro-Ile-Arg-D-Pro-Ile& -8.2 
&Ser-D-Pro-Trp-Ser-D-Pro-Trp& -7.5 
&Ser-D-Pro-D-Trp-Ser-D-Pro-Trp& -7.4 
&Ser-D-Pro-D-Ile-Ser-D-Pro-Ile& -7.3 
&Ser-D-Pro-Ile-Ser-D-Pro-Ile& -7.2 
&D-Ser-Pro-Ala-D-Ser-Pro-Ala& -7.1 
&Glu-D-Pro-Trp-Glu-D-Pro-Trp& -7.0 
&Ile-D-Pro-D-Trp-Ile-D-Pro-Trp& -6.8 
&Ser-D-Pro-Ala-Ser-D-Pro-Ala& -6.8 
&Ile-D-Pro-Trp-Ile-D-Pro-Trp& -6.7 
&D-Arg-Pro-Trp-D-Arg-Pro-Trp& -6.1 
&Ser-D-Pro-Glu-Ser-D-Pro-Glu& -6.1 
&Glu-D-Pro-D-Trp-Glu-D-Pro-Trp& -6.1 
&Ser-D-Pro-D-Glu-Ser-D-Pro-Glu& -6.1 
&Ser-Pro-Ala-Ser-Pro-Ala& -5.6 
&Glu-D-Pro-Ile-Glu-D-Pro-Ile& -4.6 
&Glu-D-Pro-D-Ile-Glu-D-Pro-Ile& -4.4 
&Gly-Pro-Ala-Gly-Pro-Ala& -2.9 
 
Table 4.1. Docking score of all the peptides from the EXORIS library. 
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The information that it is possible to extract from the in silico experiments have to be 
taken into account very carefully, due to the fact that the protein on which the virtual 
screening was performed is just a protein obtained from the homology model. In spite of 
the problems commented previously, the results obtained were really interesting, it is 
important to point out that the best six compounds had the same amino acids 
(Pro/Arg/Trp). The only difference between each other is just a change in the sequence 
and the different stereochemistry present in each compound.  
 
 
 
 
 
Figure 4.2 Different orientations and picture representations of a cyclic hexapeptide and ompA complex 
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Figure 4.3 Different orientations and picture representations of a cyclic hexapeptide and ompA complex. 
                       
Figure 4.4 Different orientations and picture representations of a cyclic hexapeptide and ompA complex. 
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Figure 4.5 Different orientations and picture representations of a cyclic hexapeptide and ompA complex. 
 
 
 
 
Figure 4.6 Different orientations and picture representations of a cyclic hexapeptide and ompA complex. 
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Figure 4.7 Different orientations and picture representations of a cyclic hexapeptide and ompA complex. 
 
 
 
 
 
 
Figure 4.8 Different orientations and picture representations of a cyclic hexapeptide and ompA complex. 
4.2. Synthesis of the hexacyclic peptides. 
 
Several of the EXORIS library peptides were synthesized in order to be tested as ompA 
inhibitors. The peptides selected are showed in the table. 4.2. 
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n° Cyclo peptide Rational 
MV6 &Arg-D-Pro-Trp-Arg-D-Pro-Trp& Candidate (Trp,Arg) 
MV5 &Trp-D-Pro-Arg-Trp-D-Pro-Arg& Sequence change 
MV3 &D-Arg-Pro-Trp-D-Arg-Pro-Trp& Different stereosiomer 
MV8 &Arg-Pro-D-Trp-Arg-Pro-D-Trp& Different stereoisomer 
MV9 &Ser-D-Pro-Trp-Ser-D-Pro-Trp& Arg replaced by Ser 
MV10 &Glu-D-Pro-Trp-Glu-D-Pro-Trp& Arg replaced by Glu 
NBA01011 &Ala-Ser-D-Pro-Ala-Ser-D-Pro& No Trp 
SXV4 Ac-Trp-D-Pro-Arg-Trp-D-Pro-Arg-OH Negative control 
Table 4.2. Peptides selected from EXORIS library to be synthesized taking into account in silico results. 
& symbol means cyclic peptides. 
 
The peptides were synthesized using SPPS, the resin used was the 2-Chlorotrityl 
chloride. The procedure used is explained in material and methods section. In the Figure 
4.9 it is possible to observe the HPLC and MALDI-TOF spectra of all the peptides 
synthesized. 
 
MV6 (&Arg-D-Pro-Trp-Arg-D-Pro-Trp&) 
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MV5 (&Trp-D-Pro-Arg-Trp-D-Pro-Arg&) 
             
 
MV3 (&D-Arg-Pro-Trp-D-Arg-Pro-Trp&) 
                   
 
MV8 (&Arg-Pro-D-Trp-Arg-Pro-D-Trp&) 
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MV9 (&Ser-D-Pro-Trp-Ser-D-Pro-Trp&) 
           
 
MV10 (&Glu-D-Pro-Trp-Glu-D-Pro-Trp&) 
     
 
NBA01011 (&Ala-Ser-D-Pro-Ala-Ser-D-Pro&) 
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SXV4 (Ac-Trp-D-Pro-Arg-Trp-D-Pro-Arg-OH) 
                      
 
4.3. In vitro evaluation of the peptides. 
 
(This worked was performed by Dr. Smani in the IBIS from the Hospital Virgen del 
Rocío, Sevilla). 
The aim of developing these compounds, as previously mentioned, was to inhibit the 
adherence between bacteria and eukaryotic cells, therefore two important features are 
necessary for these compounds, these are: i. not showing antibacterial activity by itself 
and ii. no cytotoxic activity. The first assays performed were the MTT assays in order to 
calculate the rate of toxicity of these peptides and the MIC against an A. baumannii 
strain, the results are showed in the table 4.3. 
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  Cell viability (%)  MIC (mg/L) 
  Peptide concentrations   
Peptide 0,25 mg/mL 0,5 mg/mL 1 mg/mL  ATCC 17978 
MV6 98,89±0,41 99,69±0,26 99,70±0,38  >500 
MV5 98,09±0,27 98,33±0,40 98,48±0,55  >500 
MV3B 99,47±0,39 99,77±0,17 100,13±0,18  >500 
MV8 99,27±0,21 99,7±0,14 99,36±0,3  >500 
MV9 98,86±0,08 100,05±0,39 98,89±0,43  >500 
MV10 98,31±0,35 99,14±0,44 99,38±0,34  >500 
NBA010011 98,17±0,60 98,79±0,28 98,55±0,21  >500 
SXV4 98,9±0,45 99,51±0,26 100,02±0,37  >500 
 
Table 4.3. Percentage of cell viability at different peptide concentrations and MIC of the different 
peptides. 
 
As it is possible to observe in the table above, any of the peptides tested showed 
antibacterial nor cytotoxic activities at the concentrations tested, therefore the next step 
was to test the ability of these peptides to block the interaction between eukaryotic cells 
and bacteria. The results obtained are showed in the Figure. 4.10 
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      SXV4 
 
Figure 4.10. Percentatge of bacterial adherence at different peptide concentrations in different peptides. 
*p<0.05, treatment vs ATCC17978. 
 
 
Analyzing the results of adherence, it was possible to observe that the best compound in 
the docking experiments (MV6) decrease the adherence around 60% in all the three 
concentrations tested, and with just changing the sequence for an Arg-Trp (MV5) 
instead of Trp-Arg the adherence decreases to 20 % at 1 mg/mL, and for this peptide the 
percentage of adherence was depending on the peptide concentration.  
If we move the D-stereochemistry to the Arg (MV3B) compared to the best in silico 
compound (MV6), the activity was similar compared to MV6, with a 40 % of adherence 
at the highest concentration (1 mg/mL), the activity of this peptide was also 
concentration dependent. Next stereochemistry change was moving the D-
stereochemistry to the Trp, the activity (MV8) was worse, and surprisingly the most 
active concentration is the lowest (0.25 mg/mL), in this case the activity of the peptide 
is reverse to the peptide concentration. The next two peptides are different than the ones 
tested previously, in this case the Arg was replaced by a Ser (MV9) and a Glu (MV10) 
in order to have an idea of the behavior of hexacyclic peptides containing other type of 
amino acids. The results for MV9 were peptide concentration dependent and the best 
result was achieved in the highest concentration used (1 mg/mL) with around 30 % of 
bacterial adherence, for the peptide with the Glu the results were worse with a bacterial 
adherence of around 60 % in all the three concentrations tested. Peptide NBA01011 was 
tested in order to check the behavior of the cyclic peptide without neither Arg nor Trp, 
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in this case Ala and Ser were used, and surprisingly, some activity was observed with an 
inhibition of the 70 % of the adherence at 1 mg/mL. 
 All the peptides, had at least some activity of inhibiting the adherence of bacteria to 
cells, however some demonstration that not all the peptides were able to bind was need, 
therefore a lineal peptide of the best in vitro compound MV5 was synthesized, with a 
carboxylic acid group as a C-terminal and acetylated in the N-terminal, and the results 
of this compound were the expected ones with no inhibition in the adherence (SXV4). 
 
On comparing the data obtained in the docking experiments and in the in vitro assays it 
was possible to show that the initial in silico assays fitted really good with the results 
obtained, eventhough the protein used was not the real one, therefore after analyzing all 
the data MV5 was chosen as the candidate to continue performing all the assays initially 
planned.  
A large quantity of this compound was synthesized following the same procedures as 
explained previously. 
 
The inhibition of the bacterial adherence was just tested with a highly antibiotic 
susceptible A. baumannii strain (ATCC 17978), hence it was necessary to try the same 
procedure using a strain with highly resistant profile, therefore assays using a multi-
drug resistant and pan-drug resistant A. baumannii strains were performed. The results 
are showed in figure 4.11. 
 
               a) 
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Figure 4.11. a) Percentage of inhibition assay between cells and a MDR at a different peptide 
concentrations. b) Percentage of inhibition assay between cells and a PDR at a different peptide 
concentrations. 
 
The results for both strains were similar, however were slightly better as less resistant 
was the strain, thus it was possible to observe a range of activity starting with the ATCC 
17978 with a 20 % of adherence at 0.5 mg/mL, for the same concentration the 
percentage of adherence in MDR strain increases up to 30 % and going further with a 
PDR strain, it doubles the percentage of bacterial adherence with 40 % at 0.5 mg/mL. 
Although the values increases when the resistance of the strain increases the percentage 
of inhibition was still really good, by inhibiting 60 % of adherence in a strain resistant 
to all the antibiotics.  
 
In the article published by Smani et al. (186), they demonstrate that the protein from the 
cells that was involved in the adherence to bacteria was fibronectin. Fibronectin is a 
high molecular weight protein (440 KDa) present in the extracellular matrix, it exists as 
a protein dimer, consisting of two nearly identical monomers linked by a pair of 
disulfide bonds. Fibronectin plays a major role in cell adhesion, growth, migration, and 
differentiation, and it is important for processes such as wound healing and embryonic 
development (187). Altered fibronectin expression, degradation, and organization has 
been associated with a number of pathologies, including cancer and fibrosis (188).  
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The idea was to quantify the percentage of bacteria attached to fibronectin in order to 
know that the real inhibition was by blocking this interaction. It was tested against the 
same three different strains previously used. The results are showed in the Figure 4.12. 
 
a) 
 
 
b) 
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Figure 4.12. a) Percentage of adherence between fibronectin and a very susceptible strain at a different 
peptide concentrations. b) Percentage of adherence between fibronectin and a MDR strain at a different 
peptide concentrations. c) Percentage of adherence between fibronectin and a PDR strain at a different 
peptide concentrations. *p<0.05, treatment vs A. baumannii. 
 
 
In the figures above it is possible to observe that the compound MV5 inhibit in between 
50 and 60 % the adherence between fibronectin and bacteria. It is important to highlight 
that the amount of fibronectin attached was the same in all the strains used, however in 
the previous assays, the adherence was different in the different resistant strains, 
therefore this may suggest that MV5 could block other factors involved in the 
attachment of the bacteria.  
 
Another way to measure the effectiveness of this compound was by calculating the cell 
viability in presence of the compound. Since the interaction between eukaryotic cell and 
bacteria produces the death of the cells, the role of the peptide should be to keep more 
cells alived. The results of the experiments carried out are showed in the figure 4. 13. 
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a) 
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Figure 4.13. a) Percentage cell viability when incubated with a very susceptible strain and peptide at 
different concentrations. b) Percentage cell viability when incubated with MDR strain and peptide at a 
different concentrations. c) Percentage cell viability when incubated with PDR strain and peptide at a 
different concentrations. *p<0.05, treatment vs A. baumannii. 
 
 
 
 
The results shown in figure 4.13 are very interesting. In the most susceptible strain, the 
percentage of cell viability increases from around 50% to more than 80 % when 0.5 
mg/mL of MV5 was added, however when SXV4 is added at the same concentration, 
no effect is observed. When dealing with a more resistant strain such as a MDR, it 
increases from 80% to 100 % of cell viability, and as in the previous case the effect of 
SXV4 was negligible. In the case of PDR bacteria an increase from more than 70% to 
more than 90 % was observed. It is worthy of mention that the values used as a 
treatment were significantly different compared to the no treatment. 
 
In all of these experiments performed we have observed that this cyclic peptide could be 
a good therapeutic option to treat A. baumannii infections, therefore we decided to carry 
out some in vivo experiments. The first experiments performed were the toxicity in vivo, 
the results obtained are showed in the Table 4.4. 
 
 
 LD0 LD50 LD100 
MV5 (mg/kg) 40 80 160 
 
Table 4.4. Toxicity of MV5 in vivo. 
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The results obtained showed that a dose of 40 mg/Kg all of the mice were alive after 1 
week, when a double dose was injected the percentage of survival mice was reduced to 
50, and when 160 mg/kg was administered no survival was observed. 
Next step was to determine the ED50. The concentrations used were 10, 20 and 40 
mg/Kg. The doses were administered 2h after the infection with a lethal dose, and the 
strain used for this experiment was A. baumannii ATCC 17978. 
 
  MV5 (mg/kg) 
 10 20 40 
Survival (%) 66,67 83,33 50 
 
Table 4.5. ED50 of MV5 at different doses.. 
 
The three doses tested causes more than 50% of survival, therefore the best results were 
obtained with 20 mg/Kg, with which 83.33 % of survival is achieved. However going 
up in the doses with 40 mg/Kg the survival decreases to 50% probably due to the 
combination between the infection damage and the toxicity of the peptide. The 
percentage of survival when 10 mg/kg was administered was 66.67.  
 
After calculating the ED50, the local effectiveness of the peptide was determined, thus a 
murine sepsis peritoneal model was performed and 4 groups of mice were used. A 
group control one the other three with doses at 24, 48 and 72h respectively. In each 
group the amount of bacteria in lungs and spleen were calculated. The results obtained 
are showed in table 4.6. 
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Strain and treatment n Spleen bacterial  
concentration 
(Log CFU/g) 
Lung bacterial  
concentration 
(Log CFU/g) 
ATCC 17978 (control) 6 9.52 ± 0.17 9.78 ± 0.17 
ATCC 17978 + MV5 10 mg/kg 
24 h 
6 8.79 ± 0.16 9.21 ± 0.28 
ATCC 17978 + MV5 10 mg/kg 
48 h 
6 6.9  ± 1.32 6.81 ± 1.31 
ATCC 17978 + MV5 10 mg/kg 
72 h 
6 5.48 ± 1.34 5.97 ± 1.46 
  
Table 4.6. Log CFU/g in spleen in lungs in the four different groups. 
 
The first group was sacrificed 24h after the infection and the log CFU/g was 9.52 and 
9.78 for spleen and lungs, respectively, when a dose (10 mg/Kg) 2h after the infection 
was administered the amount of bacteria decreases to 8.79 and 9.21 log CFU/g in spleen 
and lungs, respectively. When 2 doses were administered, at 2h and 24h after the 
infection the amount of bacteria in lungs and spleen decreases considerably with values 
around 7 log CFU/g, and with 3 doses the values were even better achieving 5.48 and 
5.97 log CFU/g in lungs and spleen, respectively. 
 
The last experiments performed were the pharmacokinetic of this compound, 10 mg/Kg 
were injected to several mice and at different times, the concentration of peptide in the 
serum of the animal was calculated. The results are showed in figure 4.14. 
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Figure 4.14.Concentration of MV5 in vivo at a different times using a dose of 10 mg/Kg. 
 
The results obtained in the pharmacokinetic analysis are showed in the figure above 
indicate that the maximum concentration achieved by the peptide was around 12 mg/L 
at 30 minutes, and the half-life time of the MV5 was slightly less than 50 minutes as it 
is showed in the red line 
 
In summary from the work reported in this chapter, we have indetified an hexacyclic 
peptide able to inhibit the virulence of several A .baumannii strains both in vitro and in 
vivo trough a novel mode of actionbased on blocking the binding of bacteria OmpAto 
host-cell fibronectin. 
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Nowadays daptomycin and colistin are, together with the glycopeptides, the peptidic 
antibiotics used in the clinical setting. The resistance to daptomycin and colistin in the 
different microorganisms is steadily increasing, therefore our work in the first part of 
this doctoral thesis focused in the study of the mechanisms of resistance of A. 
nosocomialis and S. mitis to colistin and daptomycin, respectively. 
The mechanism of action of daptomycin is associated with the depolarization of the 
membrane of the Gram-positive bacteria. Among the potential mechanisms of resistance 
to daptomycin an increase of the thickness of cell wall is considered. In daptomycin-
resistant S. aureus, the thickness of the cell increases or decreases (166) independently 
of the resistant grade. In our study regarding the resistance to daptomycin in S. mitis, an 
slight increase in the thickness of the cell wall was observed in the daptomycin-resistant 
strain compared to its daptomycin-susceptible counterpart, however this difference was 
not significant enough to be considered as a mechanism of resistance to daptomycin, 
therefore, there was not an strong evidence that resistance to daptomycin implicates an 
increase of the cell wall thickness in S. mitis. 
After not being successful with the first hypothesis of the implication of the increase in 
cell wall thickness, the idea of using a proteomic approach to compare the protein 
expression between daptomycin-susceptible and –resistant strains was choosen. Several 
proteins appeared to be overexpressed or repressed in the daptomycin-resistant strain 
compared to the original daptomycin-susceptible strain, however and due to the effect 
of daptomycin on the membrane we just focused in a first phase in the proteins related 
to the membrane. Two proteins have been identified to be overexpressed in the 
daptomycin-resistant strain. The first protein is streptococcal surface immunogenic 
protein which is up-regulated 2.26 fold. It is worthy of mention that this protein 
contains a lysine motif (LysM), the function of this motif is not well known however it 
is thought that it may have a general peptidoglycan binding function (189). This domain 
is typically found in the enzymes involved in the cell wall degradation (190). The 
second protein found has an unkown function, however it has a similar domain to a cell 
wall-active antibiotics response protein, in which YvqF/VraSR are included described 
in S. aureus (191) and Bacillus subtilis (192). In the article published by Kato et al. 
(193), it was found that in S. aureus strains resistant to teicoplanin (glycopeptide) some 
amino acidic changes were observed in the proteins YvqF and in the two component 
system VraSR. VraS is a two component histidine kinase sensor, and it has his analog 
LiaFSR in Bacillus subtilis, this protein is the one involved in the resistance to 
Discussion 
136 
 
bacitracin (194) and YvqF is a conserved hypothetical protein. Although the function of 
YvqF is not known there are strong evidences that it could be involved in the cell wall 
metabolism because is located upstream of vraS and the transcription of this protein is 
regulated by VraSR system.  
These are the two candidates of being the proteins involved in the daptomycin 
resistance in S. mitis. If we compare this hypothetical proteins with the already known 
proteins involved in daptomycin-resistant to S. aureus and Enterococcus. VraSR was 
also found to be up-regulated in daptomycin resistant for S. aureus (195), and its 
homologue in Enterococcus faecalis (LiaFSR) was also reported as being involved in 
daptomycin resistant (7) by mutations in the gene when the genome of both 
daptomycin-susceptible and daptmycin-resistant strains were sequenced. As it has been 
reported in the resistance to daptomycin, a two-component system seems to be involved 
in the mechanism of resistance. Another two-component system is also involved in the 
resistance of another peptide which is colistin. The two-component system implicated in 
colistin resistance in A. baumannii is PmrAB. It induces the expression of the pmrC, a 
gene encoding a Lipid A phosphoethanolamine transferase, which adds 
phosphoethanolamine moieties into the phosphate of the Lipid A, which reduces the 
negative charge of the outer membrane and thereby decreases binding of positively 
charged colistin (89, 90). Some mutations in the pmrA and pmrB genes are the 
responsible of colistin-resistance (88). In addition, Moffatt et al. (91) indicated that the 
basis for polymyxin resistance in A. baumannii was mutations in the first 3 genes of the 
lipid A biosynthesis pathway, called, lpxACD, and that this led to complete loss of LPS 
production and supersusceptibility to other antibiotics.  
A. nosocomialis together with A. pittii and A. baumannii constitute the A. baumannii 
group. In the last years the nosocomial importance of A. nosocomialis and A. pittii has 
increased, even in some reports the prevalence of these microorganisms as a causative 
agent of nosocomial infections is higher that the reported to A. baumannii (196). 
Although overall A. nosocomialis clinical isolates are more susceptible to antibacterial 
agents than A. baumannii, colisitin-resistant A. nosocomialis clinical isolates have been 
reported (197), therefore an investigation of the molecular bases of colistin resistance in 
A. nosocomialis was carried out. In order to perform this study a high level colistin-
resistant A. nosocomialis mutant was obtained by a multi-step method. During the first 
steps of selection, the mutants obtained tolerate colistin up to a concentration of 8 mg/L, 
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however the MIC of colistin of these mutants was below 1 mg/L, a sudden increase in 
the MIC from < 1 mg/L to 128 mg/L was observed. This tolerance may be related to the 
induction of specific genes by colistin. The high-colistin resistant mutant strain showed 
a different phenotype compared to the colistin-susceptible wild type strain, 
characterized by the lost of the ability to growth on MacConkey agar and to show 
increased susceptibility to different antibacterial agents. On comparing the genome 
sequence of the susceptible and highly-resistant colistin A. nosocomialis strains, no 
mutations were found in any of the three genes that conformed the pmrABC operon, 
however although no mutations were neither found in the lpxA and lpxC genes, several 
mutations and a stop codon were found the lpxD gene. All the strains before the MIC 
increase had no mutations in any of the genes commented previously, however, after the 
break point several mutations, and a codon stop appeared.  
In the study by Moffatt and colleagues several mutations in the lpxA and lpxC were 
found and only a point mutation in the lpxD gene consisting in a single base deletion at 
the nucleotide 952 generating a frameshift after amino acid K317. Therefore the stop 
codon that we found was located in the nucleotide 810, before the above described 
mutation. To corroborate that this truncated protein was detrimental for the synthesis of 
the LPS, the amount of LPS was quantified by a kinetic chromogenic LAL assay 
showing a huge difference in the production of the LPS of the colistin-susceptible strain 
compared with the colistin-resistant strain. This result corroborates that the complete 
lost of LPS production is associated with colistin resistance in A. baumannii related to 
Lpx deficiency (91).  
A proteomics study of a colistin-resistant A. baumannii ATCC 19606 strain identified 
35 proteins, including several outer membrane components, whose expression was 
downregulated relative to the colistin-susceptible phenotype (198). 
Proteomic studies comparing both colistin-susceptible and colistin-resistant A. 
nosocomialis strains were performed, and the results obtained were really surprising 
observing different results compared with the proteomic comparison between colistin-
susceptible and colistin-resistant of A. baumannii (198). Some of the proteins found in 
A. nosocomialis were the same as found in A. baumannii, however in A. nosocomialis 
were up-regulated, and in A. baumannii were down-regulated. Observing that these 
proteins are up-regulated or down-regulated does not mean that this is an effect of 
colistin-resistance, because observing the proteome comparison between a multi-drug 
resistant and very susceptible A. baumannii strain some of the proteins observed are the 
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same as in the others examples (199). It is also important to mention that the strain 
obtained has a very susceptible profile with very low MICs against most of the 
antibiotics. OmpA was overexpressed in A. nosocomialis 2-fold however in A. 
baumannii it was down-regulated around 3-fold, the same effect is observed in CarO 
downregulated 2.35 fold in A. baumannii and overexpressed 1.7 times in A. 
nosocomialis. This fact have a racional justification, in A. nosocomialis it is possible to 
observe a decrease in the MIC of ertapenem and imipenem due probably to the effect of 
CarO, however in A. baumannii despite of the fact that CarO was repressed the same 
MIC is observed for imipenem in both strains. CarO was reported to enhance the 
entrance of imipenem, and when it is deficient is a mechanism of resistance (200). An 
hypothesis of the overexpression of ompA in the resistant strain could be explained only 
with the theory that colistin could have a parallel intracellular mechanism. Colistin-
resistant A. nosocomialis is less virulent than the colistin-susceptible even though 
OmpA is overexpressed, this information showed us that there are other virulence 
factors apart from the OmpA. In the case of OmpW the same contrary effect is observed 
compared with A. baumannii, were decreased levels of this proteins are observed when 
resistance to colistin exists (201). The hypotethical protein (2.1-fold) that belong to the 
NodT family have a role in the inner membrane in a efflux system, that export small 
molecules. The only proteins that are down-regulated in the resistance strain are Porin 
(OprB) Carbohydrate-selective porin (-1.9), this protein together with OmpA have 
recently been found as a immunogenic protein candidate for a potential vaccine (202) 
and signal peptide protein (-1.2). The first protein is involved in the transit of the 
carbohydrate, which probably is directly unrelated with colistin-resistantce, and the 
second protein, which is a peptide, has a role in the degradation MetA-pathway of the 
phenol. The remaining proteins seems to be irrelevant. It is important to highlight that 
the colistin-resistant A. nosocomialis strain showed a reduced virulence compared with 
its susceptible counterpart. This result is in agreement with what has been shown in A. 
baumannii in which it was found that a more striking reduction of the virulence was 
associated with LPS loss than with phosphoethanolamine addition (203; 48). However, 
it has also been described that compensatory mutations can restore the virulence of the 
colisitin-resistant A. baumannii strains (204) 
 
We have studied the mechanism of resistance to peptidic antibiotics available in the 
pharmaceutical market such as daptomycin and colistin, although the knowledge of 
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these mechanisms of resistance is very important to adopt different approaches in the 
potential discovery of derivatives which circumvent the known mechanism of 
resistance, the search for new antibacterial agents active against multidrug resistant 
bacteria is desperate. In this sense, A. baumannii has currently described as an important 
problem since pandrug resistant clinical isolates have already been reported, therefore 
we have focused our efforts in this microorganism. In the last decade, due to the lack of 
develop of new antibacterial agents, the search of inhibitors of virulence factors have 
been improved with the aim of blocking the developing of the infection. This approach 
has several advantages such as, compounds able to inhibit a common virulence factor 
found in several bacteria or an inhibitor of a virulence factor of a specific bacteria can 
be developed, this later aspect is important since the host endogenous microbiome can 
be preserved, in addition, this inhibitor will likely exert a less selective pressure, 
therefore none selecting resistance mutants. Two different approaches were followed in 
order to discover new drugs active against colistin-resistant A. baumannii infections.  
The first approach was based on the developing of antivirulence drugs. The main target 
selected was OmpA, a major porin found in A. baumannii, since it is one of the main 
proteins involved in the adherence of this microorganism to epithelial cells causing 
pneumonia, therefore our idea was to develop a compound capable to interact with this 
protein and hence to block the interaction between the bacteria and the cell. We though 
that designing cyclic peptides able to interact with the inside part of the channel of the 
porin we can achieve this goal. The initial approach was to design the cyclic peptides by 
using in silico tools, a virtual screening of an hexacyclic peptides library was performed 
against OmpA and afterwards the peptides were synthesized and tested in vitro to probe 
that indeed they were able to block the activity of the OmpA. Among the synthesized 
cyclic peptides, MV5 shows the best results and we proceed to the in vivo studies with 
this compound, showing an excellent result since a significant decrease of mortality 
after just one dose of the peptide was observed.  
This is the first time that an inhibitor of the OmpA was developed. As mentioned above 
OmpA is one of the immunogenic proteins found in the outer membrane, therefore it 
has also been used as a vaccine to try to immunize mice and the results were good 
achieving high survival percentages (162), a similar approach was followed by 
Pachón’s group, but in this case the vaccine was not only ompA, since they include 
other outer membrane proteins and it was called outer membrane complex (OMC) 
(205).  
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A similar approach searching for a compound able to inhibit LpxC, one of the proteins 
involved in the cascade of the synthesis of the LPS has been reported. This inhibitor did 
not kill the bacteria with a concentration lower than 512 mg/l, only inhibit the 
production of LPS. LPS is recognized by Toll-like receptor 4 (TLR4), therefore the aim 
of this strategy was to find a compound able to inhibit LpxC and the synthesis of LPS, 
whit the consequent no activation of the TLR4 and protection of the mice from lethal 
infection. (206) 
 
The second approach used was the search for new antimicrobial agents. Three different 
type of compounds were used, different peptides from different sources, peptides 
isolated from frog skin secretions and a fully synthetic compounds like the ceragenins 
which were tested against three different species of colistin-resistant bacteria. Among 
the 15 peptides investigated, cecropin P1, colistin, melittin, indolicidin and mastoparan 
showed activity against colistin-susceptible A. baumannii, but only mastoparan and 
melittin showed good activity against both colistin-susceptible and colistin-resistant A. 
baumannii. It is worthy of mention that the HNP-1 showed good activity only against 
colistin-resistant A. baumannii. In previous studies performed by Saugar et al. (207) and 
Rodriguez-Hernandez et al. (132) several hybrid peptides composed of a mixture of 
cecropin A and melittin showed MICs of 2–8 mg/L against 13 clinical isolates of 
colistin-resistant (4–64 mg/L) A. baumannii. In our study, the MICs were 4 mg/L for 
mastoparan against colistin-susceptible A. baumannii and 1 mg/L for mastoparan 
against colistin-resistant A. baumannii with an MIC for colistin of 256 mg/L. On 
comparison of the MIC50 and MIC90 of cecropin A–melittin and mastoparan for colistin-
resistant A. baumannii, they were found to be slightly lower, by one or two dilutions, for 
cecropin A–melittin than for mastoparan. Several studies have investigated mastoparan 
activity, but there has been no report on the activity of mastoparan against A. baumannii 
(208). In the study performed by Giacometti et al. (209), a similar set of peptides was 
used, but only against colistin-susceptible A. baumannii, with buforin II (MIC range 
0.25–16 mg/L), magainin II (MIC range 0.50–16 mg/L) and cecropin A (MIC range 
0.50–32 mg/L) being the most active AMPs against colistin-susceptible A. baumannii, 
in contrast to our study, in which only cecropin P1 showed good activity against colistin 
susceptible A. baumannii. Mastoparan is not the only peptide isolated from wasps. All 
of the peptides isolated from wasps have very similar sequences, with changes in only 
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some amino acids, but their activity can vary, changing from an MIC of 58 mg/L to one 
of 164 mg/L with just one amino acid substitution in the peptide (210). On comparison 
of the time-killing curves of mastoparan and cecropin A–melittin, similar behaviour was 
seen. Cecropin A–melittin was bactericidal at lower concentrations in some strains 
tested, but in others there was regrowth that was not observed in mastoparan time 
killing curves (132). In a study by Li et al. (211), a time-killing curve for colistin against 
ATCC 19606 colistin-susceptible A. baumannii was obtained. On comparison of this 
time-killing curve with that obtained in our study with mastoparan, it can be seen that 
the bactericidal effect of colistin was faster than that of mastoparan. Moreover, colistin 
was bactericidal at lower concentrations than mastoparan for colistin-susceptible A. 
baumannii, but, in contrast, regrowth was observed in the colistin time-killing curve that 
did not appear when mastoparan was used. The fact that mastoparan shows activity 
against both colistin- susceptible and colistin-resistant A. baumannii may suggest that 
the mechanisms of action used by mastoparan and colistin are different.The mechanism 
of action of colistin may be related to disruption of the bacterial membrane. Mastoparan 
could act as a cell-penetrating peptide, crossing the bacterial membrane (212). However, 
Li et al. (213) analysed the effect of mastoparan against Escherichia coli and 
Staphylococcus aureus by scanning electron microscopy, and suggested that mastoparan 
acts on the cell surface, resulting in different abnormalities depending on the 
microorganism. In conclusion, mastoparan showed a good in vitro bactericidal activity 
against both colistin-susceptible and colistin-resistant A. baumannii. Several analogs of 
mastoparan were synthesized in order to increase the stability in human serum and 
maintain the same activity as mastoparan. The only peptides synthesized that had the 
same activity as mastoparan were peptide 1, peptide 10 and peptide 13, however all of 
them showed higher cytotoxicity but an increase in the stability in human serum. 
Peptide 10 together with mastoparan were selected to be tested in vivo in a mouse 
model, however no activity was observed against infections caused by A. baumannii. 
We suggest that this loss of activity in vivo may be associated with the high binding to 
the proteins found in serum, specially albumin. 
Previous studies have shown that the peptides [E4K]alyteserin-1c (183) and 
[D4K]B2RP (184) show high potency against colistin-susceptible A. baumannii clinical 
isolates. We have now extended these studies by demonstrating that these peptides show 
comparable, and in some cases even greater, potency against colistin-resistant A. 
baumannii and A. nosocomialis strains. In addition, three naturally occurring peptides 
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with low haemolytic activity (CPF-AM1, PLGa-AM1 and B2RP-ERa) and one non-
haemolytic analogue of a naturally occurring peptide ([G4K]XT-7) have been identified 
that are active both against colistin-susceptible and colistin-resistant Acinetobacter sp. 
strains. Overall, [D4K]B2RP and [E4K]alyteserin-1c were the most effective against the 
colistin-resistant strains. [E4K]alyteserin-1c has the advantage of very low haemolytic 
activity (LC50 > 1000 µg/mL compared with 250 µg/mL for [D4K]B2RP) but is active 
against only Gram-negative bacteria (183). [D4K]B2RP, however, is active against 
Gram-positive bacteria and against Candida (184). In common with the majority of frog 
skin AMPs, the peptides used in this study do not show any secondary structural 
features in aqueous solution, but in a membrane-mimetic solvent (50% trifluoroethanol–
water) they adopt a stable amphipathic α-helical conformation with the cationic lysine 
residues segregating on one face of the helix and the hydrophobic residues on the 
opposite face (214). There is no single mechanism by which the peptides produce cell 
death, but their mode of action usually involves binding to, and penetration into, the 
inner bacterial cell membrane with eventual destruction of membrane integrity (215). 
Conformation studies using proton nuclear magnetic resonance (1H NMR) indicate that 
the helix in [E4K]alyteserin-1c extends between residues Lys3 to Val21 and, in the 
presence of sodium dodecyl sulphate, dodecylphosphocholine and 1,2-dihexanoyl-sn-
glycero-3-phosphatidylcholine micelles, the N-terminal domain (amino acid residues 1–
19) in the peptide is inserted into the micelle (214).  
Cationic AMPs interact electrostatically with the outer membrane of Gram-negative 
bacteria and cross this barrier by a process termed ‘self-promoted uptake’ which is 
similar to that adopted by colistin. This involves the peptide competitively displacing 
divalent cations from surface LPS causing outer membrane perturbation and thereby 
promoting further peptide uptake (216). The fact that certain strains of A. baumannii are 
resistant to colistin but susceptible to the frog skin peptides implies that the initial 
binding site of the peptides on the outer membrane differs from that of colistin. It has 
been shown that a cecropin A–melittin hybrid peptide has a higher affinity than colistin 
towards LPS from colistin-resistant but not from colistin-susceptible strains (207). 
Despite the fact that the frog skin peptides used in this study are effective both against 
colistin-susceptible and colistin-resistant strains of A. baumannii and A. nosocomialis 
and show low cytotoxicity against human red blood cells, their therapeutic potential is 
limited, like all peptide-based drugs, by their short half-lives in the circulation. Attempts 
to prepare a long-acting derivative of [E4K]alyteserin-1c by coupling a palmitate group 
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to the α-amino group in the peptide were disappointing as the resulting analogue 
showed greatly increased haemolytic activity (183).  
If we compared the results of the activity against A. baumannii of the frog skin 
secretions peptides with the mastoparan analogues the values of MICs were similar, 
however mastoparan and the best analogues have a high stability in human serum and 
probably the skin frog secretion peptides (formed by L-amino acids) will have a lower 
time life in human serum but they are less hemolytic than mastoparan compounds, 
therefore further optimization of these natural peptides should be performed in order to 
have a future candidate to treat invasive nosocomial infections. These peptides may be 
limited to topical applications, such as aerosol treatment of respiratory infections and 
treatment of Acinetobacter sp. infected burns and wounds in war trauma patients (217). 
Ceragenins could avoid the problem of stability commented above due to the fact that 
they are not really peptides. Another advantage of this type of compounds is their ability 
of being effective against several type of bacteria, therefore showing a broad spectrum 
of activity. In our study, among the four ceragenins tests (CSA-13, -131, -44 and -138), 
CSA-131 showed the best activity with a MIC of 0.5, 2 and 8 mg/L for colistin-resistant 
P. aeruginosa, colistin-resistant A. baumannii and colistin-resistant K. pneumoniae, 
respectively. The MIC90 of CSA-131 for both colistin-resistant P. aeruginosa and 
colistin-resistant A. baumannii was of 2 mg/L. CSA-131 showed a rapid bactericidal 
activity at 2X, 4X and 8X the MIC against colistin-resistant A. baumannii strains. In the 
article reported by Pollard et al. (218) they compared the ability of acquiring resistance 
to colistin, ciprofloxacin (quinolone) and ceragenin in P. aeruginosa and A. baumannii 
and they found that ability of acquiring resistance to colistin and ciprofloxacin was 
much higher compared to ceragenin. CSA-13 was tested against carbapenem-resistant 
A. baumannii (219), and the results reported were similar as the observed in our study, 
this confirms the theory exposed that the MIC of ceragenins is independent of the level 
of resistance to several antibacterial agents of the strain tested. CSA-131 was the 
compound that gave us better results, however the similarity with CSA-13 is very high 
only differing in the length of the hydrophobic part. Further in vivo studies are needed 
to probe its use to treat systemic infections caused by multidrug-resistant bacteria. 
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1. Daptomycin resistant grade is not associated with thickness of the cell wall in S. 
mitis. 
2. Two proteins identified as conserved hypothetical protein and group B 
streptococcal surface immunogenic protein are overexpressed 1.33 and 2.26 fold 
respectively. These proteins may play an important role in daptomycin 
resistance in S. mitis due to its high homology with proteins found in other 
bacteria to be involved in daptomycin resistance. 
3. The MIC for colistin in A. nosocomilais increases drastically from <1 mg/L to 
128 mg/L, when the microorganism is exposed to colistin, observing no growth 
on McConkey. 
4. The MICs of several antibiotics for the colistin-resistant A. nosocomialis 
mutants generated decreased from 1 to 11-fold. 
5. A decrease in the virulence of colistin-resistant A. nosocomialis mutant is 
showed compared to its colistin-susceptible counterpart. 
6. Colistin resistance in A. nosocomialis was linked to the lost of LPS, associated 
with several mutations and a stop codon observed in the lpxD gene.  
7. Several proteins were found to be up-regulated or down-regulated when 
comparing colistin-susceptible and colistin-resistant A. nosocomialis strains. 
Any of them seems to play an important role in the colistin resistance, however 
they may be important in the reduction of the MICs against several antibiotics. 
8. Indolicidin, melittin and mastoparan show a good activity against both colistin-
susceptible and colistin-resistant A. baumannii strains.  
9. Mastoparan show a bactericidal behavior at 8-fold MIC in both colistin-
susceptible and colistin-resistant A. baumannii strains, and 4-fold MIC in the 
colistin-resistant A. baumannii. 
10. Mastoparan, a lineal peptide, shows an exceptional high time-life in human 
serum (6h), observing only the lost of the N-terminal isoleucine as resulting 
product of the action of proteases and peptidases. 
11. Three peptides (peptide 1(Gu-INLKALAALAKKIL-NH2), peptide 10 
(inlkalaalakkil-NH2) and peptide 13(INLKALAALAKKIL-CH2CH2NH2) from 
all the analogs synthesized, show the same activity as mastoparan. The results 
observed in all the analogs highlight the importance of the N-terminal positive 
charge. 
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12. Mastoparan and peptide 10 show a very low hemolytic activity at MIC 
concentrations, modest cytotoxicity and higher toxicity in vivo, being 8 mg/Kg 
for peptide 10 and 32 mg/Kg for mastoparan. 
13. No antibacterial effect was observed in vivo, in any of the conditions tried, for 
peptide 10 and mastoparan. The reason is likely associated with the strong 
bonding of both peptides with proteins present in the serum. Observing a higher 
MIC when MIC assays were performed in presence of serum. Albumin is the 
protein which mastoparan binds to when is incubated with serum. 
14. Mechanism of antibacterial action of these above mentioned peptides may be 
related with membrane disruption as observed both by leakage assays and 
transmission electron microscopy. 
15. [E4K]alyteserin-1c and [D4K]B2RP, peptides isolated from skin-frog 
secretions, show a good activity against both colistin-susceptible and colistin-
resistant Acinetobacter species. 
16. All the ceragenins tested, specially CSA 131, show a good activity against both 
colistin-susceptible and colistin-resistant P. aeruginosa, A. baumannii and K. 
pneumoniae. 
17. A bactericidal effect of CSA 131 is observed against colistin-resistant P. 
aeruginosa and A. baumannii at all the concentrations tested, however a 
regrowth is observed at low concentrations.  
18. All of the hexacyclic peptides tested as ompA inhibitors show inhibition of the 
OmpAmediated adherence to host cell. 
19. MV5 (cyclo[pwrpwr]) decreases the binding between OmpA and fibronectin 
and increases the host cell viability in the presence of different A. baumannii 
strains tested. MV5 has also a very low in vivo toxicity, since all of the mices 
survive at 40 mg/Kg. 
20. ED50 in mice was achieved in all the doses tested. At 10 mg/Kg a high decrease 
in the number of bacteria in lungs and spleen was observed, and reaches a 
concentration of around 12 mg/L and a half-life time of around 50 minutes. 
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1. Microbiologycal methods. 
 
1.1. Strains used in this thesis. 
 
ATCC 1906 and ATCC 17978 are reference strains, ATCC 19606 col-R is the isogenic 
strain generated after incubation with colistin as explained in the thesis. Colistin-
susceptible A. baumannii strains used in the assay of calculation of MIC50 and MIC90 of 
colistin were clinical isolates from REIPI (Spanish network research in infectious 
disease). Colistin-resistant A. baumannii strains used in the assay of calculation of 
MIC50 and MIC90 were clinical isolates from Hospital Virgen del Rocío (Sevilla), strains 
Ab113, Ab11, Ab22P and Ab1 used in the same chapter also belong to this group. CS01 
is a colistin-susceptible A. baumannii strain, and CR17, CR86 are colistin-resistant A. 
baumannii strains, the three of them belong to the same clone, and were isolated in 
Hospital Virgen del Rocío (Sevilla) . Strain 77778 is a clinical isolate from Hospital 
General de Asturias, and strain G13 (A. nosocomialis) is also a clinical isolate from 
REIPI, colistin-resistant mutants were generated also with these two strains. Five multi-
drug A. baumannii strains (NM8, NM35, NM75, NM109 and NM124) were isolated at 
four different hospitals in the Emirate of Abu Dhabi. Strain 113-16 is a clinical pan-
resistant A. baumannii isolate from the Hospital Virgen del Rocío (Sevilla). Strain 77 is 
a multi-drug resistant A. baumannii strain isolated in the Hospital Clinic (Barcelona). 
Both colistin-susceptible and colistin-resistant P. aeruginosa strains were supplied by 
Dr. Oliver from Hospital Son Dureta (Palma de Mallorca). Both colistin-susceptible and 
colistin-resistant K. pneumoniae strains were obtained from the Magic Bullet project. S. 
mitis strains used were, D6-2, D6-7 and D6-14, which were isolated from the cardiac 
valve vegetations of rabbits infected with the S. mitis strain 351, a clinical isolate from 
Hospital Clinic (Barcelona) and treated with daptomycin. 
 
1.2. Minimal inhibitory concentration 
 
The MICs of all the peptides or peptidomimetics used in this thesis were determined 
against different A. baumannii, P. aeruginosa and K. pneumoniae strains with the 
microdilution method, following the CLSI recommendations. The antibacterial activity 
of the peptides was measured in sterile 96-well plates. Samples of a final volume of 
100µL were prepared as follows: aliquots (50 µL) of a suspension containing bacteria at 
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a concentration of 105 colony-forming units/mL in culture medium (MH, Muller Hinton 
Broth, Difco), adjusted at pH 7.4, were added to 50 µL of solution containing the 
peptide prepared from a stock solution of 1,024 mg/mL peptide in water in serial 2-fold 
dilutions in MH broth adjusted to pH 7.4. Inhibition of bacterial growth was determined 
observing no growth after an incubation of 24 h at 37 ºC (220). The concentrations of 
the peptides mastoparan, indolicidin, colistin, histatin 5, cecropin B, cecropin A, 
magainin II, buforin I, magainin I, histatin 8, bactenicin, melittin, peptide (1-14), CPF-
AM1, PGLa-AM1, B2RP-Era, [E4K]alyteserin-1c, [D4K]B2RP, [G4K]XT-7, CSA-13, 
CSA-44, CSA-131, CSA-138, MV6, MV5, MV3B, MV8, MV9, MV10, NBA01011 
and SXV4 ranged from 0.5 to 256 mg/L. The concentrations of HNP-1 and HNP-2 
ranged from 0.09 to 50 mg/L, and those for cecropin P1 and β-defensin ranged from 
0.05 to 25 mg/L. Mastoparan, indolicidin, colistin, histatin 5, cecropin B, cecropin A, 
magainin II, magainin I, histatin 8, melittin were purchased in Sigma. Buforin I and 
bactenicin were purchased in Anaspec and Genscript respectively. CPF-AM1, PGLa-
AM1, B2RP-Era, [E4K]alyteserin-1c, [D4K]B2RP, [G4K]XT-7 were supplied by Prof. 
Conlon and , CSA-13, CSA-44, CSA-131, CSA-138 by Prof. Savage. 
 
1.3. MIC using E-test. 
 
With some strains the MICs of different antibiotics were carried out using E-test 
method. This method is performed preparing an initial inoculum of 108 cfu/ml 
(McFarland 0.5) and spread it homogenely into a Muller Hinton agar plate, after the 
spread, stick an E-test strip (Biomerieux) into the plate. (E-test strips are strips which 
contain increase concentrations of a certain antibiotic, this allow us to know the MIC of 
an antibiotic in a faster way compared to the normal microdilution method) 
 
1.4. MIC with serum or albumin 
 
In the assay to calculate the MIC of the peptides in presence of serum and albumin, the 
first two steps were the same as in a normal MIC determination experiment, however 
the volumes used are the double, using both 100 µl for Muller Hinton and peptide 
dilution. The third step changes slightly, an initial inoculum of 108 cfu/ml was adjusted, 
and a 1/1000 dilution was performed in 4X Muller Hinton, 3 ml of this pool was added 
Materials and  methods 
153 
 
to a 12 ml falcon together with H2O and Human serum (HS), the proportions are 
showed in the table below. 
 
% HS supplement 
 
0 
 
25 
 
50 
 
75 
 
HS (ml) 0 3 6 9 
MH+CA (x4) (ml) 3 3 3 3 
Sterile MilliQ water (ml) 9 6 3 0 
Total (ml) 
 
12 
 
12 
 
12 
 
12 
 
  
100 µl of each pool was added, and incubate during 24h at 37ºC. Next day read the 96 
well plate.  
 
1.5. Killing curves 
 
Time-killing curves were obtained with mastoparan and CSA-131, the peptides were 
tested against both colistin-susceptible and colistin-resistant A. baumannii and the 
ceragenin was tested against colistin-resistant A. baumannii and P. aeruginosa strains. 
Initial inocula between 106 and 5·106 CFU/mL of bacteria in 10-mL aliquots of 
Mueller–Hinton broth were prepared for the time-killing curves. Concentrations of 
1xMIC, 2xMIC, 4xMIC and 8xMIC were used for mastoparan and CSA-131. Samples 
were taken at 0, 4, 7 and 24 h for mastoparan and 0, 1, 4, 8 and 24 h for CSA-131 after 
the incubation. Drug carryover was addressed by dilution. An antibiotic was considered 
to be bactericidal when a reduction of 3 log10 CFU/mL as compared with the initial 
inoculum was achieved. 
 
2. Synthesis of peptides 
 
2.1. Solvent and Reagents 
 
All the reagents employed for peptide synthesis have been purchased to the following 
suppliers: Anaspec, Bachem AG, Calbiochem-Novabiochem AG, Iris Biotech, 
KaliChemie, Luxemburg Industries, Neosystems and Sigma-Aldrich. All the solvents 
employed have been purchased to the following suppliers: Panreac, Scharlau, SDS and 
Sigma-Aldrich. 
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2.2. HPLC-UV 
 
HPLC chromatograms were recorded on a Waters Alliance 2695 separation module 
coupled with a Waters 2998 photodiode array detector and Empower software (Waters) 
using a Sunfire C18 column (100 mmX 4.6 mm, 3.5 µm; Waters). Column flow was set 
at 1 ml/min, and solvents used were water (0.045 % TFA) and acetonitrile (0.036% 
TFA).  
 
2.3. Semi-preparative HPLC 
 
Peptides synthesized were purified by semi-preparative HPLC on a Waters 2700 sample 
manager equipped with a Waters 2487 dual λ absorbance detector, a Waters 600 
controller, a Waters fraction collection II and Millenium chromatography manager 
software (Waters) using a symmetry C18 column (100 mm X 19 mm, 5 µm; Waters). 
Column flow was set at 15 ml/min, the solvents used were water (0.1% formic acid) and 
acetonitrile (0.07% formic acid). 
 
2.4. MALDI-TOF 
 
The MALDI-TOF used was a MALDI-TOF/TOF Applied Biosystems 4700 with a N2 
laser of 337 nm. The samples are prepared by mixing the peptide or fraction that want to 
be analysed (1µl) with the MALDI matrix (1µl) in the MALDI plate and let it dry in the 
air. The MALDI matrix was prepared by dissolving 10 mg of α-cyano-4-
hydroxycinnamic acid (ACH) in H2O and ACN ((1:1) containing 0.1% of TFA. 
 
2.5. General synthesis 
 
All the peptides synthesized during this thesis were carried out by SPPS using the 9-
fluorenylmethoxycarbonyl/tert-butyl (Fmoc/tBu) strategy. All the synthesis were 
carried out manually in polypropylene syringes provided with a polyethylene porous 
disk. Washings between each step were DMF (5 x 30s) and DCM (5 x 30s), the volume 
used is the necessary to cover all the resin used. 
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2.6. Ninhydrin or Kaiser test 
 
The Kaiser test, also known as ninhydrin test, is test used to detect primary amines. The 
resin is washed with DCM and few resin beads are transferred to a small glass tube in 
which the reaction takes place. Next step is to add 6 drops of reagent A and 2 drops of 
reagent B, the mixture is incubated during 3 minutes at 110 ºC. Blue colour on the resin 
beads showed free primary amines, meanwhile the none colour variation indicates a 
negative test. 
Reagent A: 400 g of phenol are dissolved in 100 ml of EtOH and the mixture is heated 
until complete dissolution of the phenol, 20 ml of 10 mM KCN (65 mg in 100 ml H2O) 
are added to 1 liter of freshly distilled pyridine over ninhydrin. Both solutions are stirred 
for 45 minutes with 40 g of Amberlite MB-3 ion exchange resin, filtered and mixed. 
Reagent B: 2.5 g of ninhydrin are dissolved in 50 ml of absolute EtOH and the resulting 
solution is stored in a flask protected light. 
 
2.7. Chloroanil test 
 
The chloroanil test is used when secondary amines want to be detected, and is specially 
used when monitoring the couplings and the deprotection reactions involving secondary 
amines. The resin is washed with DCM and transferred to a small glass tube, 200 µl of 
acetone and 20 µl of saturated chloroanil solution is added (750 µg of 2,3,5,6-
tetrachloro-1,4-benzoquinone in 25 ml of toluene). The mixture is thoroughly stirred for 
5 minutes at room temperature. The blue colour indicated the presence of free secondary 
amines, meanwhile yellow is considered as negative test.  
 
2.8. Resin conditioning 
 
In the resin H-Rink amide ChemMatrix (PCAS Biomatrix) some conditioning was 
performed before the coupling of the first amino acid. For resins 1,2-Diamino-ethane 
trityl (Novabiochem) and 2-Chlorotrityl chloride (Irisbiotech) only 3x1 min washes 
with DCM are needed. 
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H-Rink amide ChemMatrix 
 
Step Treatment Solvents/Reagents Time 
1 Wash MeOH 5 x 1 min 
2 Wash DMF 5 x 1 min 
3 Wash DCM 5 x 1 min 
4 Wash DCM 1% TFA 5 x 1 min 
5 Wash DCM  5 x 1 min 
6 Wash DMF 5 x 1 min 
7 Wash DCM 5 x 1 min 
8 Wash DCM 5% DIEA 5 x 1 min 
9 Wash DCM  5 x 1 min 
10 Wash DMF 5 x 1 min 
 
2.9. Fmoc group removal 
The fmoc group was removed using basic conditions, for this reason the resin was 
treated with 20% piperidine in DMF (4 ml/g resin, 1 x 1 min and 2 x 10 min). 
Additionally when fmoc want to be removed from Fmoc-Pro-OH, an additional 
treatment with DBU, toluene, piperidine and DMF (5:5:20:70) (2 x 5 min) was 
performed.  
 
2.10. Amino acid coupling and elongation 
 
Three different protocols were used depending on the resin and the amino acids used, 
protocol A was used for H-Rink amide Chem Matrix and 1,2-Diamino-ethane trityl 
resin and Protocol B was used for 2-Chlorotrityl chloride, and Protocol C when used 2-
Chlorotrityl chloride for coupling onto secondary amines. 
 
 
 
 
 
 
 
Materials and  methods 
157 
 
Protocol A: 
Step Treatment Solvents /reagents Time 
1 Wash DMF 5 x 1 min 
2 Coupling 
Fmoc-Aa-OH (3 eq), 
TBTU (3 eq), DIEA (6 eq) 
in DMF 
1 x 60 min 
3 Wash DMF 5 x 1 min 
4 Fmoc group removal 20% piperidine in DMF 1 x 1 min, 2 x 10 min 
5 Wash DMF 5 x 1 min 
 
Protocol B: 
Step Treatment Solvents/reagents Time 
1 Wash DCM 5 x 1 min 
2 Coupling 
Fmoc-Aa-OH (0.7 eq), 
DIEA (10 eq) in DCM // 
MeOH (0.8 ml/g resin) 
1 x 60 min and 15 min 
after MeOH addition 
3 Wash DMF 5 x 1 min 
4 Fmoc group removal 20% piperidine in DMF 1 x 1 min, 2 x 10 min 
5 Wash DMF 5 x 1 min 
6 Coupling 
Fmoc-Aa-OH (3 eq), 
PyBOP (4 eq), HOAt ( 3 
eq) DIEA (6 eq) in DMF 
5 x 1 min 
7 Wash DMF 1 x 60 min 
 
 
 
 
 
 
 
 
 
 
 
Materials and  methods 
158 
 
Protocol C: 
Step Treatment Solvents/reagents Time 
1 Wash DMF 5 x 1 min 
2 Coupling 
Fmoc-Aa-OH (0.7 eq), 
DIEA (10 eq) in DCM // 
MeOH (0.8 ml/g resin) 
1 x 60 min and 15 min 
after MeOH addition 
3 Wash DMF 5 x 1 min 
4 Fmoc group removal 20% piperidine in DMF 1 x 1 min, 2 x 10 min 
5 Wash DMF 5 x 1 min 
6 Coupling 
Fmoc-Pro-OH (3 eq), 
PyBOP (4 eq), HOAt ( 3 
eq) DIEA (6 eq) in DMF 
2 x 60 min 
7 Wash DMF 5 x 1 min 
8 Fmoc group removal 
DBU, toluene, piperidine 
in DMF (5:5:20:70) 
2 x 5 min 
9 Fmoc group removal 20% piperidine in DMF 1 x 1 min, 2 x 10 min 
 
2.11. N-terminal acetylation 
 
After the peptide elongation, acetylation was performed in order to protect the N-
terminal. Ac2O (50 eq) and DIEA (50 eq) in were added to the resin together with DCM 
30 minutes, before and after the treatment, washes of DCM (5 min) need were 
performed. 
 
2.12. N-terminal guanidination 
 
After the peptide elongation, acetylation was performed in order to protect the N-
terminal, the reagents used were 1,3-Di-Boc-2-(trifluoromethylsulfonyl)guanidine (5 
eq) and Et3N (5 eq) in DCM during 18 hours, before and after the treatment, washes of 
DCM (5 min) need to be performed. 
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2.13. Cleavage of peptides from the resin 
 
Peptides synthesized using Protocol A were cleaved using a cocktail that contains TFA, 
H2O and TIS (95:2.5:2.5). The mixture of the resin and peptide with the cocktail was 
located in the shaker and allow it to react during 2 hours in a Falcon tube. After 2h the 
supernatant was evaporated using N2, to dry the resin as much as possible. Once the 
resin is dried 30 ml of methyl t-butyl ether were added to allow the peptide released 
from the resin to precipitate, incubate during 10 minutes on ice and centrifuge during 10 
minutes at 4ºC (3,500 rpm), discard the supernatant carefully, add again methyl t-butyl 
ether, and repeat again the procedure three times more. Dissolve the white precipitate 
using H2O and ACN (1:1), and filtrate it to separate the resin from de peptide, after the 
separation the peptide was lyophilized. 
For the peptides synthesized using Protocol B and C, which were the cyclic peptides, a 
different procedure was used. The cocktail used contained 2% of TFA in DCM, and 5 
washes of 30 seconds to the resin were performed. This procedure only cleaves the 
peptide from the resin, and did not remove the protecting groups present in the side 
chains of the amino acids. The resultant from the washes was collected in a container 
with H2O, mixed with ACN and lyophilized. 
 
2.14. Cyclization and deprotection 
 
For cyclization the solvent used was DCM/DMF (98:2), PyAOP (2 eq) was dissolved in 
DMF and afterwards the peptide (5 mM) was dissolved with DCM and once is mixed 6 
equivalents of DIEA were added, the reaction was completed in 2 or 3 hours. The end of 
the reaction was checked by HPLC. The mixture was rotavapored until an oil (DMF) 
was obtained, the oil was treated with the same cocktail as used for peptides synthesized 
with protocol A (TFA/TIS/ H2O.95:2.5:2.5) and the same procedure as explained 
previously was carried out, except that no separation from the resin was needed. 
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3. Characterization of peptides 
 
3.1 Tickets of all the peptides synthesized 
 
Amino acids in lower case have a D configuration 
Gu-INLKALAALAKKIL-NH2 
Side-chain protecting groups: Lys (Boc), Asn (Trt) 
Resin: H-Rink amide Chem Matrix 
Initial loading: 0.49 mmol/g 
MW: 1521 Da 
Cleavage cocktail: 95% TFA/ 2.5% H2O/ 2.5% TIS 
Yield: 3.4 % 
HPLC, tR (min, G0-100% MeCN in 8 min): 5.3 min 
MALDI-TOF, [M+H]+: 1521.1 Da 
 
iNLKALAALAKKIL-NH2 
Side-chain protecting groups: Lys (Boc), Asn (Trt) 
Resin: H-Rink amide Chem Matrix 
Initial loading: 0.49 mmol/g 
MW: 1479 Da 
Cleavage cocktail: 95% TFA/ 2.5% H2O/ 2.5% TIS 
Yield: 5.6 % 
HPLC, tR (min, G0-100% MeCN in 8 min): 5.2 min 
MALDI-TOF, [M+H]+: 1479 Da 
 
InLKALAALAKKIL-NH2 
Side-chain protecting groups: Lys (Boc), Asn (Trt) 
Resin: H-Rink amide Chem Matrix 
Initial loading: 0.49 mmol/g 
MW: 1479 Da 
Cleavage cocktail: 95% TFA/ 2.5% H2O/ 2.5% TIS 
Yield: 5.9 % 
HPLC, tR (min, G0-100% MeCN in 8 min): 5.2 min 
MALDI-TOF, [M+H]+: 1479 Da 
 
NLKALAALAKKIL-NH2 
Side-chain protecting groups: Lys (Boc), Asn (Trt) 
Resin: H-Rink amide Chem Matrix 
Initial loading: 0.49 mmol/g 
MW: 1365.8 Da 
Cleavage cocktail: 95% TFA/ 2.5% H2O/ 2.5% TIS 
Yield: 6.0 % 
HPLC, tR (min, G0-100% MeCN in 8 min): 5.2 min 
MALDI-TOF, [M+H]+: 1365.9 Da 
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Ac-INLKALAALAKKIL-NH2 
Side-chain protecting groups: Lys (Boc), Asn (Trt) 
Resin: H-Rink amide Chem Matrix 
Initial loading: 0.49 mmol/g 
MW: 1520.9 Da 
Cleavage cocktail: 95% TFA/ 2.5% H2O/ 2.5% TIS 
Yield: 5.1 % 
HPLC, tR (min, G0-100% MeCN in 8 min): 5.7 min 
MALDI-TOF, [M+H]+: 1521 Da 
 
INLKALAALAKKIL-NH2 (Mastoparan) 
Side-chain protecting groups: Lys (Boc), Asn (Trt) 
Resin: H-Rink amide Chem Matrix 
Initial loading: 0.49 mmol/g 
MW: 1479 Da 
Cleavage cocktail: 95% TFA/ 2.5% H2O/ 2.5% TIS 
Yield: 6.5 % 
HPLC, tR (min, G0-100% MeCN in 8 min): 5.3 min 
MALDI-TOF, [M+H]+: 1479 Da 
 
inLKALAALAKKIL-NH2 
Side-chain protecting groups: Lys (Boc), Asn (Trt) 
Resin: H-Rink amide Chem Matrix 
Initial loading: 0.49 mmol/g 
MW: 1479 Da 
Cleavage cocktail: 95% TFA/ 2.5% H2O/ 2.5% TIS 
Yield: 4.1 % 
HPLC, tR (min, G0-100% MeCN in 8 min): 5.2 min 
MALDI-TOF, [M+H]+: 1479 Da 
 
LIKKALAALAKLNI-NH2 
Side-chain protecting groups: Lys (Boc), Asn (Trt) 
Resin: H-Rink amide Chem Matrix 
Initial loading: 0.49 mmol/g 
MW: 1479 Da 
Cleavage cocktail: 95% TFA/ 2.5% H2O/ 2.5% TIS 
Yield: 7.1 % 
HPLC, tR (min, G0-100% MeCN in 8 min): 4.7 min 
MALDI-TOF, [M+H]+: 1479.1 Da 
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likkalaalaklni-NH2 
Side-chain protecting groups: Lys (Boc), Asn (Trt) 
Resin: H-Rink amide Chem Matrix 
Initial loading: 0.49 mmol/g 
MW: 1479 Da 
Cleavage cocktail: 95% TFA/ 2.5% H2O/ 2.5% TIS 
Yield: 6.8 % 
HPLC, tR (min, G0-100% MeCN in 8 min): 4.6 min 
MALDI-TOF, [M+H]+: 1479.1 Da 
 
inlkalaalakkil-NH2 
Side-chain protecting groups: Lys (Boc), Asn (Trt) 
Resin: H-Rink amide Chem Matrix 
Initial loading: 0.49 mmol/g 
MW: 1479 Da 
Cleavage cocktail: 95% TFA/ 2.5% H2O/ 2.5% TIS 
Yield: 8.1 % 
HPLC, tR (min, G0-100% MeCN in 8 min): 5.3 min 
MALDI-TOF, [M+H]+: 1479.1 Da 
 
INLKAKAALAKKIL-NH2 
Side-chain protecting groups: Lys (Boc), Asn (Trt) 
Resin: H-Rink amide Chem Matrix 
Initial loading: 0.49 mmol/g 
MW: 1493.9 Da 
Cleavage cocktail: 95% TFA/ 2.5% H2O/ 2.5% TIS 
Yield: 6.3 % 
HPLC, tR (min, G0-100% MeCN in 8 min): 5.5 min 
MALDI-TOF, [M+H]+: 1494.2 Da 
 
 
In(Orn)kalaalakkil-NH2 
Side-chain protecting groups: Lys (Boc), Asn (Trt), Orn (Boc) 
Resin: H-Rink amide Chem Matrix 
Initial loading: 0.49 mmol/g 
MW: 1480 Da 
Cleavage cocktail: 95% TFA/ 2.5% H2O/ 2.5% TIS 
Yield: 6.5 % 
HPLC, tR (min, G0-100% MeCN in 8 min): 4.7 min 
MALDI-TOF, [M+H]+: 1479.9 Da 
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INLKALAALAKKIL-CH2CH2NH2 
Side-chain protecting groups: Lys (Boc), Asn (Trt) 
Resin: 1,2-Diamino-ethane trityl resin 
Initial loading: 1.18 mmol/g 
MW: 1522 Da 
Cleavage cocktail: 95% TFA/ 2.5% H2O/ 2.5% TIS 
Yield: 4.6 % 
HPLC, tR (min, G0-100% MeCN in 8 min): 6.1 min 
MALDI-TOF, [M+H]+: 1522.2 Da 
 
LIKKALAALAKLNI-CH2CH2NH2 
Side-chain protecting groups: Lys (Boc), Asn (Trt) 
Resin: 1,2-Diamino-ethane trityl resin 
Initial loading: 1.18 mmol/g 
MW: 1522 Da 
Cleavage cocktail: 95% TFA/ 2.5% H2O/ 2.5% TIS 
Yield: 6.1 % 
HPLC, tR (min, G0-100% MeCN in 8 min): 5.6 min 
MALDI-TOF, [M+H]+: 1521.9 Da 
 
Cyclo[RpWRpW] 
Side-chain protecting groups: Arg (Pbf), Trp (Boc) 
Resin: 2-Chlorotrityl chloride 
Initial loading: 0.65 mmol/g 
MW: 879.04 Da 
Cleavage cocktail: 2% TFA/ 98% DCM 
Yield: 25% 
HPLC, tR (min, G0-100% MeCN in 8 min): 4.8 min 
HPLC-MS: 879.36 Da 
 
Cyclo[WpRWpR] 
Side-chain protecting groups: Arg (Pbf), Trp (Boc) 
Resin: 2-Chlorotrityl chloride 
Initial loading: 0.74 mmol/g 
MW: 879.04 Da 
Cleavage cocktail: 2% TFA/ 98% DCM 
Yield: 38% 
HPLC, tR (min, G0-100% MeCN in 8 min): 4.7 min 
HPLC-MS: 879.29 Da 
 
Cyclo[rPWrPW] 
Side-chain protecting groups: Arg (Pbf), Trp (Boc) 
Resin: 2-Chlorotrityl chloride 
Initial loading: 0.62 mmol/g 
MW: 879.04 Da 
Cleavage cocktail: 2% TFA/ 98% DCM 
Yield: 23% 
HPLC, tR (min, G0-100% MeCN in 8 min): 5.0 min 
HPLC-MS: 879.49 Da 
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Cyclo[RPwRPw] 
Side-chain protecting groups: Arg (Pbf), Trp (Boc) 
Resin: 2-Chlorotrityl chloride 
Initial loading: 0.63 mmol/g 
MW: 879.04 Da 
Cleavage cocktail: 2% TFA/ 98% DCM 
Yield: 32% 
HPLC, tR (min, G0-100% MeCN in 8 min): 4.6 min 
HPLC-MS: 879.52 Da 
 
Cyclo[SpWSpW] 
Side-chain protecting groups: Ser (tBu), Trp (Boc) 
Resin: 2-Chlorotrityl chloride 
Initial loading: 0.69 mmol/g 
MW: 741.33 Da 
Cleavage cocktail: 2% TFA/ 98% DCM 
Yield: 16% 
HPLC, tR (min, G0-100% MeCN in 8 min): 6.0 min 
HPLC-MS: 741.15 Da 
 
Cyclo[EpWEpW] 
Side-chain protecting groups: Glu (tBu), Trp (Boc) 
Resin: 2-Chlorotrityl chloride 
Initial loading: 0.62 mmol/g 
MW: 825.35 Da 
Cleavage cocktail: 2% TFA/ 98% DCM 
Yield: 23% 
HPLC, tR (min, G0-100% MeCN in 8 min): 825.26 min 
HPLC-MS: 825.26 Da 
 
Cyclo[ASpASp] 
Side-chain protecting groups: Glu (tBu), Trp (Boc) 
Resin: 2-Chlorotrityl chloride 
Initial loading: 0.61 mmol/g 
MW: 511.50 Da 
Cleavage cocktail: 2% TFA/ 98% DCM 
Yield: 19% 
HPLC, tR (min, G0-100% MeCN in 8 min): 4.0 min 
HPLC-MS: 511.19 Da 
 
Ac-WpRWpR-OH 
Side-chain protecting groups: Arg (Pbf), Trp (Boc) 
Resin: 2-Chlorotrityl chloride 
Initial loading: 0.60 mmol/g 
MW: 938.48 Da 
Cleavage cocktail: 2% TFA/ 98% DCM 
Yield: 42% 
HPLC, tR (min, G0-100% MeCN in 8 min): 4.5 min 
MALDI-TOF, [M+H]+: 939.51 Da 
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3.2. Stability assay  
 
Peptides were incubated at 37ºC in the presence of 100% human serum (from human 
male AB plasma). At a range of times, 50 µL aliquots were extracted and serum 
proteins were precipitated by the addition of 150 µL of acetonitrile at 4ºC to stop 
degradation. After 30 min at 4ºC, the samples were centrifuged at 10,000 rpm (9,300 x 
g) for 10 min at 4ºC. The supernatant was analyzed by HPLC. Fractions were also 
analized by MALDI-TOF mass spectrometry. 
 
3.3. MTT cytotoxicity assay  
 
For these experiments HeLa cells were used for mastoparan and analogues and A549 
pulmonar cells were used for the cyclic peptides. Their doubling time and the lineal 
absorbance at 570 nm were taken into account for seeding purposes. Cell viability in the 
presence of peptides was tested using a 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. For each assay, 5x103 HeLa cells or A549 
pulonar cells were seeded on a 96-well plate (Nalge Nunc) and cultured for 24 h. 
Samples were added at concentrations ranging from 1µM to 500 µM depending on the 
peptide, and 0.25, 0.5 and 1 mg/ml for the peptides from the EXORIS library. Cells 
were incubated for 24 h at 37°C under a 5% CO2 atmosphere. After 20 h, medium with 
compounds were removed, and MTT was added to a final concentration of 0.5 mg/ml. 
MTT was incubated for a further 4 h, and the medium was then discarded. DMSO was 
added to dissolve the formazan product, and absorbance was measured at 570 nm after 
15 min. Cell viability percentages were calculated by dividing the absorbance value of 
cells treated with a given compound by the absorbance of untreated cells. 
 
3.4. Hemolysis assay 
 
In the hemolysis test, peptides concentrations ranged from 32 to 1024 mg/L for peptides 
isolated from frog skins and from 0.5-256 mg/L for mastoparan and peptide 10. 
Peptides were incubated with washed human erythrocytes from a healthy donor in 100 
µL of Dulbecco’s phosphate-buffered saline (pH 7.4) for 1 h at 37◦C. Following 
centrifugation (12,000 x g for 15 s), the absorbance of the supernatant at 450 nm was 
measured. A parallel incubation in the presence of 1% v/v Tween 20 was carried out to 
determine the absorbance associated with 100% hemolysis. 
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3.5. In vivo toxicity assay 
 
The Reed and Munch method (221) was applied. Groups of six C57BL/6 mice were 
intraperitoneally (i.p.) inoculated with a single 250 µL dose of peptide, starting at 32 
mg/kg for mastoparan and peptide 10 and starting at 10 mg/Kg for MV5, this initial 
doses were further increased or decreased until 100% mortality was reached. Maximum 
tolerated dose (LD0), lethal dose 50 (LD50), and lethal dose 100 (LD100), were defined 
as those causing 0%, 50%, and 100% mortality, respectively. 
 
3.6. Calculation bacterial minimal lethal dose (BMLD) 
 
Three groups of four C57BL/6 mice were i.p inoculated with a single 250 µL dose of 
105, 106 and 107 cfu/ml of a pan-resistant A. baumannii strain. The survival of the mice 
was monitored during one week. 
 
3.7. Calculation of the Effective dose 50 (ED50) 
 
Groups of different amount of mice were used in all the ED50 experiments, but the 
procedure was the same. C57BL/6 mice were inoculated i.p with the BMLD, and after 
certain time (1h, 2h and 4h was tested) an i.p dose of the peptide was administered. The 
evolution of the mice was monitored during one week. ED50 is achieved when the 50% 
of the mice survive to the infection. 
 
3.8. Monitoring the infection 
 
Four groups of three C57BL/6 mice were used for this experiment, all the mice were 
infected i.p with the BMLD, after 1, 2, 3 and 4h, each group was sacrificed at a different 
time point and lungs and spleen were aseptically removed and weighted, followed by an 
homogenization (2 min) in 2 mL of sterile saline solution ( Tekmar Co.). After ten-fold 
dilution of the homogenate, 100 µL aliquots were plated on Columbia sheep blood agar 
and CFUs determined and expressed as log10 CFU/g of tissue. Number of bacteria in 
each organ at all the time points was calculated. 
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3.9. Murine pneumonia model 
 
Seven groups of three C57BL/6 mice were used for this experiment. The animals were 
anaesthetized ip with 5% (w/v) sodium thiopental (Braun Medical, Spain) and 
intratracheally inoculated with the BMLD and different doses of the peptides were 
administered i.p. The first group was sacrificed and the amount of bacteria present in 
lungs was calculated with the same procedure explained above but just in lungs, the 
other six groups were the control and two peptides at 2h and 24h, at each time point the 
amount of bacteria in lungs was calculated.  
 
3.10. Murine peritoneal sepsis model 
 
Three groups of ten C57BL/6 mice were used for this experiment, all the mice were 
infected i.p with the BMLD, and 1h after the infection different doses of peptides were 
administered, after another hour the mice were sacrificed. The CFUs in peritoneal fluid 
were determined by i.p. injection of 2 ml sterile saline serum and, after mild abdominal 
massage, 1 mL of peritoneal fluid was aspirated with a sterile pipette tip. One hundred 
µL aliquots of serial ten-fold dilutions were plated on Columbia sheep blood agar and 
incubated at 37°C. CFUs were counted after 24 h and expressed as of log10 CFU/mL. 
 
3.11. Leakage assay 
 
Aliquots containing the appropriate amount of lipid in chloroform/methanol (1:1, v/v) 
were placed in a test tube, the solvents were removed by evaporation under a stream of 
O2-free nitrogen, and finally traces of solvents were eliminated under vacuum in the 
dark for more than 3 h. After, 1 ml of buffer containing 10 mM HEPES, 100 mM NaCl, 
0.1 mM EDTA, pH 7.4 buffer and carboxyfluorescein at a concentration of 40 mM was 
added, and multilamellar vesicles were obtained. Large unilamellar vesicles (LUVs) 
with a mean diameter of 200 nm were prepared from the multilamellar vesicles by the 
LiposoFast device from Avestin, Inc., using polycarbonate filters with a pore size of 0.2 
µm (Nuclepore Corp). Breakdown of the vesicle membrane leads to content leakage, 
i.e., CF fluorescence. Non-encapsulated CF was separated from the vesicle suspension 
through a Sephadex G-25 filtration column eluted with buffer containing 10 mM 
HEPES, 150 mM NaCl, and 0.1 mM EDTA, pH 7.4. Leakage of intraliposomal CF was 
assayed by treating the probe-loaded liposomes (final lipid concentration, 0.125mM) 
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with the appropriate amount of peptide in Costar 3797 round-bottom 96-well plates, 
each well containing a final volume of 100 µl. The microtiter plate was incubated at RT 
for 1 h to induce dye leakage. Leakage was measured at various peptide concentrations. 
Changes in fluorescence intensity were recorded using the FL600 fluorescence 
microplate reader with excitation and emission wavelengths set at 492 and 517 nm, 
respectively. One hundred percent release was achieved by adding Triton X-100 to a 
final concentration of 1% v/v to the microtiter plates. Fluorescence measurements were 
made initially with probeloaded liposomes, afterwards by adding peptide and, finally by 
adding Triton X-100 to obtain 100% leakage. The results were expressed as percentage 
of CF released relative to the positive control (Triton X-100). 
 
3.13. Transmission electron microscopy 
 
Bacteria were grown in LB media and in the mid-log exponential phase of growth were 
incubated with mastoparan and peptide 10 for 1h at 37ºC, using the MIC concentration. 
A control without peptide was also performed. After the incubation, centrifugation at 
3,500 rpm 4ºC was performed. The pellets were then fixed for 1h with 2% of 
gluteraldehyde, three times washed with water and fixed again with 1% of OsO4. The 
post-fixation positive stain was carried out with 3% of uranyl acetate acqueous solution 
during 1.5 h, afterwards graded ethanol series (30, 50, 70, 90 and 100%) every 15 min 
were carried out in order to be dehydrated. The samples were embedded in a epoxy 
resin. Tecnai Spirit microscope (EM) (FEI) equipped with a LaB6 cathode. Images were 
acquired at 120 kV and room temperature with a 1376 x 1024 pixel CCD camera (FEI). 
 
4. Proteomic approaches 
 
4.1. iTRAQ 
 
4.1.1. Protein extraction 
 
An overnight culture of bacteria was grown in BHI (Becton and Dickinson), Fresh BHI 
was inoculated with a 1:50 dilution of the overnight culture and grown to a OD 0.6 
aprox. at 37ºC with shaking. Bacteria were harvested by centrifugation at 3,500 rpm 
(Thermo Scientific) for 30 minutes and washed twice with 10 ml of 0.9% NaCl, 
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supernatant was discarded and the pellet was resuspended in Tris 10mM pH 8.0/NaCl 
1% (Merck). Bacteria were incubated with lysozime and lysostaphine in order to 
weaken the cell membrane of the bacteria. Samples were sonicated at maximum Hz 
(Sonics) on ice during 10 minutes with intervals of 1 min. After the sonication, the 
extract was centrifuged 3,500 rpm and the pellet was discarded.  
 
4.1.2. Digestion 
 
 Protein extraction samples from S. mitis were quantified using Micro BCA™ Protein 
Assay Kit (Thermo Scientific), and 300 µg of each were digested with trypsin using the 
filter aided sample preparation (FASP) digestion approach. Briefly, samples were 
diluted up to 500 µL with 500 mM triethyl ammonium bicarbonate (TEAB; pH 8.0-8.5), 
reduced with tris (2- carboxyethyl) phosphine (5mM; 60 min at 60 oC) and alkylated 
with iodoacetamide (30 mM; 20 minutes at 21 ºC in the dark). Afterwards, Samples 
were loaded onto an Amicon Ultra filter (10KDa, 0.5mL capacity; Millipore) to clean-
up and denature sample proteins by two washes with 300 µL of 2M Urea/500 mM 
TEAB exchange buffer (12000g, 30 min, RT). Finally the filtered sample protein were 
resuspended on the filter with a 300 µL of a solution containing 1M Urea/ 500 mM 
TEAB, and then digested with 4µg trypsin/sample of porcine trypsin (Sequence grade 
modified Trypsin, Promega) at 37ºC for 16h. After tryptic digestion, the resulting 
peptide mixture was recovered by centrifugation (12,000g, 15 min, RT), and washing 
the filter twice with 200 µL of 500 mM TEAB solution as well. The peptide mixture 
were dried-down on a SpeedVac system and stored at -20ºC. 
 
4.1.3. Peptide labeling 
 
Samples were resuspended in 100 µL 1% formic acid (FA) solution and digests were 
desalted and concentrated by a C18 microcolunm (toptip, PolyLC) and eluted from the 
tip with 200 µL (2X 100 µL) of 70% acetonitrile (ACN)/0.1% FA and dried in 
SpeedVac. The peptide labeling was done with iTRAQ (iTRAQ™ 4plex Multiplex kit) 
according to the product specifications. Briefly, samples were resuspended in 60 µL 500 
mM TEAB and divided by two to be labeled with two different markers. 70 µl of 
ethanol were added to each vial of iTRAQ labeling reagents, vortexed for 1 minute and 
spinned. The contents of label vials were transferred to the each sample tube, mixed 
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well and incubated at room temperature for 1 h. Samples were labeled as following: 
sample 351 was labeled with 114, and D6 G14 with 115 and 117. A small portion of 
each reaction was analyzed to ensure complete labeling. Reaction mixtures were diluted 
with 100 µl of water to quench the reaction and labeled samples were combined. 
The cleanup of the samples was done in two steps: C18 clean-up (reverse phase, toptip 
C18) and then SCX cleanup (strong cationic exchange, P200 toptip, 
PolySULFOETHYL A). Firstly, samples were resuspended in 100 µL 1% FA solution, 
loaded to a C18 toptip, washed twice (50 µL 0.1% FA), eluted from the tip with 200 µL 
(2X 100 µL) of 70% ACN/0.1% FA and dried in SpeedVac. Then, samples were 
resuspended in 100 µL in 20% ACN/0.1% FA (pH 2.7-3), loaded to a SCX P200 toptip, 
washed (3X 50 µL 20% ACN/0.1% FA) and finally were eluted from the tip with 200 
µL (4X 50 µL) 5% ammonium hydroxide/30 %methanol. 100 µL of water (HPLC 
grade) were added to the samples and then were dried down in SpeedVac. 
 
4.1.4. LC-MS/MS analysis 
 
The dried-down peptide mixture was analyzed in a nanoAcquity liquid chromatographer 
(Waters) coupled to a LTQ-Orbitrap Velos (Thermo Scientific) mass spectrometer. 
Tryptic labeled peptides were resuspended in 5% ACN/1% FA solution and an aliquot 
(500 ng) was injected for their chromatographic separation. Peptides were trapped on a 
Symmetry C18TM trap column (5µm 180µm x 20mm; Waters), and were separated 
using a C18 reverse phase capillary column (75 µm Øi, 25 cm, nano Acquity, 1.7µm 
BEH column; Waters). The gradient used for the elution of the peptides was 2 to 35 % 
B in 155 minutes, followed by gradient from 35% to 45% in 20 min (A: 0.1% FA; B: 
100% ACN, 0.1%FA), with a 250 nL/min flow rate. 
Eluted peptides were subjected to electrospray ionization in an emitter needle 
(PicoTipTM, New Objective) with an applied voltage of 2000V. Peptide masses (m/z 
350-1700) were analyzed in data dependent mode where a full Scan MS in the Orbitrap 
with a resolution of 30,000 FWHM at 400m/z was obtained. Up to the 10 most 
abundant peptides (minimum intensity of 2000 counts) were selected from each MS 
scan and then fragmented using HCD (Higher Energy Collision Dissociation) in C-trap 
using nitrogen as collision gas, with 50% normalized collision energy and analyzed in 
the Orbitrap with a resolution of 7,500 FWHM at 400m/z. The scan time settings were: 
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Full MS: 250ms (1 microscan) and MSn: 300ms (2 microscans). Generated raw data 
were collected with Thermo Xcalibur (v.2.1.0.1140).  
 
4.1.5. Database search 
 
Thermo Proteome Discover (v.1.3.0.339) was used to generate a text file (mgf) to 
perform a decoy database search by Mascot search engine against NCBI database. Both 
target and decoy database were searched to obtain a false discovery rate (FDR), and 
thus estimate the number of incorrect peptide-spectrum matches that exceed a given 
threshold. From database search, Mascot generated a DAT file which was used to 
relative quantify the ratios based on reporter ions intensities. 
 
4.2. Outer membrane protein (OMP) extraction  
 
The protocol for the isolation of outer membrane proteins is the same as commented for 
the extraction of proteins for the iTRAQ, however extra steps to extract the outer 
membrane proteins from the rest of the proteins were needed. After the sonication the 
supernatant was ultracentrifuged (Thermo) during 45 minutes 70,000 x g at 4ºC, prior to 
be introduced in the ultracentrifuge it is important to check that all the tubes introduced 
have the same weight. After centrifugation, the supernatant was discarded and the pellet 
was resuspended with 100 µl of N-lauryl-sarcosyl 0.3% and let it react during 30 
minutes at room temperature, the action of the N-lauryl-sarcosyl it to solubilize the 
inner membrane protein from the cell envelope proteins. The pellet, outer membrane 
proteins, was solubilized using the suitable buffer. Proteins were quantified using 
Bradford method. 
 
4.3. One-dimensional SDS-PAGE. 
 
Gel is prepared following the proportions showed in the table below, the first lower part 
of the SDS-PAGE gel is prepared the day before running the gel, and let it polymerize 
overnight. The upper part or stacking part is prepared the same day.  
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12.5% Lower Upper 
H2O 13.02mL 6.49 mL 
40% Acrylamide/Bisacryilamide 
37,5:1 (N,N-methylene-bis-
acrylamide) 
9.41 mL 1.002 mL 
Upper (Tris 1.5 M pH 6.8 + SDS) - 2.505 mL 
Lower (Tris 1.5 M pH 8.8 + SDS) 7.53 mL - 
PSA 10% 0.3 mL 0.1 mL 
TEMED 0.012 mL 0.01 mL 
 
5 µg of outer membrane proteins were mixed with Laemmli buffer 5X, and boiled 
during 5 minutes. The samples were loaded into the gel and run at 25 mA until the blue 
front has overtaken the stacking gel, at that time the voltage can be increased to 30 mA. 
The electrophoresis was run until the blue tracking front arrived to 1 cm of the end of 
the gel. 
After the electrophoresis was run, gel was removed from the cassette and silver stained. 
Briefly, the gel was fixed with ethanol (40%) and acetic acid (10%) during at least 30 
minutes. This step can be extended to over-weekend. After the fixation step the gel was 
sensitized with Ethanol 30%, 2g sodium thiosulphate and 68g sodium acetate in 1 liter 
during another 30 minutes, three washes with water of 5 minutes each were performed 
previous to the incubation with the silver solution (2.5 g silver nitrate in 1 liter) during 
20 minutes. Two fast washes of 1 minute were carried out previously to the 
development solution [50 gr sodium carbonate, 800 ul formaldehide 37% (Add just 
before use) in 1 liter] the time of incubation is depending on the abundance of proteins 
in the gel but normally is around 10 minutes or until the desired contrast is reached. At 
that time the gel is incubated with the stopping solution (14.6 gr EDTA-Na2 in 1liter) 
during 20 minutes to finish the reaction. For silver staining high purity reagents were 
used. 
4.4. 2D gel electrophoresis 
 
The 2-DE was performed using GE Healthcare reagents and equipment. First-dimension 
isoelectric focusing was performed on immobilized pH gradient strips (24 cm, pH 3–10) 
using an Ettan IPGphor System (GE Healthcare). Samples were applied near the basic 
end of the strips by cup-loading, after being incubated o/n in 450 µl of rehydration 
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buffer (7 M urea, 2 M thiourea, 2.5% w/v CHAPS, 2% ASB-14 w/v, 0.5% pharmalytes, 
pH 3–10, 100 mM DeStreak reagent). After focusing at 70 kVh, strips were 
equilibrated, first for 15 min in 10 ml of reducing solution (6 M urea, 100 mM Tris-
HCl, pH 8, 30% v/v glycerol, 2% w/v SDS, 5 mg/ml dithiothreitol [DTT]) and then in 
10 ml of alkylating solution (6 M urea, 100 mM Tris-HCl, pH 8, 30% v/v glycerol, 2% 
w/v SDS, 22.5 mg/ml iodoacetamide) for 15 min on a rocking platform. Second 
dimension SDS-PAGE was performed by laying the strips on 12.5% isocratic Laemmli 
gels (24×20 cm), cast in low fluorescence glass plates, on an Ettan DALT Six system. 
Gels were run at 20°C at a constant power of 2.5 W per gel for 60 min followed by 17 
W per gel until the bromophenol blue tracking front had run off the end of the gel. Four 
replicas were run for each sample using independent biological replicates. Fluorescence 
images of the gels were obtained on a Typhoon 9400 scanner (GE Healthcare). Cy2, 
Cy3 and Cy5 images were scanned at excitation/emission wavelengths of 488/520 nm, 
532/580 nm and 633/670 nm, respectively, at a resolution of 100 µm. Both image 
analysis and statistical quantification of relative protein levels were performed using 
Progenesis SameSpots V.4 (Nonlinear Dynamics). The data were analyzed as pairwise 
comparisons.  
 
4.5. DIGE sample preparation 
 
OMPs samples were resuspended in lysis solution (8 M urea, 2 M thiourea, 2.5% 3-[(3-
cholamidopropyl) dimethylammonio]-1 propanesulfonate (CHAPS), 2% ASB-14, 40 
mM Tris-HCl, pH 8.8). ASB-14 was used to increase the presence of membrane 
proteins in the 2DE. Then samples were centrifuged in order to discard any insoluble 
debris. In order to remove salts and other contaminants, samples were cleaned with 2D 
Clean-Up Kit (GE Healthcare). Resulting pellets were resuspended in the above-
mentioned lysis solution. Protein concentration was determined with 2D-Quant Kit (GE 
Healthcare) and adjusted to 2 mg/ml by the addition of a DIGE labeling buffer (7 M 
urea, 2 M thiourea, 2.5% w/v CHAPS, 40 mM Tris, pH 8.8). A pool consisting of equal 
amounts of each of the two samples analyzed in the experiment was prepared as an 
internal standard for quantitative comparisons. The colistin-resistant strain was labeled 
with Cy3 in two replicas and the colistin-susceptible was labeled with Cy5, while 
colistin-resistant strain was labeled with Cy5 in the other two replicas and the colistin-
susceptible was labeled with Cy3. This experimental design avoids possible bias as 
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result of differences in the labeling reaction. A third fluorescent dye, Cy2, was used to 
label the internal standard sample. Labeling was carried out by the addition of 400 pmol 
of the required Cydye in 1 µl of anhydrous N,N-dimethylformamide per 50 µg of 
protein. After 30 min of incubation on ice in the dark, the reaction was quenched with 
10 mM lysine and the samples incubated for a further 10 min. Samples were combined 
according to the experimental design, using 50 µg of protein per Cy dye per gel, and 
diluted two-fold with isoelectric focusing (IEF) sample buffer (7 M urea, 2 M thiourea, 
4% w/v CHAPS, 2% dithiothreitol [DTT], 2% pharmalytes, pH 3–10). One colistin-
resistant and colistin-susceptible strain sample, together with an aliquot of the internal 
standard pool, were then separated by two-dimensional electrophoresis (2-DE) in each 
of the gels. This experimental design allows the accurate quantification and statistical 
assessment of the differences in protein abundances observed between the two sample 
groups. 
For spot picking, gels were silver stained as described previously. 
 
4.6. In gel triptic digestion 
 
Silver-stained spots were destained with 200 µL of 30 mM potassium ferricyanide and 
100 mM sodium thiosulfate (1:1) for 20 min in the dark, and then spots were washed 
with Milli-Q water until they were completely clear. Before tryptic digestion, reduction 
and alkylation with DTT/IAA was performed by incubating samples with 200 µL of 10 
mM DTT in 50 mM ammonium bicarbonate for 1 h at 56 °C, followed by alkylation 
with 200 µL of 55 mM IAA in 50 mM ammonium bicarbonate for 30 min, protected 
from light. Gel pieces were digested overnight with 6 ng/µL trypsin at 37 °C. The 
peptide extraction was carried out with three consecutive washes with 0.2% TFA for 
MALDI-TOF identifications. The eluted peptides were dried in a SpeedVac and stored 
at −20 °C until they were analyzed by mass spectrometry. 
 
4.7. Protein identification by MALDI-TOF 
 
For MALDI analysis, 1 µL of sample was mixed with the same volume of a solution of 
α-cyano-4-hydroxy-trans-cinnamic acid matrix (0.5 mg/mL in ethanol/acetone 6:3) and 
spotted onto a MALDI target plate (Bruker). The drop was air-dried at room 
temperature. MALDI-mass spectra were recorded in the positive ion mode on an 
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Ultraflex Extreme time-of-flight instrument. Ion acceleration was set to 25 kV. All mass 
spectra were externally calibrated using a standard peptide mixture containing 
angiotensin II (1046.54), angiotensin I (1296.68), substance P (1347.74), bombesin 
(1619.82), rennin substrate (1758.93), adrenocorticotropic hormone 1-17 (2093.09), 
adrenocorticotropic hormone 18-39 (2465.20), and somatostatin 28 (3147.47). 
Calibration was considered good when a value below 1 ppm was obtained. For PMF 
analysis, the MASCOT search engine (Matrix Science) was used with the following 
parameters: one missed cleavage permission, 50 ppm measurement tolerance, and at 
least four matching peptide masses. Cysteine carbamidomethylation was set as fixed 
modification when appropriate, with methionine oxidation as the variable modification. 
Common contaminants were removed using the contaminants database available in the 
Mascot search engine. Searches were carried out using the NCBInr July 2014 database. 
Positive identifications were accepted with a Mascot score higher than that 
corresponding to a P value of 0.05. 
 
5. Molecular biology tools 
 
5.1. Polymerase chain reaction (PCR) 
 
PCR of the lpxACD and pmrABC genes of three colistin-susceptible and three colistin-
resistant A. nosocomialis strains were performed. 
These are the primers used for the PCRs which were designed specifically for this 
study.  
 
 
Primers Forward Annealing 
Temperature (ºC) 
Reverse Annealing 
Temperature(ºC) 
pmrA ATGACAAAAATCTT
GATGATTGAAGAT 
59.2 TTATGATTGCCCCAA
ACGGTAG 
60.3 
pmrB GACTTCATGAACGT
GCAT 
51.6 CAAGAGCTTAGTTAA
GCTC 
53.0 
pmrC CAGCAGTTTCTGTG
CCATGT 
58.4 TTTTGCATAGCCAAG
TTGACC 
57.4 
lpxA CCTTATTGTATTAT
TGGTCC 
52.3 CGTACAATTCCACGC
TC 
52.4 
lpxC GCGAGTGGAATAG
GTCTT 
53.8 CGTATGGAATTGGAC
AGTC 
55.2 
lpxD GCCTATGACGCTAA
GTATGA 
55.3 TCTGCATTGGTAATTC
AGGG 
55.3 
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Three or four colonies were added to 50 µl of water, the mixture was incubated during 
10 minutes at 96ºC in order to destroy all the bacteria, centrifugation at 12,000 rpm for 
10 min. was performed and the pellet was discarded.  
Reagent Volume 
DNA 5 µl 
Primer forward (5 µM) 5 µl 
Primer reverse (5 µM) 5 µl 
dNTPs (2 mM) 5 µl 
Mg2Cl (15 mM) 5 µl 
Buffer 10 µl 
Taq polymerase 0.4 µl 
H2O 14.6 µl 
  
A mixture of the reagents indicated above was performed before the PCR. 
 
 
 
The PCR conditions were as follow: 
 
Temperature Time  
95ºC 3 min  
95ºC 30 seg  
Annealing temperature 2 min X 30 cycles 
72ºC 1.5 min  
72ºC 7 min  
12ºC ∞  
 
The PCR products were loaded into a 1% agarose (Conda) gel, and runned the 
electrophoresis until the end of the agarose gel. Due to the present of Sybr Safe 
(Invitrogen) into the gel it was possible to observe the DNA fragment amplified, these 
PCR products were removed from the agarose gel and purified using the kit (Omega). 
Once the PCR product was clean, it was send to (Beckman Coulter Genomics) for 
elucidation of the sequence amplified. 
5.2. Preparation of the knockout genes 
 
The nucleotide sequences of the target genes were used to design flanking 
primers pairs to perform a two-step nested PCR mutagenesis reaction. The general 
procedure for the two-step nested PCR mutagenesis is depicted in Fig. 2 and it involves 
designing two flanking primer pairs on either side of the target sequence to create an 
internal deletion and introduce a restriction site to allow the insertion of a selection 
marker cassette.  
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Primers B and C in showed in the figure below contain an extra sequence tail 
complementary to each other and incorporate a restriction site (BamHI). The 
complementary sequences allow the overlap of the PCR products after the first round of 
amplification (using primer pairs A/B and C/D). The resulting PCR products from the 
first round of amplification were then mixed together in the second PCR round using 
only primers A and D. The overlapping ends allow both fragments to hybridise creating 
a final PCR product with a deleted region within the target sequence. The restriction site 
introduced during the PCR reaction allowed the subsequent insertion of a selection 
marker by BamHI enzymatic digestion/DNA ligation. In this study we introduced an 
armA cassette encoding a 16S rRNA methylase that confers resistance to all 
aminoglycosides. 
 
 
 
Name Primer 
forward 
Annealing 
T (ºC) 
Primer 
Reverse 
Annealing 
T (ºC) 
Immunoprot 
Upstream 
GAACCTTATT
GGACTCTTAC
G 
50.4 CAGCTAGACAG
TCGATGGATCC
TGGATTTGCTC
AACGCT 
66.7 
Immunoprot 
Downstream 
GGATCCATCG
ACTGTCTAGC
TGCAACTACA
TCATCTGGAA
GC 
66.4 AAGTGCTCCAA
GCCTATCTC 
54.3 
Membraneprot 
Upstream 
GGAGATGTGA
TGAAGTTACG 
50.4 CAGCTAGACAG
TCGATGGATCC
GCTGATGTTAG
ATGACGAC 
66.2 
Membraneprot 
Downstream 
GGATCCATCG
ACTGTCTAGC
TGTTGAAACC
TCCTTTGGTG
C 
67.1 TCGGCGGATAT
TTACTCT 
49.9 
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Construction of knock-out strain in the gens that encoded the up-regulated poteins 
found in the iTRAQ assay was performed following the procedures explained before. 
The PCR products after the first round of amplification were loaded into an agarose gel 
(1 %) and two bands corresponding with the expected size were recovered and gel-
purified.  
Next step was to perform the second PCR round by adding 1 µl of each PCR product 
recovered in the previous step. Upon loading an agarose gel, a PCR product of the 
expected size (containing the target flanking sequences as well as an internal deletion) 
was observed and purified from the gel. This truncated gene was inserted into a cloning 
vector (pGEM-T) by A/T cloning, since the terminal transferase activity of the Taq 
DNA polymerase adds a single 3´-A overhang to each end of the PCR product. 
For the insertion of the PCR product of the truncated gene into the plasmid (1µl of the 
PCR product of the truncated gene, 1µl pGEM-T, 1µl T4 DNA ligase, 2µl H2O, 5µl 
buffer 2X) overnight at 16ºC.  
The plasmid with the inserted truncated gene was transformed using competent cells of 
E. coli DH5α strain. Transformants were selected into LB agar plates containing 50 
µg/ml ampicillin (pGEM-T plasmid contain an ampicillin resistant gene) and a cell-
cracking procedure was used to confirm carriage of the plasmid. Cracking method 
consist in adding several colonies to 25µl of H2O, afterwards 25µl of cracking lysis 
buffer (860µl H2O, 40µl NaOH (5M), 20µl SDS 10%) was added and incubated at room 
temperature for 5 minutes. The mixture was then loaded into a 0.7% agarose gel, and an 
intense band belonging to the plasmid should be observed. As soon as the presence of 
the plasmid was confirmed, an overnight bacterial culture in the presence of ampicillin 
was set up. An extraction of the plasmid from the overnight culture was carried out 
using a commercial plasmid extraction kit (Promega). The plasmid was digested with 
BamHI (1µl buffer 10X, 6µl H2O, 2 µl plasmid and 1µl enzyme) and a BamHI-digested 
armA cassette (encoding a 16S rRNA methylase that confers resistance to all the 
aminoglycosides) was ligated with the previous construct (2µl T4 DNA ligase buffer 
10X, 2µl armA, 2µl plasmid, 1µl T4 DNA ligase, 13µl H2O). The ligation reaction was 
performed at 16ºC for 4 h after which it was introduced into E. coli DH5α competent 
cells as explained above. Transformants were selectec on LB-agar plates containing 50 
50 µg/ml kanamycin. The presence of the plasmid was checked as before and plasmids 
extracted from the E. coli cells were used to naturally transform an overnight culture of 
S. mitis (351). S. mitis is a natural transformant and no competent cells are needed, only 
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the action of a stimulating peptide (Genscript) to enhance the efficiency of 
transformation (222, 223). Mutants arisen from a double crossover event were further 
selected on LB agar plates supplemented with gentamicin and evaluated by PCR after 
DNA extraction using a standard kit (Promega). 
5.3. Preparation of competent cells 
 
An overnight culture of E. coli DH5α was diluted 1/1000 in LB and was incubated at 
37ºC until OD of 0.6 aprox. was achieved. Bacteria were incubated on ice during 15 
minutes, and centrifuge at 7,000 rpm during 10 minutes at 4ºC. Supernatant was 
discarded and the cells were resuspended in 1/10 of the previous volume of 0.05M 
CaCl2 -glycerol 25% (cold). Store in 200 µl aliquots at -80ºC. 
 
5.4. Genome sequence  
 
DNA from the strains sequenced was extracted using the DNA extraction kit (Promega). 
Genomic DNA from A. nosocomialis strains was fully sequenced by pyrosequencing 
using the genome sequencer Titanium (454 Life Sciences). A library of paired-end 
fragments was created following the manufacturer’s instructions (454 Life Sciences). 
This library was sequenced using the GS Titanium sequencer (454 Life Sciences). 
Reads originated from each strain were assembled into contigs using Newbler 2.53 (454 
Life Sciences). The assembly was verified using the CLC genomics software (CLC 
Bio). Predicted protein proteins were compared against a nonredundant Genbank 
database using BLASTP for functional annotation. 
 
6. Other methodologies. 
 
6.1. Caenorhabditis elegans model 
 
The aim of using the in vivo model of C. elegans was to have an idea of the virulence of 
the generated mutants compared to the original strain. The C. elegans killing assay was 
performed using E. coli OP50 as a control, and the two A. nosocomialis strains 
(colisitin-susceptible and colistin-resistant).  
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                  C. elegans life cycle at 22ºC. (artwork by Altun and Hall, Wormatlas) 
 
C. elegans embryos develop rapidly and hatch after 14 hours. The first larval stage is 
completed after another 12 hours and the animals proceed through four molt cycles 
before becoming adults. Under crowded conditions or in the absence of food larvae can 
choose an alternative development pathway leading to the dauer larva, which does not 
feed but can survive adverse conditions for several months. When life gets better normal 
development is resumed, the animals exit the dauer larval stage and develop into the 
normal fourth larval stage before becoming adult. Adult animals are hermaphrodites and 
produce both sperm and eggs. Over the course of 3-4 days some 300 eggs are laid. The 
overall life span of C. elegans is 2-3 weeks. 
The method used in the killing assay is showed in the figure below. 
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6.2. Quantitation of the LPS  
 
The procedure to determine the amount of LPS present in a certain bacteria was the 
commercial Kit QCL-1000 Limulus amebocyte assay from Lonza, following the 
instructions.  
 
6.3. Docking and molecular modeling 
 
Molecular docking is a computational method which predicts the preferred orientation 
of one molecule (ligand) to a second (protein) when bound to each other to form a stable 
complex. This knowledge is used to predict the strength of association (binding affinity) 
between the two molecules using scoring functions. 
We used Glide XP scoring function and molecular docking software from 
SCHRODINGER package (www.schrodinger.com). Protein structure was obtained with 
the help of homology modeling technique. Homology modeling constructs a model of 
the "target" protein from its amino acid sequence and an experimental three-
dimensional structure (X-Ray crystal or NMR) of a related homologous protein (the 
"template").  
I-TASSER online server (http://zhanglab.ccmb.med.umich.edu/I-TASSER/) was used 
for homology modeling. The amino acid sequence is taken from Genbank, and template 
structures used in the modeling are taken from the ompA structures present in the PDB. 
Best ranked model was prepared (all preparation was done with SCHRODINGER 
including short MD simulations) for docking calculations. EXORIS library was used for 
docking. 
 
6.4. Bacterial adherence 
 
An overnight bacterial culture was grown in LB (Luria Broth), at the same time 105 
cells (A549, pulmonary cells) were seeded in a 24 wells microplate, DMEM together 
with bacteria and different concentration of peptides were incubated with cells at 37ºC 
during 2h, after two hours the supernatant was separated and cells were treated with 
EDTA and trypsin, this mixture was also treated with 0.5% of Triton X-100 to disrupt 
all the cells, microdilutions to the extract were performed prior to be seed into blood 
agar plates in order to count the amount of bacteria present in each well, 100% of 
bacterial adherence is considered when the peptide was not added  
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6.5. Adherence to fibronectin 
 
An overnight incubation of 1.25 µg of fibronectin in 1X of PBS in a 96 well plate was 
performed to allow fibronectin to bind to the internal wall of the well. Next day BSA 
(Bovine serum albumin) was added for 1h in order to block the free positions present in 
the 96 wells plate, after 1h, bacteria together with different concentrations of the 
peptides were added during 2 hours, after that supernantant was removed and 0.5% of 
triton X-100 was added to 96 well plate, microdilutions were performed and seeded into 
blood agar plates, which were incubated during 24h at 37ºC. 100 % adherence was 
considered when no peptide inhibitor was incubated. 
 
6.6. Cell viability analysis 
 
The procedure of determining the cell viability is similar to the MTT assay, however 
bacteria are incubated together with the peptide, the rest of the procedure is the same. 
 
6.7. Pharmacokinetic assay 
 
A dose of 10 mg/Kg was injected into 30 mice, and 3 of them were sacrificed at a 
different time points (5, 10, 15 and 30 minutes, and 1, 2, 4, 6, 12 and 24 hours). The 
maximum blood of the mice was extracted and incubated with EDTA, afterwards the 
serum was obtained from the blood. Once the serum was obtained , the rest of the 
protocol was the same as the calculation of the stability of the peptide. However, once 
the peptide was in solution, a certain amount of pure peptide (in a knowledge 
concentration) was added, therefore in the HPLC the peak will increase and we will 
have the contribution of the same peptide from two different sources, this fact will allow 
us to calculate the concentration of peptide we will have in serum at a certain time 
point.  
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Introducció.  
Avui en dia estem davant d’un problema molt greu d’abast mundial, aquest problema té 
dos factors importants que són: i. el augment d’infeccions resistents a la majoria dels 
antibiòtics disponibles. ii. la poca inversió per part de la indústria farmacèutica en el 
desenvolupament de nous antibiòtics. A l’últim informe de la OMS es va alertar sobre 
aquesta situació. Tenint en conte la situació mencionada anteriorment es va anomenar 
ESKAPE (Enterococcus faecium, Staphylococcus. aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa, Entereobacter species) al grup de 
bacteris més resistents. El grup ESKAPE està composat per bacteris tant Gram-positius 
com Gram-negatius, i realment son dianes molts atractives per al disseny de nous 
fàrmacs.  
Una altre factor important a tindre en conte es l’escala de resistència d’un bacteri en 
front a certs tipus d’antibiòtics. S’ha definit com a multi resistència quan el bacteri es no 
sensible a ≥ 1 agent en ≥ 3 categories d’agents antimicrobians, el següent grau de 
resistència es el de resistència extensa, el qual es defineix com a no sensible a ≥ 1 agent 
de com a màxim dues categories, i per últim pan resistència, que es defineix com la 
resistència a tots els tipus i famílies d’antibiòtics. Fins fa uns anys no hi havia 
controvèrsia en el tema de definir el grau de resistència del antibiòtics degut a que no 
s’havien aïllat soques resistents a tots els antibiòtics, però en els últims anys el nombre 
de soques pan resistents han augmentat considerablement sobretot A. baumannii, fent 
necessari que hi hagi una definició del grau de resistència d’una bacteri.  
Es pot apreciar l’evolució d’A. baumannii en els estudis realitzats, on es pot veure el 
augment de la resistència a imipenem del 3 al 70% entre el període de 1993 i 2007, el 
mateix efecte s’observa en quinolones amb un increment del 30 al 97% durant el mateix 
període de temps.  
Com hem comentat anteriorment hi ha una necessitat urgent de nous antibiòtics, i 
especialment per antibiòtics actius en front a bacteris Gam-negatius degut al fet que els 
últims antibiòtics llençats al mercat (daptomicina i linezolid) només son efectius en 
front bacteris Gram-positius. Tot i esser els últims antibiòtics llençats al mercat ja s’han 
aïllat soques que presenten resistència a aquests dos antibiòtics.  
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Com em comentat anteriorment ens centrarem en Acinetobacter, que són principalment 
patògens nosocomials i oportunistes, això vol dir que normalment afecten a pacients 
amb un sistema immunològic deteriorat. Entre el 2 i el 10 % de les infeccions produïdes 
a les UCI son causades per aquest patogen. Solen ser una de les causes més freqüents en 
pneumònia però també estan implicats en bacterièmia, infeccions del tracte urinari o 
meningitis. 
El gènere Acinetobacter està format per diverses especies, les quals tenen en comú que 
son coc-bacils Gram-negatius, no fermentadors, incapaços de reduir nitrats, catalasa 
positius, oxidasa negatius, i sense motilitat, d’aquí es d’on prové el nom Acinetobacter, 
que es deriva del terme grec (a-kineto) que significa no mòbil, per això indica que 
aquest gènere no te motilitat en superfícies. Actualment, al 2014, 34 especies diferents 
del gènere Acinetobacter han estat definides.  
Les colònies formades per les especies pertanyents al gènere Acinetobacter son d’un 
color groc però poden arribar tindre un color blanc grisós i entre 1 i 2 mm de diàmetre. 
El test d’oxidasa es el emprat per diferenciar el gènere Acinetobacter d’altres bacteris 
Gam-negatius no fermentadors. Per a un aïllament ràpid de soques clíniques s’utilitza 
un medi sòlid selectiu que no permeti el creixement d’altres microorganismes, tipus 
Herellea agar o medi Leeds Acinetobacter. 
Les dues característiques mes importants que fan que Acinetobacter sigui un gènere tan 
resistent es l’habilitat per desenvolupar patrons de multi resistència i l’habilitat per 
sobreviure en diferents condicions. Les especies d’Acinetobacter poden ser trobades al 
sòl, aigua, animals o humans, creixent normalment a totes les mostres aïllades del sòl o 
l’aigua. Els llocs on han sigut aïllades aquests bacteris son tan diversos com aigua fresca 
natural, mostres d’aire d’hospitals o fins i tot a escoles o escoles bressol. Aquesta alta 
resistència a qualsevol condició ambiental prové de la habilitat d’emprar diferents fonts 
de carboni, això es pot veure clarament en la comparació entre les soques tipus (ATCC) 
i les soques dels aïllats clínics.  
Si comparem la capacitat de supervivència amb altres bacteris la diferencia es notable 
essent al voltant de 24 hores per E. coli i menys de 24 hores per P. aeruginosa, quan a 
les mateixes condicions qualsevol bacteri pertanyent al gènere Acinetobacter sol viure 
varis dies inclús arribant a 25 com en el cas d’A. baumannii. 
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Els factors de virulència són necessaris per la patogènia d’infeccions causades per A. 
baumannii, aquest factors son claus alhora d’infectar i colonitzar el hoste. Hi ha molts 
tipus de factors de virulència, com per exemple el biofilm, el qual es defineix com una 
matriu polimèrica formada per carbohidrats, proteïnes, àcids nucleics i d’altres 
macromolècules que manté units els bacteris un cop adherits a la cèl·lula del hoste i els 
ajuda a sobreviure. Un altre factor de virulència es el de la motilitat i adherència, com 
hem comentat anteriorment el gènere Acinetobacter manca de motilitat degut a 
l’absència de flagels, però això no implica que no tingui mobilitat tipus twiching, degut 
a la presencia de pilis. 
El lipopolisacàrid (LPS) present a la membrana del bacteri també es un factor important 
de virulència, com es pot apreciar en les soques d’Acinetobacter tant baumannii com 
nosocomialis, la pèrdua del LPS implica també una perduda de la virulència de la soca. 
Un altre component de les membranes dels bacteris Gram-negatius, com son les outer 
membrane proteins (OMPs), son també importants factors de virulència, on cal destacar 
OmpA, que s’ha descrit com la proteïna involucrada a l’adherència dels bacteris a les 
cèl·lules del pacient infectat.  
Hi han altres factors de virulència que no pertanyen a la estructura de la bacteri sinó que 
son elements mòbils com son les outer membrane vesicles, que son nano vesícules 
esfèriques compostes per DNA, RNA, lípids, LPS o inclús OMP, la seva funció 
principal es la de transportar factors de virulència. Un altre factors important es l’acció 
dels sideròfors, compostos que tenen l’habilitat de quelar el ferro, que com es conegut 
es un factor determinant en el creixement bacterià i per últim, el quòrum sensing, que es 
un sistema de comunicació entre bacteris depenent de la densitat cel·lular o la fase de 
creixement, aquestes molècules poden controlar diversos factors de virulència 
comentats anteriorment tals com el biofilm o la motilitat. 
 Com s’ha comentat anteriorment, Acinetobacter te una facilitat innata per adquirir 
elements de resistència a tot tipus d’antibiòtics. 
La resistència a β-lactamics, pot esser de dos tipus, el mediat per un enzim (β-
lactamases), el qual actua obrint l’anell β-lactamic de la molècula hidrolitzant-lo i així 
desactivar l’efecte antibacterià del compost, o per altre banda, mecanismes no 
enzimàtics.  
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Hi ha diferents tipus de β-lactamases depenent  del compost sobre el que actuen, hi ha 
per exemple les AmpC que actuen inhibint penicil·lines i cefalosporines d’espectre estès 
excepte cefepime, o les oxacilinases capaces d’inhibir l’efecte de l’oxacilin i el 
cloxacilin i per últim les metallo-β-lactamases, esteses mundialment i caracteritzades 
pel seu ampli espectre d’acció degut a que son capaces d’inhibir tots els antibiòtics β-
lactamics excepte aztreonam. 
Els mecanismes no enzimàtics estan relacionats amb alteracions a la membrana com 
poden ser la sobre expressió de bombes de flux o alteracions a les OMPs, o fins i tot 
modificacions a les PBPs (Penicilin binding proteins). 
La resistència a aminoglicòsids també està dividida en dos tipus de mecanismes 
diferents com son les acetiltransferases, nucleotidiltransferases o fosfotransferases, 
enzims que modifiquen el grup amino o hidroxil dels aminoglicòsids, i per altre banda, 
les bombes de flux en especial la bomba AdeABC que confereix resistència a 
aminoglicòsids apart d’altres tipus d’antibiòtics. 
La resistència a quinolones ve donada per mutacions, com succeix a totes les especies, a 
la zona QRDR (Quinolone-resistance determinig region) de la subunitat A de la DNA 
girasa i de la DNA topoisomerasa IV. Paral·lelament a aquestes mutacions també s’han 
descrit diverses bombes d’expulsió involucrades en la resistència a quinolones. 
La resistència a polimixines estan basats principalment en la modificació de gens que 
estan involucrats en algun procés de la síntesi d’algun component del LPS del bacteri, 
com per exemple mutacions al sistema regulador de doble component pmrABC, que esta 
relacionat amb la modificació del lípid A del LPS o mutacions als gens lpxACD que 
estan directament relacionats amb la biosíntesi  del lípid A. 
Actualment dos tipus d’antibiòtics peptídics, colistina i daptomicina, son emprats per a 
tractar certes infeccions produïdes per bacteris Gram-negatius i Gram-positius 
respectivament. 
Colistina es un antibiòtics peptídic aïllat als anys seixanta però reemplaçat pels 
aminoglicòsids als setanta degut a la seva nefrotoxicitat. Però en els últims anys degut al 
increment de la resistència dels antibiòtics emprats s’ha hagut de tornar a reutilitzar 
aquest tipus d’antibiòtic, però tot i així ja s’han aïllat diverses soques resistents a 
colistina. Arrel de la reutilització de la colistina com a antibiòtic, els estudis de la seva 
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toxicitat s’han intensificat, trobant que la toxicitat d’aquest compost està al nivell 
d’altres antibiòtics utilitzats com la tobramicina, o que realment lo important es la dosi 
acumulada més que la dosi diari administrada, per tant ara es coneix com aquesta 
toxicitat es totalment reversible amb el temps.  
 
 
 
 
Figura. R.1. Estructura químicade la colistina i els anàlegs aïllats  
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L’estructura química de la colistina està formada per un decapèptid cíclic i un àcid gras, 
la unió per formar el cicle està entre el àcid diaminobutíric de la posició 4 i la treonina 
de la posició 10. De totes les polimixines aïllades la única variació present, son els 2 
aminoàcids de la posició 6 i 7 i l’àcid gras.  
La colistina o polimixina E, té una D-Leu a la posició 6 i un Leu a la posició 7. S’ha de 
tindre en conte que la colistina inclou diferents especies però una gran majoria (més del 
80%) pertanyen a la mescla entre polimixina E1 i polimixina E2. 
Com s’ha comentat anteriorment el mecanisme de resistència a colistina esta lligat 
d’alguna manera al LPS i per això el mecanisme d’acció de les polimixines està 
relacionat amb la membrana dels bacteris Gram-negatius tot i que no està del tot clar 
quin es el mecanisme exacte. 
Un altre pèptid emprat com a antibiòtic es la daptomicina, aquest antibiòtic va ser 
aprovat per la FDA al 2003, té una estructura molt semblant a la de les polimixines, 
amb un pèptid cíclic i un àcid gras. La part peptídica esta composada per 13 aminoàcids, 
10 d’ells estan formant un cicle, la ciclació del pèptid es produeix entre els aminoàcids 
L-Kyrunenine (residu 13) i L-treonina (residu 4). 
 
Figura. R.2. Estructura química de la daptomicina 
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Taula.R.1 Diferents cadenes d’’acid gras de la daptmicina relacionat amb la seva activitat en front S. 
aureus. 
Diferents compostos varen ser aïllats al mateix temps que la daptomicina, la única 
diferencia entre ells es l’estructura de l’àcid gras, però de tots ells la daptomicina era el 
que presentava un millor balanç entre toxicitat i activitat. 
 
El mecanisme d’acció de la daptomicina està relacionat amb la membrana dels bacteris 
Gram-positius però tal com passa en el cas de les polimixines, el mecanisme complert 
no ha estat elucidat, de totes maneres es coneix que l’acció de la daptomicina esta 
intrínsecament relacionat amb la concentració de Ca2+ present al sèrum. 
To i que la daptomicina es un antibiòtic relativament nou, varis casos de soques 
resistents s’han aïllat en S. aureus i en Enterococcus. Com en el cas de la colistina, tots 
els bacteris aïllats resistents a daptomicina presenten algun tipus de modificació 
relacionat amb la membrana. 
 
Fins ara només em comentat sobre els problemes que hi ha en el tractament d’infeccions 
però no em proposat alternatives als antibiòtics ja emprats, aquí es descriuen diferents 
opcions pel tractament d’A. baumannii. 
Antimicrobial peptides.  
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Hi ha diferents maneres per obtindré un pèptid actiu, alguna d’elles son utilitzant 
extractes naturals i fent un “screening” en front el bacteri desitjat, o d’altres maneres 
com pot esser la dissenyar el compost d’acord amb una diana concreta. El ús de pèptids 
com a agents antibacterians té certs avantatges com són el ampli espectre d’acció, o la 
inespecificitat de la diana que fa que sigui més difícil d’adquirir resistència, també te 
certs desavantatges com son la baixa estabilitat en sèrum humà i la seva ràpida excreció. 
Algunes soques comercials han estat testades en front de soques d’A. baumannii, amb 
diferents perfil de resistència de les soques emprades, els millors resultats s’observen en 
el cas de buforin II i magainin II, amb una MIC50 i MIC90 de 2 i 16 mg/l respectivament, 
la mateixa MIC90 es observada en el cas de cecropin P1 i melittin però la MIC50 presenta 
una dilució més (4 mg/l). Cecropin A, indolicidin i ranalexin presenten uns valors de 
MIC més elevats. Dos dels pèptids comentats anteriorment, cecropin A (CA) i melittin 
(M), van ser barrejats per obtindré una millor activitat en front a soques d’A. baumannii 
resistents a colistina. CA (1-7)M(2-9) va ser testat en front de soques multi resistents i 
en soques colistina resistents d’A. baumannii. El millor resultat es el obtingut en front 
de soques colistina resistents amb uns valors de MIC50 i MIC90 de 2 i 4 mg/L 
respectivament, comparat amb la soca multi-resistent (MIC50 4 mg/l, MIC90 12 mg/l). 
La font d’on els pèptids antimicrobians poden ser trobats es molt diversa des de 
secrecions de pell de granota a verí d’escorpí australià. 
Fins ara només em parlat de pèptids naturals, tot i així pèptids totalment sintètics han 
estat també testats en front soques d’A. baumannii, com es el cas d’un pèptid format 
només per lisines i leucines (LKLLKKLLKKLLKLL), el mateix pèptid però amb un 
33% de D-aminoàcids va ser sintetitzat i també té una millor activitat 5.6 mg/l. Altres 
pèptids que contenen majoritàriament lisines i leucines van ser sintetitzats però en 
aquest cas una o dues cisteïnes van ser funcionalitzades. C(LLKK)2C i (LLKK)2C van 
ser sintetitzats i testats amb valors de MIC molt elevats però tot i així deguts a la seva 
poca toxicitat in vivo, presenten una alta efectivitat quan son provats en ratolins. 
 
Polimixines. 
Com s’ha comentat anteriorment, un dels problemes de la utilització de les polimixines 
es la seva nefrotoxicitat, per aquest motiu una de les opcions es intentar sintetitzar 
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anàlegs de les polimixines intentant reduir la seva nefrotoxicitat i augmentar la seva 
activitat en front soques tant sensibles com resistents a colistina d’A. baumannii. Una de 
les opcions per augmentar l’efectivitat del compost es introduir nous grups hidrofòbics a 
les posicions 6 i 7 i a la cua d’àcid gras, es important mencionar que l’activitat d’aquests 
nous compostos es independent de la MIC a colistina per part de la soca. Un altre grup 
va escollir una altre estratègia que va ser canviant el Dab de la posició 3 per un Dap 
(àcid 2,3-diaminopropionic) i sobre aquest esquelet canvien la cua d’àcid gras, es pot 
veure com l’anàleg amb la cua com a 6-oxo-1-fenil-1,6-deshidropiridina-3-carbonil, té 
millor resultats in vitro però in vivo falla en comparació amb la polimixina B. 
 
A part dels típics compostos antimicrobians, hi ha altres maneres de tractar les 
infeccions causades per A. baumannii. 
Una de les opcions es la utilització de compostos capaços de quelar el ferro, que com 
hem comentat anteriorment es realment important pel creixement bacterià. Una opció 
alternativa a quelar el ferro es la de substituir al catió Fe3+ pel Ga3+, on es produeix una 
competició degut a que tenen la mateixa valencia i semblant radi atòmic. La diferencia 
es  que el Ga3+ no pot fer les funcions que fa el ferro i per això el bacteri mor a causa de 
la deficiència de ferro.  
Una altre tipus de teràpia alternativa es inhibint la generació de biofilm, on s’ha trobat 
un compost marí amb l’habilitat per inhibir el biofilm i posteriorment ha estat optimitzat 
obtenint un compost amb una activitat elevada. 
Es conegut que els fags poden tindre la capacitat de llisar les bactèries, per tant es un 
altre alternativa d’ús en front de soques d’A. baumannii, on després d’èsser optimitzat 
s’han assolit bons resultats in vivo.  
L’ús de vacunes com a prevenció per l’adquisició d’infeccions causades per A. 
baumannii es una altre bona estratègia, tenint en conte que l’adquisició d’aquest tipus 
d’infeccions be donada en llocs i en pacients molt puntuals. Fins ara diferents tipus de 
vacunes en front A. baumannii han sigut testades assolint resultats in vivo força bons. 
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L’última teràpia alternativa i potser la més innovadora es la teràpia fotodinamica, on 
l’idea es generar oxigen reactiu que interactuarà amb el DNA o proteïnes de membrana i 
així destruint el bacteri. 
 
 Mecanisme de resistència a daptomicina en S. mitis. 
Com hem comentat breument, el mecanisme d’acció de la daptomicina es a nivell de 
membrana dels bacteris Gram-positius, per això el mecanisme de resistència del bacteri 
ha d’estar lligat d’alguna manera a la membrana, així que la nostra primera hipòtesi va 
ser la de veure si es produïa un augment del gruix de la paret cel·lular del bacteri quan 
s’adquiria resistència a daptomicina.  Es van analitzar el gruix de la paret cel·lular de 3 
soques resistents a daptomicina i una soca sensible a daptomicina i els resultats 
obtinguts son els següents. 
 
a) 351     b) D6-2 
    
Figura.R.3. a) TEM de la soca S. mitis susceptible a daptomicina. b) TEM de la soca S. mitis resistent a 
daptomicina 
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Soques Gruix de la membrana (nm) MIC a daptomicina (mg/L) 
351 (daptomycin S) 20.03±1.47 0.38 
D6-2 (daptomycin R) 25.21±2.05 >256 
D6-7 (daptomycin R) 22.35±2.84 >256 
D6-14 (daptomycin R) 24.44±2.56 >256 
Taula.R.2. Gruix de la membrana del bacteri relacionat amb la seva activitat en front daptomicina 
Es pot apreciar com hi ha un lleuger augment en el gruix però sense arribar a ser 
significativament diferent. En altres bacteris resistents a daptomicina tals com S. aureus, 
no sempre es produeix un augment de la paret cel·lular quan la soca adquireix 
resistència a daptomicina per tant es un factor secundari. 
Com a segona hipòtesi vàrem decidir utilitzar tècniques de proteòmica comparativa per 
veure si hi havia alguna proteïna interesant que varies el seu nivell d’expressió 
significativament, per això es va emprar el mètode d’ITRAQ, i els resultats obtinguts es 
poden veure a les taula inferior. 
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Diferencia 
Dapto R/Dapto S 
Proteïna identificada 
     
0,24 NADP-specific glutamate dehydrogenase [Streptococcus agalactiae COH1]  
0,30 PF08006 family protein [Streptococcus oralis SK100]   
0,36 30S ribosomal protein S3 [Streptococcus pneumoniae TIGR4]  
0,55 PTS system transporter subunit IIB [Streptococcus pneumoniae TIGR4]  
0,62 glutamate--ammonia ligase [Streptococcus oralis ATCC 35037]  
0,64 ABC transporter, ATP-binding protein, partial [Streptococcus oralis SK255]  
0,65 peptidyl-prolyl cis-trans isomerase [Streptococcus sp. oral taxon 071 str. 73H25AP]  
0,65 peptidyl-prolyl cis-trans isomerase [Streptococcus oralis ATCC 35037]  
0,69 ABC superfamily ATP binding cassette transporter, binding protein [Streptococcus sanguinis ATCC 49296]  
0,72 hypothetical protein HMPREF0851_00776 [Streptococcus sp. M334]  
0,73 PTS family maltose and glucose porter, IIABC component [Streptococcus oralis ATCC 35037]  
0,74 peptidyl-prolyl cis-trans isomerase [Streptococcus sp. GMD6S]  
1,19 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase [Streptococcus oralis ATCC 35037]  
1,22 serine protease HtrA [Streptococcus oralis ATCC 35037]  
1,27 phosphotransacetylase [Streptococcus mitis B6]   
1,29 putative PTS system, IIC component [Streptococcus sp. M143]  
1,33 conserved hypothetical protein [Streptococcus oralis ATCC 35037]  
1,36 L-lactate oxidase [Streptococcus pneumoniae G54]   
1,36 group B streptococcal surface immunogenic protein [Streptococcus sanguinis ATCC 49296]  
1,48 glycogen biosynthesis protein,glucose-1-phosphate adenylyltransferase [Streptococcus oralis Uo5]  
1,50 pyruvate oxidase [Streptococcus oralis SK100]   
1,59 glucose-1-phosphate adenylyltransferase [Streptococcus oralis ATCC 35037]  
2,26 group B streptococcal surface immunogenic protein [Streptococcus mitis ATCC 6249]  
Taula. R.3.Proteines identificades en S. mitis amb un grau diferent d’expressió entre soques susceptible i 
resistent a daptomicina 
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Es pot apreciar com hi ha moltes proteines que varien el seu nivell d’expressió però ens 
centrarem només en aquelles que estiguin relacionades amb la membrana i puguin 
tindre algun homòleg en altres bacteris que estigui implicat en la resistència a 
daptomicina.  
Aquestes proteïnes son la conserved hypothetical protein que esta sobre expressada 1,33 
vegades, i la group B streptococcal surface immunogenic protein que esta sobre 
expressada 2,26 vegades, aquesta última proteïna conté un domini amb homologia a la 
proteïnaYvqF/VraSR involucrada a la resistència a daptomicina en certs bacteris, i la 
hypothetical protein te un grau d’homologia amb un domini de lisina motif que es pot 
trobar en enzims involucrats en la degradació de la paret cel·lular   
Un cop em decidit que aquestes podrien ser les proteïnes involucrades en la resistència a 
daptomicina un knockout dels gens que les codifiquen s’han dut a terme per comprovar 
que realment esta involucrades, les construccions plasmídiques s’ha dut a terme 
perfectament però la transformació en S. mitis no funcionà però futurs experiments es 
duran a terme per verificar la funció d’aquestes proteïnes. 
Mecanisme de resistència a colistina en A. nosocomialis. 
Soques resistents a colistina d’A. nosocomialis va ser generades in vitro degut al fet que 
mai ha estat descrit resistència a colistina per part d’aquest tipus d’espècie 
d’Acinetobacter. La curiositat d’aquests mutants generats va ser la seva alta tolerància a 
colistina sense generar resistència, a 8mg/L de colistina on hi ha un punt d’inflexió en 
que la MIC passa de ser menor a 1 mg/l a 128 mg/l.  
Aquests mutants generats presenten una disminució considerable de la MIC a gairebé 
tots els antibiòtics testats a part d’una disminució important de la virulència en el model 
de C. elegans. 
 
Tenint en conte que mai abans s’ha descrit el mecanisme de resistència a colistina en 
soques d’A. nosocomialis , la única referencia es la de resistència a colistina en soques 
d’A .baumannii, els operons pmrABC i lpxACD, son els descrits que presenten 
mutacions que confereixen resistència a colistina. En el operó pmrABC no es pot 
apreciar cap tipus de mutació entre la soca colistina sensible i la soca colistina resistent. 
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En canvi al operó lpxACD, es poden veure mutacions presents al gen lpxD, a més a més 
d’un codó stop a la proteïna lpxD, mai descrit anteriorment. El operó lpxACD està 
directament involucrat en la síntesi del LPS de la membrana del bacteri Gram-negatiu, 
aquestes mutacions i el codó stop porten a una modificació del procés de síntesis d’una 
part del LPS que porta a la inexistència de LPS en les soques colistina resistents, com 
s’ha comprovat utilitzant un kit comercial.  
 
També s’ha comprovat que les mutacions presents al gen lpxD, estan presents a totes les 
soques resistents a colistina i desapareixen quan les soques son sensibles a colistina. 
Per una altre part també s’han dut a terme estudis de proteomica comparatius entre la 
soca sensible i la soca resistent. Primer es van comparar mitjançant gels bidimensionals 
però posteriorment es va realitzar pel mètode comparatiu de DIGE , aquí es pot observar 
el gel resultant i les proteïnes amb variació en l’expressió.   
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Figura.R.4. Gel bidimensional de proteïnes de soques d’A. nosocomialis colistina 
sensibles (0.125/2/8) i colistina resistents (16/32/512). 
 
     0,125                      2 
         8                     16 
         32                    512 
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Figura.R.5. Gel comparatiu de DIGE. 
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Taula.R.4. Proteines identificades en A. nosocomialis amb un grau diferent d’expressió entre soques 
susceptible i resistent a colistina 
 
Aquí es pot veure el grau d’expressió comparativa de les proteïnes de membrana entre 
les soques de colistina sensible i colistina resistent d’A. nosocomialis. Gairebé totes les 
proteïnes estan sobre expressades en la soca resistent a colistina, que contradiu 
totalment els resultats publicats per colistina resistent en A .baumannii, però aquesta 
diferent expressió de proteïnes ja es pot apreciar quan es comparen una soca sensible 
amb una multi-resistent, així que aquestes variacions en l’expressió de les proteïnes 
siguin degudes al canvi en les MICs dels altres antibiòtics. 
Número 
spot 
Proteïna id Proteïna 
Canvi a 
l’expressió* 
Anova 
P-valors 
1 gi|407441282 OmpA_C-like 1.3 0.0239 
2 gi|490848590 hypothetical protein F984_02367 (NodT 
family RND efflux system) 
2.1 0.00911 
3 gi|497190250 hypothetical protein (tetratricopeptide repeat 
family protein) 
1.5 0.0167 
4 gi|593656836 
 
putative carbapenem-associated resistance 
protein  (CarO) 
1.7 0.00914 
5 gi|446899273 OmpW-like protein 1.4 0.0274 
6 gi|354459714 OmpA (Isoform) 2 0.0233 
7 gi|487978330 succinate dehydrogenase flavoprotein 
subunit 
1.7 0.000768 
8 gi|487978520 Porin (OprB) Carbohydrate-selective porin -1.9 0.00533 
9 gi|493628869 membrane protein (outer membrane beta-barrel 
domain protein) 
1.4 0.0774 
10 gi|487981035 signal peptide protein -1.2 0.0237 
11 gi|587819016 putative porin 1.1 0.0613 
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Fins ara només hem estat comentant els mecanismes de resistència de dos dels 
antibiòtics peptídics emprats habitualment pel tractament d’infeccions, però per altre 
part també es important proposar alternatives per a poder solucionar el problema de la 
resistència.  
 
En aquesta tesi em utilitzat dos tipus d’aproximació diferents,. La primera aproximació, 
es la típica aproximació provant diferents compostos fins a trobar-ne un d’actiu en front 
la soca desitjada i posterior optimització, i per altre banda la segona aproximació es més 
innovadora inhibint la virulència creada per la proteïna OmpA.  
 
Pèptids i peptidomimetics actius en front de soques d’Acinetobacter resistents a 
colistina. 
Hi ha pocs compostos testats in vitro actius en front de soques d’Acinetobacter 
resistents a colistina, per tant diferents pèptids comercials van ser provats en front de 
dues soques d’A. baumannii, una sensible a colistina i l’altre resistent. Els millors 
resultats pertanyen als pèptids mastoparan, melittin i indolicidin. Aquest últim amb 
MICs de 8 i 16 mg/l en soques colistina sensible i colistina resistent respectivament. 
Melittin té una MIC de 4 mg/l quan es testat en front d’una soca sensible a colistina i 
disminueix fins a 2 mg/l quan la soca es resistent, i per últim mastoparan, amb la 
mateixa MIC en soques sensibles a colistina i una MIC d’1 mg/l quan la soca es 
resistent a colistina. Dos dels tres pèptids amb millor activitat, melittin va ser descartat 
degut a la seva toxicitat, va ser testats en front de més soques d’A. baumannii tant 
sensibles com resistents a colistina. Els resultats obtinguts son molts semblants als que 
es pot apreciar al screening inicia, essent més elevats en el cas d’indolicidin comparat 
amb mastoparan, per això ens centrarem en mastoparan. 
Corbes de letalitat de diverses concentracions de mastoparan en front de soques d’ A. 
baumannii colistina sensible i colistina resistent va ser dutes a terme, on es pot apreciar 
el comportament bacteriostàtic a 8 vegades la MIC en soques d’A. baumannii colistina 
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sensible i colistina resistent i a 4 vegades la MIC en soques colistina resistents sense 
observar cap recreixement.  
Hem escollit mastoparan com el pèptid candidat a ser optimitzat, i com hem comentat 
anteriorment la baixa estabilitat en sèrum es un dels inconvenients d’utilitzar els pèptids 
com a fàrmacs. L’estabilitat del mastoparan en sèrum va ser calculada i els punts més 
susceptibles a proteases. L’estabilitat obtinguda va ser sorprenent tenint en conte que es 
un pèptid lineal (6h) però tot i així la seva estabilitat va ser optimitzada tenint en conte 
que l’únic lloc observable susceptible a proteases era la leucina present al extrem N-
terminal. Sis pèptids anàlegs juntament amb el mastoparan van ser sintetitzats. 
  
 Concentració mínima inhbitoria mg/l (µM) 
  
  Antimicrobial peptide CR17 CR86 Ab11 Ab113 
Estabilitat 
en sèrum 
humà 
Toxicitat MTT 
IC50 (HeLa) 
1 Gu-INLKALAALAKKIL 4 (2,6) 4 (2,6) 4 (2,6) 4 (2,6) > 24h 13 µM 
2 iNLKALAALAKKIL 32 (21,6) 32 (21,6) 64 (43,3) 64 (43,3) > 24h 41 µM 
3 InLKALAALAKKIL 32 (21,6) 64 (43,3) 128 (86,5) 256 (173) > 24h 73 µM 
4 NLKALAALAKKIL 32 (19,2) 64 (38,4) 128 (76,8) 128 (76,8) > 24h 109 µM 
5 Ac-INLKALAALAKKIL 16 (10,5) 32 (21) 64 (42) 64 (42) > 24h 29 µM 
6 Mastoparan 4 (2,7) 4 (2,7) 4 (2,7) 4 (2,7) 6h 32 µM 
7 inLKALAALAKKIL 128 (86,5) 128 (86,5) 128 (86,5) 256 (173) > 24h 21 µM 
 
       
Taula.R.5. Activitat en front soques amb alta resistència d’A. baumannii, estabilitat en sèrum humà i 
citotoxicitat en HeLa de diferents anàlegs del mastoparan i el mastoparan. 
El pèptid 1, que porta un grup guanidini al extrem N-terminal es el únic compost que 
presenta una activitat igual que el mastoparan i a més a més te una estabilitat major a les 
24h, però té una toxicitat més elevada comparat amb el mastoparan.  
Tenint en conté els resultats obtinguts als primers anàlegs i informació obtinguda a la 
literatura sobre toxicitat d’anàlegs del mastoparan, set nous anàlegs van ser sintetitzats. 
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Concentració mínima inhbitoria mg/l (µM) 
  
  Antimicrobial peptide CR17 CR86 Ab11 Ab113 
Estabilitat 
en sèrum 
humà 
Toxicitat 
MTT IC50 
(HeLa) 
8 LIKKALAALAKLNI 256 (173) 256 (173) 256 (173) 256 (173) 2h 192 µM 
9 likkalaalaklni 256 (173) 256 (173) 256 (173) 256 (173) > 24h 200 µM 
10 inlkalaalakkil 4 (2,7) 4 (2,7) 4 (2,7) 4 (2,7) > 24h 10 µM 
11 INLKAKAALAKKIL 
256 
(171,5) 
256 
(171,5) 
256 
(171,5) 256 (171,5) 6h 290 µM 
12 in(or)kalaalakkil 128 (86,5) 64 (43,2) 64 (43,2) 128 (86,5) >24h 200 µM 
13 
INLKALAALAKKIL-
CH2CH2NH2 4 (2,6) 4 (2,6) 2 (1,3) 4 (2,6) 6h 5 µM 
14 
LIKKALAALAKLNI-
CH2CH2NH2 64 (42) 128 (84,1) 128 (84,1) 64 (42) 2h 150 µM 
Taula.R.6. Activitat en front soques amb alta resistència d’A. baumannii, estabilitat en sèrum humà i 
citotoxicitat en HeLa de diferents anàlegs del mastoparan i el mastoparan 
En aquest cas 2 anàlegs conserven l’activitat del mastoparan, el seu enantiòmer (pèptid 
10) i el mastoparan original amb una càrrega positiva extra al extrem C-terminal (pèptid 
13), aquests dos pèptids, com passa amb el pèptid 10, tenen una toxicitat superior al 
mastoparan i el pèptid 10 una estabilitat superior (>24h) però el pèptid 13 igual que el 
mastoparan.  
 
Dels quatre pèptids obtinguts amb activitat s’havia d’escollir quins son els que s’ha de 
provar in vivo, ens vàrem decantar pel mastoparan degut a que es el menys tòxic i pel 
pèptid 10 que al estar format per D-amino àcids es molt més estable tot i ser més tòxic. 
Aquests dos pèptids van ser provats in vivo en tot tipus d’experiments sense veure cap 
tipus d’activitat antibacteriana, la qual cosa ens va fer sospitar sobre alguns tipus d’unió 
a alguna proteïna, per aquest motiu vàrem fer assajos d’inhibició en presencia de sèrum 
i vàrem veure com la MIC dels dos pèptids pujava progressivament amb la concentració 
de sèrum a l’assaig.  
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MIC mg /l(µM)   CR17     Ab14  
% of Sèrum 0% 25% 50% 75%  0% 25% 50% 75% 
          
Mastoparan 4(2.7) 16(10.8) 64(43.3) 128(86.5)  4(2.7) 32(21.6) 128(86.5) 128(86.5) 
Pèptid 10 4(2.7) 16(10.8) 64(43.3) 128(86.5)  2(1.35) 32(21.6) 64(43.3) 128(86.5) 
Taula.R.7. Activitat de mastoparan i pèptid 10 en front soques pan-resistents d’A. baumannii en presencia 
de sèrum. 
Com hi ha moltes proteïnes presents al sèrum vàrem testar en front albúmina que es una 
de les més abundants. 
 
MIC mg/l (µM) 
  CR17     Ab14  
% of albúmina 0% 25% 50% 75%  0% 25% 50% 75% 
          
Mastoparan 4(2.7) 16(10.8) 32(21.6) 64(43.3)  4(2.7) 16(10.8) 32(21.6) 64(43.3) 
Peptide 10 4(2.7) 4(2.7) 4(2.7) 4(2.7)  4(2.7) 4(2.7) 4(2.7) 4(2.7) 
Taula.R.8. Activitat de mastoparan i pèptid 10 en front soques pan-resistents d’A. baumannii en presencia 
de d’albumina. 
 
Es pot observar com la MIC de mastoparan augmenta quan augmenta la concentració de 
sèrum però en canvi amb el pèptid 10 la concentració roman constant, això ens indica 
que mastoparan té una unió amb l’albúmina però el pèptid 10 amb alguna altre proteïna 
present al sèrum més minoritària. 
També s’han estudiat els mecanismes d’acció dels anàlegs a mastoparan sintetitzats 
utilitzant el mètode de leakage i els pèptids utilitzats in vivo, per microscòpia electrònica 
de transmissió.  
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Figura R.6. Percentatge d’alliberació de carboxifluorisceina en liposomes negatius de tots els pèptids 
sintetitzats a diferents concentracions. 
 
Figura.R.7. Percentatge d’alliberació de carboxifluorisceina en liposomes neutres de tots els pèptids 
sintetitzats a diferents concentracions. 
 
En els assajos de leakage es pot apreciar com els pèptids que tenen millor activitat in 
vitro, també son els que alliberen més fluorofor del liposoma. Els assajos de leakage 
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s’ha dut a terme utilitzant dos tipus de lípids diferents, un conjunt de lípids amb carrega 
global negativa, mimetitzant la membrana d’A. baumannii, on es pot veure una activitat 
força elevada dels millors pèptids, en canvi quan la carrega global del liposoma es 
neutre el efecte dels pèptids es molt menor inclús nul per algun pèptid. 
Utilitzant microscòpia electrònica de transmissió es pot apreciar comparant el control 
sense pèptid amb els bacteris incubats tant amb mastoparan com amb pèptid 10 uns 
forats a la membrana del bacteri. 
 
Figura.R.8. Imatge utilitzant TEM del efecte del mastoparan sobre una soca d’A. baumannii 
En aquesta part de la tesi em trobat un compost actiu in vitro i la posterior optimització, 
tot i no tindre èxit in vivo, hem trobat els motius pels quals aquests compostos no són 
actius i d’aquesta manera es poden trobar diferents alternatives o modificacions per a 
poder fer aquests pèptids actius in vivo.  
Hem utilitzat una altre tipus d’estratègia que es provant pèptids naturals extrets 
directament del cru natural, en aquest cas vàrem fer una col·laboració amb el Prof. 
Conlon de la universitat del Emirats àrabs. Diferents pèptids aïllats de secrecions de pell 
de granota vàrem ser provats en front de soques d’Acinetobacter especies tant resistents 
com sensibles a colistina. 
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Pèptid Acinetobacter sp.Strains 
 colistina  sensible       
mg/L (µM)  19606 77778 G13 NM8 NM35 NM75 NM109 NM124 
[G4K]XT-7 32(17.3) 32(17.3) 4(2.2) 32(17.3) 32(17.3) 32(17.3) 16(8.7) 16(8.7) 
[E4K]alyteserin-1c 8(3.5) 8(3.5) 8(3.5) 8(3.5) 16(7) 8(3.5) 4(1.8) 4(1.8) 
PGLa-AM1 64(30.9) 64(30.9) 128(61.9) 16(7.7) 16(7.7) 16(7.7) 16(7.7) 16(7.7) 
B2RP-Era 32(17) 32(17) 8(4.2) 32(17) 32(17) 16(8.5) 32(17) 32(17) 
CPF-AM1 64(39.5) 64(39.5) 128(78.9) 16(9.9) 16(9.9) 16(9.9) 16(9.9) 16(9.9) 
[D4K]B2RP 16(6.9) 8(3.4) 8(3.4) 8(3.4) 8(3.4) 8(3.4) 4(1.7) 4(1.7) 
Colistin 0.5(0.43) 2(1.7) <0.5(<0.43) 1(0.86) 1(0.86) 1(0.86) <0.5(<0.43) <0.5(<0.43) 
 
        
Taula.R.9. Assaig d’activitat de diferents pèptids aïllats de les secretions de les granotes en front soques 
d’Acinetobacter susceptible a colistina 
Pèptid Acinetobacter sp.Strain 
 colistina   resistent     
(mg/L) 
19606 
mutant 
77778 
mutant G13 mutant Ab22P Ab1 Ab113 
[G4K]XT-7 4(2.2.) 32(17.3) 4(2.2) 8(4.3) 32(17.3) 64(34.7) 
[E4K]alyteserin-1c 4(1.8) 8(3.5) 8(3.5) 4(1.8) 8(3.5) 16(7) 
PGLa-AM1 16(7.7) 64(30.9) 16(7.7) 16(7.7) 64(30.9) 128(61.9) 
B2RP-ERa 8(4.2) 64(34) 8(4.2) 8(4.2) 32(17) 64(34) 
CPF-AM1 4(2.5) 64(39.5) 8(4.9) 8(4.9) 64(39.5) 128(78.9) 
[D4K]B2RP 4(1.7) 16(6.9) 16(6.9) 8(3.4) 16(6.9) 16(6.9) 
Colistin 256 (221.6) >256 (>221.6) >256 (>221.6) 64(55.4) 
>512 
(>443.3) 256 (221.6) 
Taula.R.10. Assaig d’activitat de diferents pèptids aïllats de les secretions de les granotes en front soques 
d’Acinetobacter resistent a colistina 
 
De tots els pèptids testats [E4K]alyteserin-1c i [D4K]B2RP són els que presenten una 
millor activitat tant en soques resistents com en soques sensibles a colistina. 
Per últim, els tipus de compostos que vàrem testar en front de soques colistina resistents 
i colistina sensibles van ser uns compostos anomenats ceragenines. Les ceragenines són 
compostos provinents del àcid còlic, algunes modificacions del àcid còlic són 
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introduïdes dins l’estructura de tal manera que queda una part catiònica i una part 
hidrofòbica. Aquest tipus d’estructura, molt semblant als pèptids antimicrobians, poden 
anomenar-se peptidomimetics. Aquests compostos van ser testats en front de soques 
colistina sensible i colistina resistents en A. baumannii, K. Pneumoniae i P. aeruginosa. 
MIC (mg/l)  A. baumannii  K. pneumoniae  P .aeruginosa 
[µM]          
ceragenines  Col-S col-R  col-S col-R  col-S col-R 
138  2 [2.7] 4[5.4]  16[21.4] 16[21.4]  1[1.3] 1[1.3] 
13  4[5.9] 4[5.9]  8[11.8] 16[23.6]  <0,5[<0.7] <0,5[<0.7] 
131  2[2.7] 2[2.7]  8[10.9] 8[10.9]  <0,5[<0.7] <0,5[<0.7] 
44  8[10.9] 4[5.4]  4[5.4] 16[21.8]  1[1.4] 1[1.4] 
Taula.R.11. Assaig d’activitat de diferents pèptids ceragenines en front soques tant resistents com 
sensibles a colistina de A. baumannii, K. pneumoniae i P. aeruginosa. 
 
Tots els compostos presenten bones activitats en front de totes les soques, de totes 
maneres caldria destacar el compost 131 per sobre dels altres i especialment en front de 
soques de P. aeruginosa. També es pot apreciar com l’activitat dels diferents 
peptidomimetics es independent del grau de resistència de les soques emprades. 
 
Fins ara tots els tipus d’aproximació utilitzats son el clàssic antimicrobià, però la idea 
que vàrem utilitzar parteix de la idea d’inhibir la adherència dels bacteris a les cèl·lules 
mitjançant la inhibició de la proteïna ompA. 
Aprofitant una llibreria d’hexapèptids cíclics van ser provats in silico com a inhibidor 
de la proteïna ompA. Els resultats obtinguts in silico demostren que els pèptids que 
contenen Pro/ Trp /Arg tenen major afinitat per la proteïna.  
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Figura.R.9. Imatge de la interacció entre un compost de la llibreria EXORIS i la proteïna OmpA. 
 
Figura.R.10. Imatge de la interacció entre un compost de la llibreria EXORIS i la proteïna OmpA. 
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Figura.R.11. Imatge de la interacció entre un compost de la llibreria EXORIS i la proteïna OmpA. 
Diferents pèptids vàrem ser provats com a inhibidors de la adherència de bacteris en 
cèl·lules.  
MV5 
 
De tots els pèptids provats, el que te millor activitat es el compost MV5, a més a més de 
presentar una bona activitat inhibidora, també es poc tòxic i no es antibacterià.  
MV5 ciclo [Trp-D-Pro-Arg-Trp-D-Pro-Arg] 
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L’activitat d’aquest pèptid va ser testada utilitzant soques més resistents i es va veure 
com seguia mantenint la seva efectivitat. 
Després de veure que era un pèptid efectiu, es va provar en ratolins. Primer de tot només 
el pèptid per veure la toxicitat in vivo, on es va veure que a una dosi de 40 mg/kg tots 
els ratolins sobrevivien. Posteriorment es va duu a terme la dosi efectiva 50 a diferents 
concentracions.  
  MV5 (mg/kg) 
 10 20 40 
Survival (%) 66,67 83,33 50 
 
A les 3 concentracions utilitzades es pot veure com hi ha dosi efectiva 50 perquè es veu 
una supervivència superior al 50% de la població, fent èmfasi especialment en 20 mg/kg 
on sobreviuen 5 ratolins dels 6 tractats. 
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